

CONTENTS

Sum	nmary		4		B.3.2 Risk management model –	25
A.	Busines	ss and Performance	9		three lines of defence	25
A.1	Busines	SS	9		B.3.3 Risk appetite and strategyB.3.4 Risk management processes:	26
A.2	Underv	vriting Performance	10		identification, assessment and	27
A.3	Investn	nent Performance	12		treatment	
	A.3.1 N	Ion-Linked Investments	12		B.3.5 Risk management processes:	28
	A.3.2 L	Init-Linked Investments	13		monitoring, measurement and	
	A.3.3 C	Other information	14		reporting B.3.6 Prudent Person Principle	29
A.4	Perform	nance of other activities	14		B.3.7 Credit assessments	29
A.5	Any oth	ner information	15		B.3.8 ORSA	29
	A.5.1 I	LA Ownership Restructure	15	B.4	Internal control framework	31
	A.5.2 I	LA Recapitalisation	15		B.4.1 Internal control framework	31
	A.5.3 II	_A Subordinated Debt Repayment	15		B.4.2 Compliance Function	31
	A.5.4 (Other Information	15	B.5	Internal Audit Function	31
B. System of Governance			16	В.6	Actuarial Function	32
	B.1.1	Governance Structure	16	B.7	Outsourcing	32
	B.1.2	Key Function Holders	19	В.8	Any other information	32
	B.1.3	Adequacy of and Review		c.	Risk Profile	33
		of Systems of Governance	19		Underwriting risk	34
	B.1.4	Remuneration Practices	19		Market risk	36
	B.1.4.1	Share options, shares or variable	20		Credit risk	37
	D 1 4 3	components of remuneration	20		Liquidity risk	38
	B.1.4.2	Supplementary pension or early retirement schemes for the			C.4.1 Expected profit included in future	38
		members of the management			premiums	
		body and other key functions	21	C.5	Operational risk	39
	B.1.4.3	Material transactions during the	24	C.6	Other material risks	39
	D 1 F	reporting period	21	C.7	Any other information	40
D 2	B.1.5	Key functions	21		C.7.1 Risk Sensitivities	40
В.2		proper requirements	24		C.7.2 Use of Special Purpose Vehicles	40
		Policies and processes in place to meet fit and proper requirements	24	D.	Valuation for Solvency Purposes	41
B.3		anagement system including		D.1	Assets	41
		n risk and solvency assessment	24	D.2	Technical provisions	49
		Enterprise Risk Management Framework	25		D.2.1 Solvency II Technical Provisions and Reinsurance Recoverables: Overview	49

D.2.1.3 Reinsurance recoverables D.2.2.1 Demographic assumptions: Contracts with profit participation D.2.2.2 Demographic assumptions: Other Life Insurance D.2.2.3 Demographic assumptions: Unit-Linked D.2.2.4 Demographic assumptions: Unit-Linked D.2.2.5 Significant simplifications used in the calculation of technical provisions D.2.3 Level of uncertainty associated with the value of technical provisions D.2.4 Differences between Solvency II technical provisions D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.2.8 Level of uncertainty associated with the value of technical provisions D.2.9 Long Term Guarantee Measures D.2.0 Long Term Guarantee Measures D.2.1 Changes in assumptions compared to previous reporting period D.2.2 Changes to assumptions D.2.3 Other liabilities D.2.4 Alternative methods for valuation D.2.5 Any other information D.2.6 Any other information D.2.7 Changes to assumptions compared to previous reporting period D.2.8 Capital Management D.2.9 Appendix 5 Appendix 6 Solvency Capital Requirement D.2.9 Appendix 6 Solvency Capital Requirement D.2.9 Appendix 7 Minimum Capital Requ						
D.2.1.2 Best estimate technical provisions 50 D.2.1.3 Reinsurance recoverables 50 D.2.1.4 Risk margin 50 D.2.1.5 Solvency II Technical Provisions and Reinsurance Recoverables bases, methodology and assumptions 50 D.2.2.1 Demographic assumptions: Contracts with profit participation 51 D.2.2.2 Demographic assumptions: Other Life Insurance 51 D.2.2.3 Demographic assumptions: Other Life Insurance 51 D.2.2.4 Demographic assumptions: Unit-Linked 51 D.2.2.5 Significant simplifications used in the calculation of technical provisions and insurance contract liabilities and investment contract liabilities and investment contract liabilities included in the financial statements 52 D.2.6 Transitional Measures 52 D.2.7 Changes to assumptions compared to previous reporting period 54 D.2.8 Alternative methods for valuation 59 A Alternative methods for valuation 50 Any other information 59 Any other information 50 Capital Management 61 Capital Management 61 Capital Management 65 E.1.4 Equity in financial statements 50 E.1.5 A Equity in financial statements 50 E.1.6 Ancillary own funds 64 E.1.5 Transitional arrangements 65 E.2.1 Use of simplified methods 66 E.2.1 Use of simplified methods 66 E.2.2 Undertaking specific parameters and capital Requirement split by risk module 65 E.2.3 Calculation of the Minimum Capital Requirement 66 E.2.4 Changes since the previous reporting period 67 E.2.5 Significant simplifications used in the calculation of the Solvency Capital Requirement 66 E.3 Use of duration based sub-module in the calculation of the Solvency Capital Requirement 67 E.3 Use of simplified methods 66 E.2.1 Use of simplified methods 66 E.2.2 Undertaking specific parameters and capital Requirement 66 E.2.1 Use of simplified methods 66 E.2.2 Undertaking specific parameters and capital Requirement 66 E.2.3 Calculation of the Alinimum Capital Requirement 67 E.3 Use of simplified methods 66 E.2.3 Calculation of the Solvency Capital Requirement 67 E.3 Use of simplified methods 66 E.2.4 Changes since the previous eporting be for the		D.2.1.1			\sim	
technical provisions D.2.1.3 Reinsurance recoverables D.2.1.4 Risk margin D.2.2 Solvency II Technical Provisions and Reinsurance Recoverables: bases, methodology and assumptions: Contracts with profit participation D.2.2.2 Demographic assumptions: Other Life Insurance D.2.2.3 Demographic assumptions: Health D.2.2.4 Demographic assumptions: Unit-Linked D.2.2.5 Significant simplifications used in the calculation of technical provisions D.2.3 Level of uncertainty associated with the value of technical provisions D.2.4 Differences between Solvency II technical provisions D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.2.8 Alternative methods for valuation D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information Capital Requirement E.5 Gapital Management Solvency Capital Requirement E.6 Appendix 1 Balance Sheet Appendix 2 Premiums, claims and expenses by line of business Appendix 5 Appendix 6 Solvency Capital Requirement Ca		D 2 4 2		50		
D.2.1.3 Reinsurance recoverables D.2.1.4 Risk margin D.2.2 Solvency II Technical Provisions and Reinsurance Recoverables: bases, methodology and assumptions D.2.2.1 Demographic assumptions: Contracts with profit participation D.2.2.2 Demographic assumptions: D.2.2.3 Demographic assumptions: Unit-Linked D.2.2.5 Significant simplifications used in the calculation of technical provisions D.2.2.5 Significant simplifications used in the calculation of technical provisions D.2.4 Differences between Solvency II technical provisions D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.2.8 Changes to assumptions compared to previous reporting period D.2.9 Changes to assumptions compared to previous reporting period D.2.9 Changes to assumptions compared to previous reporting period D.2.9 Changes to assumptions D.2.1 Long Term Guarantee Measures D.2.2 Changes to assumptions compared to previous reporting period D.2.3 Other liabilities D.2.4 Alternative methods for valuation D.2.5 Any other information D.2.6 Any other information D.2.7 Changes to assumptions compared to previous reporting period D.2.8 D.29 Changes to assumptions compared to previous reporting period D.2.9 Alternative methods for valuation D.2.9 Any other information D.2.9 Any other informatio		D.2.1.2		50		64
D.2.1.4 Risk margin D.2.2 Solvency II Technical Provisions and Reinsurance Recoverables: bases, methodology and assumptions: D.2.2.1 Demographic assumptions: Contracts with profit participation D.2.2.2 Demographic assumptions: Other Life Insurance D.2.2.3 Demographic assumptions: Health D.2.2.4 Demographic assumptions: Unit-Linked D.2.2.5 Significant simplifications used in the calculation of technical provisions D.2.2.5 Significant simplifications used in the calculation of technical provisions D.2.3 Level of uncertainty associated with the value of technical provisions D.2.4 Differences between Solvency II technical provisions and insurance contract liabilities and investment contract liabilities and investment contract liabilities and insurance contract material statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions: Compared to Solvency II Cown Funds E.1.5 Transitional arrangements E.2.1 Use of simplified methods E.2.2 Undertaking specific parameters and capital add-ons E.2.2 Undertaking specific parameters and capital Requirement Capital Requirement E.2.4 Changes since the previous reporting period E.3 Use of duration based sub-module in the calculation of the Solvency Capital Requirement E.4 Differences between standard formula and any internal model used E.5 Non-compliance with the Minimum Capital Requirement tended formula and any internal model used E.5 Non-compliance with the Minimum Capital Requirement for E.6 Any other information Glossary Appendics Appendix 1 Balance Sheet Appendix 2 Premiums, claims and expenses by line of business J.4 Alternative methods for valuation Appendix 4 Impact of long term guarantees measures and transitionals Appendix 5 Own funds Appendix 6 Solvency Capital Requirement - for undertakings on Standard formula Appendix 7 Minimum Capital Requirement - for undertakings on Standard formula Appendix 7 Minimum Capital Requirement - Only life or only non-life		D 2 1 3			E.1.4 Equity in financial statements	
D.2.2 Solvency II Technical Provisions and Reinsurance Recoverables: bases, methodology and assumptions: Contracts with profit participation D.2.2.2 Demographic assumptions: Other Life Insurance D.2.2.3 Demographic assumptions: Health D.2.2.4 Demographic assumptions: Unit-Linked D.2.2.5 Significant simplifications used in the calculation of technical provisions D.2.3 Level of uncertainty associated with the value of technical provisions D.2.4 Differences between Solvency II technical provisions and insurance contract liabilities and investment contract liabilities included in the financial statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.2.8 Alternative methods for valuation D.2.9 Any other information Compared to previous reporting period D.2.9 Any other information Compared to previous reporting period D.2.9 Any other information Compared to previous reporting period D.2.9 Any other information Compared to previous reporting period D.2.9 Any other information D.2.9 Any other information D.2.9 Appendix 5 Own Funds D.2.9 Appendix 6 Solvency Capital Requirement D.2.9 Appendix 1 Balance Sheet D.2.9 Changes to assumptions compared to previous reporting period D.2.9 Alternative methods for valuation D.2.9 Appendix 5 Own Funds D.2.9 Appendix 6 Solvency Capital Requirement D.2.9 Appendix 6 Solvency Capital Requirement D.2.9 Appendix 7 Minimum Capital Requirement D.2.9 Appendix 8 Diversions Appendix 9 Solvency Capital Requirement D.2.9 Appendix 9 Solvency Capital Re					compared to Solvency II	
Technical Provisions and Reinsurance Recoverables: bases, methodology and assumptions D.2.1 Demographic assumptions: Contracts with profit participation D.2.2.2 Demographic assumptions: Other Life Insurance D.2.2.3 Demographic assumptions: Health D.2.4 Demographic assumptions: Unit-Linked provisions D.2.5 Significant simplifications used in the calculation of technical provisions D.2.3 Level of uncertainty associated with the value of technical provisions D.2.4 Differences between Solvency I technical provisions and insurance contract liabilities and investment compared to previous reporting period D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures 50 E.2. Solvency Capital Requirement 51 E.2.2 Undertaking specific parameters and capital add-ons E.2.3 Calculation of the Minimum Capital Requirement E.2.4 Changes since the previous reporting period E.3 Use of duration based sub-module in the calculation of the Solvency Capital Requirement E.4 Differences between standard formula and any internal model used E.5 Non-compliance with the Minimum Capital Requirement and non-compliance with the Solvency Capital Requirement E.6 Any other information Glossary Appendices D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures 51 E.2.1 Use of simplified methods E.2.2 Undertaking specific parameters and capital add-ons E.4 Changes since the previous reporting period E.4 Differences between standard formula and any internal model used E.5 Non-compliance with the Minimum Capital Requirement E.6 Any other information Glossary Appendix 1 Balance Sheet Appendix 2 Premiums, claims and expenses by line of business Appendix 3 Life and health SLT technical provisions Appendix 4 Impact of long term guarantees measures and transitionals Appendix 5 Own funds Appendix 6 Minimum Capital Requirement - for undertaking son Standard formula Append					Own Funds	64
methodology and assumptions D.2.2.1 Demographic assumptions: Contracts with profit participation D.2.2.2 Demographic assumptions: Other Life Insurance D.2.2.3 Demographic assumptions: Health D.2.2.4 Demographic assumptions: Health D.2.2.5 Significant simplifications used in the calculation of technical provisions D.2.3 Level of uncertainty associated with the value of technical provisions D.2.4 Differences between Solvency II technical provisions and insurance contract liabilities and investment contract liabilities and investment contract liabilities and investment contract liabilities and investment contract liabilities and compared to previous reporting period D.2.7 Changes to assumptions compared to previous reporting period D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information Contract with the solvency Capital Requirement of the Solvency Capita		5.2.2			E.1.5 Transitional arrangements	65
D.2.2.1 Demographic assumptions: Contracts with profit participation D.2.2.2 Demographic assumptions: Other Life Insurance D.2.2.3 Demographic assumptions: Health D.2.2.4 Demographic assumptions: Unit-Linked D.2.2.5 Significant simplifications used in the calculation of technical provisions D.2.3 Level of uncertainty associated with the value of technical provisions D.2.4 Differences between Solvency II technical provisions and insurance contract liabilities included in the financial statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information Contracts with profit E.2.1 Use of simplified methods E.2.2 Undertaking specific parameters and capital add-ons E.2.3 Calculation of the Minimum Capital Requirement E.2.4 Changes since the previous reporting period E.3 Use of duration based sub-module in the calculation of the Solvency Capital Requirement and any internal model used E.5 Non-compliance with the Minimum Capital Requirement and non-compliance with the Solvency Capital Requirement E.6 Any other information Glossary Appendices Appendics Appendix 1 Balance Sheet Appendix 2 Premiums, claims and expenses by line of business Appendix 3 Life and health SLT technical provisions Appendix 5 Own funds Appendix 5 Own funds Appendix 6 Own funds Appendix 6 Own funds Appendix 7 Minimum Capital Requirement For undertakings on Standard Formula Appendix 7 Minimum Capital Requirement Only life or only non-life					E.1.6 Ancillary own funds	65
Contracts with profit participation 51 E.2.1 Use of simplified methods E.2.2 Undertaking specific parameters and capital add-ons 66 E.2.3 Calculation of the Minimum Capital Requirement 67 E.2.4 Changes since the previous reporting period 67 E.3 Use of duration based sub-module in the calculation of technical provisions 52 E.4 Differences between Solvency II technical provisions and insurance contract liabilities included in the financial statements 52 Appendix 5 D.2.7 Changes to assumptions compared to previous reporting period 54 Alternative methods for valuation 65 Capital Management 66 E.2.1 Use of simplified methods 66 E.2.2 Undertaking specific parameters and capital add-ons 66 E.2.2 Undertaking specific parameters and capital add-ons 66 E.2.2 Undertaking specific parameters and capital add-ons 66 E.2.2 Capital Requirement 67 E.2.3 Level of uncertainty assumptions: reporting period 67 E.2.4 Changes since the previous reporting period 67 E.2.5 Unages to assumptions compared to previous reporting period 54 Appendix 1 Balance Sheet 70 Appendix 2 Premiums, claims and expenses by line of business 73 Appendix 5 Own funds 74 Appendix 5 Own funds 75 Appendix 6 Solvency Capital Requirement 76 Formula 77 Formula 77 Appendix 7 Minimum Capital Requirement 77 Formula 77 Appendix 7 Minimum Capital Requirement 78 Appendix 7 Minimum Capital Requirement 78 Appendix 7 Minimum Capital Requirement 79 Conful Information 60 Capital Management 61 Appendix 7 Minimum Capital Requirement 62 Capital Management 61 Appendix 7 Minimum Capital Requirement 62 Capital Requirement 63 Capital Management 61 Capital Management 62 Capital Requirement 63 Capital Requirement 64 Capital Management 65 Capital Requirement 65 Capital Requirement 65 Capital Management 61 Capital Management 61 Capital Management 6			methodology and assumptions	50		
participation D.2.2.2 Demographic assumptions: Other Life Insurance D.2.2.3 Demographic assumptions: Health D.2.2.4 Demographic assumptions: Unit-Linked D.2.2.5 Significant simplifications used in the calculation of technical provisions D.2.3 Level of uncertainty associated with the value of technical provisions D.2.4 Differences between Solvency II technical provisions and insurance contract liabilities included in the financial statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions: D.2.8 Alternative methods for valuation D.2.9 Alternative methods for valuation D.2.10 Methods D.2.21 Demographic assumptions: Capital Requirement E.2.22 Undertaking specific parameters and capital add-ons E.2.3 Calculation of the Minimum Capital Requirement E.2.4 Changes since the previous reportions for and any internal mobal used with the calculation based sub-module in the calculation based sub-module in the calculation of the Solvency Capital Requirement E.3 Use of duration based sub-module in the calculation of the Solvency Capital Requirement E.4 Differences between standard formula and any internal model used E.5 Non-compliance with the Minimum Capital Requirement E.6 Any other information Glossary Appendices 70 Appendix 1 Balance Sheet Appendix 2 Premiums, claims and expenses by line of business Appendix 3 Life and health SLT technical provisions Appendix 4 Impact of long term guarantees measures and transitionals Appendix 5 Own funds Appendix 6 Solvency Capital Requirement - for undertakings on Standard Formula Appendix 7 Minimum Capital Requirement - Only life or only non-life		D.2.2.1			risk module	65
D.2.2.2 Demographic assumptions: Other Life Insurance D.2.2.3 Demographic assumptions: Health D.2.2.4 Demographic assumptions: Unit-Linked D.2.2.5 Significant simplifications used in the calculation of technical provisions D.2.3 Level of uncertainty associated with the value of technical provisions D.2.4 Differences between Solvency II technical provisions and insurance contract liabilities included in the financial statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information Capital Requirement E.4 Differences between standard formula and any internal model used E.5 Non-compliance with the Minimum Capital Requirement and non-compliance with the Solvency Capital Requirement E.6 Any other information Glossary Appendix 1 Balance Sheet Appendix 2 Premiums, claims and expenses by line of business Appendix 3 Life and health SLT technical provisions Appendix 4 Impact of long term guarantees measures and transitionals Appendix 5 Own funds Appendix 7 Minimum Capital Requirement - Only life or only non-life				F 1		66
Other Life Insurance D.2.2.3 Demographic assumptions: Health D.2.2.4 Demographic assumptions: Unit-Linked D.2.2.5 Significant simplifications used in the calculation of technical provisions D.2.3 Level of uncertainty associated with the value of technical provisions D.2.4 Differences between Solvency II technical provisions and insurance contract liabilities included in the financial statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information Capital Requirement E.2.4 Changes since the previous reporting the calculation of the Minimum Capital Requirement E.3 Use of duration based sub-module in the calculation of the Solvency Capital Requirement E.4 Differences between standard formula and any internal model used E.5 Non-compliance with the Minimum Capital Requirement and non-compliance with the Solvency Capital Requirement Glossary Appendices Appendix 1 Balance Sheet Appendix 2 Premiums, claims and expenses by line of business Appendix 3 Life and health SLT technical provisions Appendix 4 Impact of long term guarantees measures and transitionals Appendix 5 Own funds Appendix 6 Solvency Capital Requirement - for undertakings on Standard Formula Appendix 7 Minimum Capital Requirement - Only life or only non-life				51		
D.2.2.3 Demographic assumptions: Health D.2.2.4 Demographic assumptions: Unit-Linked D.2.2.5 Significant simplifications used in the calculation of technical provisions D.2.3 Level of uncertainty associated with the value of technical provisions D.2.4 Differences between Solvency II technical provisions and insurance contract liabilities included in the financial statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.2.8 Object of duration based sub-module in the calculation of the Solvency Capital Requirement D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.2.8 Alternative methods for valuation D.2.9 Any other information D.2.9 Any other information D.2.0 Alternative methods for valuation D.2.1 Capital Requirement D.2.2 Capital Requirement D.2.3 Capital Requirement E.2.4 Changes since the previous reporting beriod E.3. Use of duration based sub-module in the calculation of the Solvency Capital Requirement The capital Requirement The calculation of the Solvency Capital Requir		D.2.2.2		51		66
Health D.2.2.4 Demographic assumptions: Unit-Linked D.2.2.5 Significant simplifications used in the calculation of technical provisions D.2.3 Level of uncertainty associated with the value of technical provisions D.2.4 Differences between Solvency II technical provisions D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.2.7 Changes to assumptions compared to previous reporting period D.2.8 Appendix 1 Balance Sheet D.2.9 Changes to assumptions and investment contract liabilities D.2.7 Changes to assumptions compared to previous reporting period D.2.8 Appendix 2 Premiums, claims and expenses by line of business D.2.9 Changes to assumptions compared to previous reporting period D.2.5 Any other information D.2.5 Any other information D.2.6 Alternative methods for valuation D.2.7 Changes to assumptions compared to previous reporting period D.2.8 Alternative methods for valuation D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information D.5 Any other information D.6 Any other information D.7 Any other information D.8 Appendix 7 Minimum Capital Requirement for undertakings on Standard Formula D.8 Appendix 7 Minimum Capital Requirement for only life or only non-life		D 2 2 2		١ (
D.2.2.4 Demographic assumptions: Unit-Linked D.2.2.5 Significant simplifications used in the calculation of technical provisions D.2.3 Level of uncertainty associated with the value of technical provisions D.2.4 Differences between Solvency II technical provisions and insurance contract liabilities included in the financial statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information Capital Requirement and non-compliance with the Solvency Capital Requirement E.6 Any other information Glossary Appendix 1 Balance Sheet Appendix 2 Premiums, claims and expenses by line of business Appendix 3 Life and health SLT technical provisions Appendix 4 Impact of long term guarantees measures and transitionals Appendix 5 Own funds Appendix 6 Solvency Capital Requirement - for undertakings on Standard Formula Appendix 7 Minimum Capital Requirement - for undertakings on Standard Formula Appendix 7 Minimum Capital Requirement - Only life or only non-life		D.2.2.3	<u> </u>	51		66
Unit-Linked D.2.2.5 Significant simplifications used in the calculation of technical provisions D.2.3 Level of uncertainty associated with the value of technical provisions D.2.4 Differences between Solvency II technical provisions and insurance contract liabilities included in the financial statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information Capital Requirement and non-compliance with the Minimum Capital Requirement information Glossary Appendices Appendix 1 Balance Sheet Appendix 2 Premiums, claims and expenses by line of business Appendix 3 Life and health SLT technical provisions Compared to previous reporting period Appendix 5 Own funds Appendix 6 Solvency Capital Requirement - for undertakings on Standard Formula Appendix 7 Minimum Capital Requirement - Only life or only non-life		D 2 2 4		71		67
D.2.2.5 Significant simplifications used in the calculation of technical provisions D.2.3 Level of uncertainty associated with the value of technical provisions D.2.4 Differences between Solvency II technical provisions and insurance contract liabilities included in the financial statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information Signatural model used E.5 Non-compliance with the Minimum Capital Requirement and non-compliance with the Solvency Capital Requirement E.6 Any other information Glossary Appendices Appendix 1 Balance Sheet Appendix 2 Premiums, claims and expenses by line of business Appendix 3 Life and health SLT technical provisions Appendix 4 Impact of long term guarantees measures and transitionals Appendix 5 Own funds Appendix 6 Solvency Capital Requirement - for undertakings on Standard Formula 1. Own Funds 4. Appendix 7 Minimum Capital Requirement - Only life or only non-life		D.2.2.4		51		07
in the calculation of technical provisions D.2.3 Level of uncertainty associated with the value of technical provisions D.2.4 Differences between Solvency II technical provisions and insurance contract liabilities included in the financial statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information Capital Requirement E.4 Differences between standard formula and any internal model used E.5 Non-compliance with the Minimum Capital Requirement end non-compliance with the Solvency Capital Requirement E.6 Any other information Glossary Appendices Appendix 1 Balance Sheet Appendix 2 Premiums, claims and expenses by line of business Appendix 3 Life and health SLT technical provisions Appendix 4 Impact of long term guarantees measures and transitionals Appendix 5 Own funds Appendix 5 Own funds Appendix 6 Solvency Capital Requirement - for undertakings on Standard Formula Appendix 7 Minimum Capital Requirement - for undertakings on Standard Formula Appendix 7 Minimum Capital Requirement - Only life or only non-life		D 2 2 5				
D.2.3 Level of uncertainty associated with the value of technical provisions D.2.4 Differences between Solvency II technical provisions and insurance contract liabilities included in the financial statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information Capital Requirement and non-compliance with the Solvency Capital Requirement E.6 Any other information E.6 Any other informatio		0.2.2.				67
with the value of technical provisions D.2.4 Differences between Solvency II technical provisions and insurance contract liabilities and investment contract liabilities included in the financial statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.3. Other liabilities D.4 Alternative methods for valuation D.5 Any other information Statement Statement Statements Statement			provisions	52	E.4 Differences between standard formula	
D.2.4 Differences between Solvency II technical provisions and insurance contract liabilities and investment contract liabilities included in the financial statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information Capital Requirement and non-compliance with the Solvency Capital Requirement E.6 Any other information Glossary Appendix 1 Balance Sheet Appendix 2 Premiums, claims and expenses by line of business Appendix 3 Life and health SLT technical provisions Appendix 4 Impact of long term guarantees measures and transitionals Appendix 5 Own funds Appendix 6 Solvency Capital Requirement - for undertakings on Standard Formula Appendix 7 Minimum Capital Requirement - Only life or only non-life		D.2.3	Level of uncertainty associated		and any internal model used	67
D.2.4 Differences between Solvency II technical provisions and insurance contract liabilities and investment contract liabilities included in the financial statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information Capital Management Mith the Solvency Capital Requirement E.6 Any other information E.6 Any other information Mith the Solvency Capital Requirement E.6 Any other information Mith the Solvency Capital Requirement E.6 Any other information Mith the Solvency Capital Requirement E.6 Any other information Mith the Solvency Capital Requirement E.6 Any other information Malance Sheet Appendix 2 Premiums, claims and expenses by line of business Appendix 3 Life and health SLT technical provisions Appendix 4 Impact of long term guarantees measures and transitionals Appendix 5 Own funds Appendix 6 Solvency Capital Requirement - for undertakings on Standard Formula Appendix 7 Minimum Capital Requirement - Only life or only non-life					E.5 Non-compliance with the Minimum	
technical provisions and insurance contract liabilities and investment contract liabilities included in the financial statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information E. Capital Management Technical provisions and investment contract liabilities and investment contract liabilities and investment contract liabilities E.6 Any other information Glossary Appendix 1 Balance Sheet Appendix 2 Premiums, claims and expenses by line of business Appendix 3 Life and health SLT technical provisions Appendix 4 Impact of long term guarantees measures and transitionals Appendix 5 Own funds Appendix 6 Solvency Capital Requirement for undertakings on Standard Formula Appendix 7 Minimum Capital Requirement - Only life or only non-life				52		
insurance contract liabilities and investment contract liabilities included in the financial statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information In Capital Management In Own Funds Clossary Appendices Appendix 1 Balance Sheet Appendix 2 Premiums, claims and expenses by line of business Appendix 3 Life and health SLT technical provisions Appendix 4 Impact of long term guarantees measures and transitionals Appendix 5 Own funds Appendix 6 Solvency Capital Requirement - for undertakings on Standard Formula Appendix 7 Minimum Capital Requirement - Only life or only non-life		D.2.4	-		with the Solvency Capital Requirement	67
investment contract liabilities included in the financial statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information Capital Management Divided in the financial statements D.2 Appendix 1 Balance Sheet Appendix 2 Premiums, claims and expenses by line of business Appendix 3 Life and health SLT technical provisions Appendix 4 Impact of long term guarantees measures and transitionals Appendix 5 Own funds Appendix 6 Solvency Capital Requirement for undertakings on Standard Formula Appendix 7 Minimum Capital Requirement Only life or only non-life					E.6 Any other information	67
included in the financial statements D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information Capital Management Appendix 1 Balance Sheet Appendix 2 Premiums, claims and expenses by line of business Appendix 3 Life and health SLT technical provisions Appendix 4 Impact of long term guarantees measures and transitionals Appendix 5 Own funds Appendix 5 Own funds Appendix 6 Solvency Capital Requirement for undertakings on Standard Formula Appendix 7 Minimum Capital Requirement Only life or only non-life					Glossary	68
D.2.5 Long Term Guarantee Measures D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information D.5 Any other information D.6 Capital Management D.7 Long Term Guarantee Measures D.8 Appendix 2 Premiums, claims and expenses by line of business D.9 Life and health SLT technical provisions D.9 Appendix 4 Impact of long term guarantees measures and transitionals D.9 Appendix 5 Own funds D.9 Appendix 5 Own funds D.9 Appendix 6 Solvency Capital Requirement for undertakings on Standard Formula D.9 Appendix 7 Minimum Capital Requirement D.9 Appendix 7 Minimum Capital Requirement D.9 Only life or only non-life					Appendices	70
D.2.6 Transitional Measures D.2.7 Changes to assumptions compared to previous reporting period D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information D.5 Any other information D.6 Capital Management D.7 Changes to assumptions Compared to previous reporting period D.5 Any other liabilities D.6 Appendix 4 Impact of long term guarantees measures and transitionals D.6 Appendix 5 Own funds D.7 Appendix 6 Solvency Capital Requirement D.6 Formula D.7 Appendix 7 Minimum Capital Requirement D.7 Appendix 7 Minimum Capital Requirement D.8 Appendix 7 Minimum Capital Requirement D.9 Appendix 8 Difference of business D.9 Appendix 9 Difference of business D.9 Difference of b			statements	52	Appendix 1 Balance Sheet	71
D.2.7 Changes to assumptions compared to previous reporting period D.3 Other liabilities D.4 Alternative methods for valuation D.5 Any other information Capital Management D.6 Appendix 3 Life and health SLT technical provisions Appendix 4 Impact of long term guarantees measures and transitionals Appendix 5 Own funds Appendix 5 Own funds Appendix 6 Solvency Capital Requirement - for undertakings on Standard Formula Appendix 7 Minimum Capital Requirement - Only life or only non-life		D.2.5	Long Term Guarantee Measures	54		
compared to previous reporting period D.2.7 Changes to assumptions compared to previous reporting period Appendix 4 Impact of long term guarantees measures and transitionals Appendix 5 Own funds Appendix 5 Own funds Appendix 6 Solvency Capital Requirement for undertakings on Standard Formula E. Capital Management Appendix 7 Minimum Capital Requirement Only life or only non-life		D.2.6	Transitional Measures	55		73
Appendix 4 Impact of long term guarantees measures and transitionals 75 Appendix 5 Own funds 76 Appendix 6 Solvency Capital Requirement 77 Appendix 7 Minimum Capital Requirement 78 Appendix 7 Minimum Capital Requirement 79 Appendix 7 Minimum Capital Requirement 70 Appendix 7 Minimum Capital Requirement 70 Appendix 7 Minimum Capital Requirement 70 Appendix 7 Minimum Capital Requirement 71 Appendix 7 Minimum Capital Requirement 72 Appendix 7 Minimum Capital Requirement 73 Appendix 7 Minimum Capital Requirement 75 Appendix 8 Own funds 76 Appendix 9 Own funds 77 Appendix 7 Minimum Capital Requirement 78 Appendix 9 Own funds 79 Appendix 9 Own funds 70 Appendix 9 Own funds 70 Appendix 9 Own funds 70 Appendix 9 Own funds 71 Appendix 9 Own funds 72 Appendix 9 Own funds 73 Appendix 9 Own funds 74 Appendix 9 Own funds 75 Appendix 9 Own funds 76 Appendix 9 Own funds 77 Appendix 9 Own funds 77 Appendix 9 Own funds 78 Appendix 9 Own funds 79 Appendix 9 Own funds 70 Appendix 9 Own funds		D.2.7	Changes to assumptions			71
measures and transitionals 75 Appendix 5 Own funds 76 Appendix 6 Solvency Capital Requirement 77 Appendix 6 Solvency Capital Requirement 78 To apital Management 79 Appendix 7 Minimum Capital Requirement 70 Appendix 7 Minimum Capital Requirement 70 Appendix 7 Only life or only non-life						/4
Appendix 5 Own funds 76 Appendix 5 Own funds 77 Appendix 5 Own funds 77 Appendix 6 Solvency Capital Requirement 77 For undertakings on Standard 77 Appendix 7 Minimum Capital Requirement 78 Appendix 7 Minimum Capital Requirement 79 Appendix 7 Only life or only non-life				54		75
D.4 Alternative methods for valuation D.5 Any other information D.6 Appendix 6 Solvency Capital Requirement Formula D.7 Appendix 7 Minimum Capital Requirement D.5 Any other information D.6 Appendix 6 Solvency Capital Requirement Formula D.7 Appendix 7 Minimum Capital Requirement Formula D.7 Appendix 7 Minimum Capital Requirement Formula D.8 Appendix 8 Solvency Capital Requirement Formula D.8 Appendix 9 Solvency Capital Requirement	0.3	Other lia	bilities	55		76
2.5 Any other information Capital Management Capital Requirement Capital Requ).4	Alternati	ve methods for valuation	59		
 Capital Management Own Funds Appendix 7 Minimum Capital Requirement Only life or only non-life).5	Any other	er information	60	- for undertakings on Standard	77
E.1 Own Funds 61 - Only life or only non-life		. Capital Management		61		//
		'				
I Management of Own rungs	. 1					78
E.1.2 Components of Own Funds 62						
E. 1.2 Components of Own Funds		L. 1.2 C		02		



SUMMARY

OUR PARENT GROUP

Irish Life Assurance plc is part of the Irish Life Group. Since 2013, the Irish Life Group has been a part of the Great-West Lifeco group of companies, one of the world's leading and most secure life assurance organisations. Great-West Lifeco and its subsidiaries - including the Great-West Life Assurance Company which was founded in Winnipeg, Canada, more than a century ago - have around \$1.35 trillion in consolidated assets under administration. They are members of the Power Financial Corporation group of companies.

As an international financial group, we always look for opportunities to grow through acquisition where it makes sense for our organisation, our customers and our shareholders. Over the past year, the Great-West Lifeco group acquired Financial Horizons Group in Canada, Retirement Advantage in the U.K., and just recently, announced the acquisition of the real estate investment firm EverWest in the U.S.

The Irish Life Group successfully completed the integration of its two health insurance businesses in 2017. They now operate under the Irish Life Health brand, a sister company of Irish Life Assurance plc. It also uses the strength of its award winning sister companies - Irish Life Investment Managers Limited, Canada Life Asset Management Limited and Setanta Asset Management Limited - to provide Irish Life Assurance plc with investment management services and expertise.

On 20 April 2018, the Company's parent, Irish Life Group Limited, reached an agreement to acquire a strategic holding in Invesco Ltd (Ireland), an independent financial consultancy firm based in Ireland. Invesco manages 275 occupational pension plans on behalf of large corporations in Ireland, along with pension plans for over 500 small and medium companies. In total, Invesco has almost 55,000 members in corporate pension schemes and €4.8 billion in assets under administration (as at 31st August 2017). The acquisition is subject to regulatory approval and customary closing conditions, and is expected to be completed in the third

quarter of 2018 and will be financed with internal resources. The transaction is expected to be earnings accretive, although it is not expected to have a material impact on the group's financial results.

For over 75 years, the Irish Life Group has been helping people in Ireland look after their life insurance, pension and investment needs. As one of Ireland's leading financial services companies, with more than one million customers, the Group empowers people to look to the future with more certainty and confidence.

OUR STRUCTURE AND ACHIEVEMENTS

We operate through two main divisions: Irish Life Retail (Retail Life) and Irish Life Corporate Business (Corporate Life). Each division's current strategic plan includes a significant cash investment during the 2015 to 2019 period. This investment today and in the future will continue to help us develop our businesses to meet the demands of an ever-changing market. We constantly review and enhance our strategic plans, always making sure they're in line with evolving customer expectations.

We are passionate about helping people build better futures. Every day, all over the country, our Financial Advisers and Distribution partners give sound financial advice to individuals, SMEs and corporates. We are there for people when they need us most. We pay out more claims for serious illness or death, and pay more pensions, than any other company in Ireland.

We have spent many years supporting our policyholders and listening to their feedback, so we know and understand our customers, their interests and concerns, and their ambitions for themselves and their families. Our customers depend on us. That is why looking after these relationships is our number one priority.

Our passion for innovation and customer service strengthens our ability to anticipate challenges and find fresh ways to overcome them. Our goal is to give our customers greater security and

certainty. We continue to research and develop pioneering products, and support them with the highest standards of customer service. As part of Great-West Lifeco, we have access to experience and expertise on a global scale, boosting our ability to continuously enhance our customer offering.

We are a leader in our industry, our community and wider society and are working hard to build on that. Our strategy centres on three pillars: customers, staff and financials. Maintaining and further developing a collaborative, innovative culture, that equips us to meet our customers' changing needs throughout their lives, remains a key driver within our business.

Delivering top class service to our customers and partners is one of our key business goals. We use an external company to help us measure our Retail Life customer satisfaction every month. At the end of 2017 we achieved our highest ever score of 87% (2016: 85%). This put us in the top quartile of companies measured on The Leadership Factor's Customer Satisfaction Index. Each year the Corporate Life division surveys their corporate broker and clients. The 2017 survey results from both groups show improvement year on year.

In 2017 we invested in an innovation hub within our Dublin campus. This hub has a team of cross functional experts from across the company. Their aim is to keep improving our digital innovation, embedding an innovative approach to problem solving into our culture and deciding how we engage with next generation technologies and processes. I am excited about what this will bring to our company and how this will challenge our people.

We are always working hard not only to attract and retain the most talented people, but to support and develop them. We look for creative, original thinkers who will challenge us to be the best we can be. As a result, we have built a skilled and enthusiastic workforce with exceptional knowledge and expertise.



CUSTOMER FIRST

We keep our promises to our customers and always keep their interest in mind.



PROFESSIONAL PEOPLE

We deliver on Customer expectations through continuous development and improvement to maintain the highest standards throughout our organisation.



INTEGRITY

We are committed to the highest standards of good governance and business ethics.



RESPECT & REWARD

People feel respected, supported and rewarded for positively contributing to our shared success.

OUR VISION AND VALUES

In early 2016, following 18 months of collaboration and consultation with employees across the Group, we launched our new Vision and Values below.

These are our core principles, and they will guide the organisation and all of us working in it for years to come. By living our values, each of our employees delivers great products and great service daily which help us deliver our vision to "help people build better futures".

During 2017, for the third year in a row, the company ran a staff survey to get feedback on how our employees believe we are living to these values. 83% of the team responded. The results show that 80% of the company's employees identify with and share with the company's values - the industry equivalent benchmark is 70%. This is important to us as we continue on our journey in 2018 and beyond.

I and my management team acknowledge that diversity makes us stronger and drives our success and growth as individuals and as a business. In 2017 a cross-functional Diversity and Inclusion leadership group was established. This group will act on initiatives to reduce our differences, and to bring together our unique perspectives and capabilities in a way that is consistent with our Vision and Values.

In December 2017, following significant engagement with the Trustees of the company's defined benefit pension plan and other employee interest groups, the company announced that the scheme was closing to future accruals on 30 June 2018. This was a difficult decision to take but was in the interests of all stakeholders. Since the announcement, the Company has embarked on a communication programme that offers details of the closure to future accrual to all the active members of the scheme, who are the main parties directly impacted by this decision. The decision reflects the quantum of the liabilities managed within the scheme (end 2017: €1.3bn), the cost of funding future accruals and to ensure all scheme members are treated equally.

As Ireland's leading provider of pensions, managing the financial needs of more than 1.3 million Irish customers, Irish Life is acutely aware of the need to identify opportunities and anticipate challenges of the changing demographics. That is why we are delighted to support The Irish Longitudinal Study on Ageing (TILDA). In 2006, Irish Life gifted TILDA with philanthropic funding to support data collection under a 10-year agreement and this year we committed to renew the partnership by providing a further €1.6 million in support over the next five years.

I welcome the State's paper on pension reform ('A Roadmap for Pensions Reform, 2018-2023'1). Key lessons from international experience indicated that auto-enrolment in pensions could be a major factor in improving Irish pension coverage in the decades ahead. Our analysis shows that in terms of influencing both

¹ https://m.welfare.ie/en/pressoffice/pdf/PensionsRoadmap.pdf

employers and employees to be more engaged with pensions, auto-enrolment is the best tool currently available to dramatically raise the levels of pension coverage and adequacy to where they need to be. We know from our own research and international experience that there are lots of factors to be considered when looking at auto-enrolment. As Ireland's leading pension provider, we look forward to playing an active part in any future consultation process to help solve one of the biggest challenges facing Ireland's ageing population.

We believe institutions that operate responsibly, take care of their customers and successfully manage risk, stand out in the long-term. They build a reputation that clients, customers and decision-makers can trust. Our approach is founded on operating ethically, influencing better outcomes and shaping the wider industry. It is an approach that improves results for our customers and society.

PURPOSE OF THE SOLVENCY AND FINANCIAL CONDITION REPORT

This report will help you better understand our regulatory capital and financial position following the new European-wide Solvency II regulations introduced on 1 January 2016. To facilitate your understanding, the Appendices to this report also detail seven specific Qualitative Reporting Templates (QRTs) for the company in the predefined format required under the regulations. The specifics of these templates are discussed in more detail across various sections of this report including sections A.2 (Underwriting Performance), A.3 (Investment Performance), D (Valuation for Solvency Purposes) and E (Capital Management).

It also covers how we are run, as well as a description of our business and performance, system of governance, risk profile, valuation for Solvency II purposes and our approach to capital management.

BUSINESS AND PERFORMANCE

We have put Solvency II's capital, control and reporting regime into practice in Irish Life. The structures and routines we apply to support this are outlined in section B. System of Governance.

We have detailed our financial performance - which was influenced by market conditions, premium inflow and claims outflows - in section A. Business and Performance.

At the end of 2017, we reported solvency capital, post dividends, that was €714m (2016: €620m) above the €1,189m (2016: €1,152m) Solvency Capital Requirement (SCR).

The company's underwriting performance of €134m in 2017 fell from €165m in 2016. The most material variance year-on-year in this underwriting result was influenced by the positive impact of assumption changes on the underwriting result in 2016 which did not re-occur in 2017, along with a difference in claims and

investment experience in 2017 relative to 2016. This is discussed in more detail in sections A.2 Underwriting Performance and A.3 Investment Performance.

After tax, our financial performance generated a profit for the financial year (excluding profits from the participating funds) of €131m (2016: €157m).

Certain one-off items influenced the results. For example:

- the impact of changes in the assumptions we use to calculate our insurance and investment contract liabilities was -€3m (2016: +€55m)
- interest rate changes had an impact of +€5m (2016: -€17m)
- the termination of a reinsurance treaty created a surplus of +€10m (2016: €nil)

The impacts above are shown net of tax.

We calculate our SCR using the standard formula set by the European Insurance and Occupational Pensions Authority (EIOPA). We control and report solvency capital in line with the capital management and metrics detailed in section E. Capital Management. The table below summarises our position at year end:

€m	2017	2016
<u>Tier 1 - unrestricted</u>		
Issued share capital	1	1
Share premium account	340	340
Surplus funds	0	0
Reconciliation reserve	1,635	1,485
<u>Tier 1 - restricted</u>		
Subordinated debt	0	201
Available Own Funds (before foreseeable dividends and adjustments)	1,976	2,027
Foreseeable dividends, distributions and charges	(73)	(55)
Ring fenced funds adjustment (Participating Funds)	0	0
Total available Own Funds to meet the SCR	1,903	1,972
Less subordinated debt repaid February 2017	0	(200)
Total after allowing for February 2017 subordinated debt repayment	1,903	1,772
Solvency Capital Requirement (SCR)	1,189	1,152
Solvency ratio	160%	154%
Minimum Capital Requirement (MCR)	498	460
Eligible Own Funds as a percentage of MCR	382%	385%

Note: all tables in this document use units of millions and thousands. Because we have rounded the figures, the totals in the tables may not equal the sum of the components exactly.

Our subordinated debt was repaid on 8 February 2017.

SYSTEM OF GOVERNANCE

We have a specific Solvency II governance process to help the Board verify the accuracy of our quantitative and qualitative returns to the Central Bank. The process draws on:


- our own subject matter experts
- our wider group (particularly group companies that fall under these regulations)
- external companies.

The process was also:

- · overseen by our senior executive and management teams and
- reviewed and challenged by both internal audit and external accounting firms during its initial development and while we were putting it into action.

GOVERNANCE STRUCTURE

You can find out more about our governance process in section B. System of Governance. We have summarised the structure of our Board below. There are more details in section B.1.1 Governance Structure.



^{*}The Executive Investment Management Committee also reports to the Board.

In April 2018, the company's Board established its own Audit Committee and Risk Committee. Previously these committee's operational responsibilities were performed by the company's parent Board committees.

RISK PROFILE

Our risk profile reflects our main business activities, particularly those activities that are to do with creating and selling life insurance products, and unit-linked investment and saving products.

We control the way we accept risks, using our expertise to manage them and create shareholder value from them. The Board approves our risk appetite at least once a year, defining a risk preference for all significant risks.

We categorise our risk exposures under major risk headings. The SCR, split by risk category, is as follows:

€m	End 2017	End 2016
Market risk	722	733
Life Underwriting risk	712	665
Health Underwriting risk	220	207
Counterparty risk	33	40
Requirement before diversification	1,687	1,644
Post diversification	1,277	1,259
Operational risk	81	57
Deferred tax adjustment	(169)	(164)
Total SCR	1,189	1,152

Note: In the table above, we have shown the SCR for each risk category after allowing for the impact of the loss absorbing capacity of technical provisions. This mainly impacts the market risk category. In Appendix 6, the SCR for each risk category is shown before allowing for the loss absorbing capacity of technical provisions, and the loss absorbing capacity of technical provisions is shown separately. Another reason for a difference in the SCRs in comparison to Appendix 6 is how the adjustment for diversification due to ring fenced funds is allocated to the individual SCRs. The presentation of the QRT in Appendix 6 is in line with the EIOPA SFCR guidelines.

Section C. Risk Profile provides further information.

RISK MANAGEMENT MODEL

We manage risk using a three lines of defence model.

• The first line of defence

This is the business divisions and they are the ultimate owners of the risk. Primarily responsible for day-to-day Enterprise Risk Management (ERM) operations within the established ERM Framework, they identify, measure, manage, monitor and report risk.

The second line of defence

This is the oversight function - including the Risk, Compliance, Actuarial and Finance Functions. The Risk Function oversees the ERM framework, using it to challenge the compliance of the first line of defence.

The third line of defence

This is Internal Audit. This team carries out independent risk assessments of the internal risk control framework and the oversight provided by the second line of defence.

You can find out more in section B.3.2 Risk management model - three lines of defence.

VALUATION FOR SOLVENCY PURPOSES

In section D. Valuation for Solvency Purposes we explain how we have valued our assets and liabilities under Solvency II regulations. We compare this to our annual audited financial statements, which are prepared under International Financial Reporting Standards (IFRS). The main differences include deferred acquisitions costs, intangible assets, deferred front end fees, technical provisions, reinsurance recoverables and deferred tax arising from these differences.

Section D.2 Technical Provisions outlines the way we have calculated the amount we need to meet our contractual obligations under the policies we have written using Solvency II regulations. This amount has had an external peer review which the Board has assessed and approved.

CAPITAL MANAGEMENT

Our policy is to manage the capital base so that we meet all regulatory requirements. We also aim to maintain investor, creditor and market confidence, and to make sure there is enough capital to support our future growth. Our business planning process, which considers projections over a five year time frame, informs our capital management.

Our 'Own Funds' are composed of the excess of our assets over the value of our liabilities, where liabilities includes technical provisions and other liabilities. Overall, Available Own Funds have increased by €131m in 2017 to €1,903m (2016: €1,772m) after taking into account the planned dividend payment.

During 2017, we were in compliance with the SCR and MCR requirements.

Further information is provided in section E. Capital Management.

The Board reviewed and approved this report on 30 April 2018.

David Harney,

Chief Executive Officer, Irish Life Assurance plc



This section describes our organisational structure and financial performance over the last financial year.

A.1 BUSINESS

COMPANY NAME:

Irish Life Assurance plc

Name and contact details of the supervisory authority who is responsible for financial supervision of the company:

Central Bank of Ireland New Wapping Street North Wall Quay Dublin 1.

We are a wholly owned subsidiary of Canada Life Limited, a U.K. registered company, via our immediate parent Irish Life Group Limited. The supervisory authority of Canada Life Limited is the Prudential Regulation Authority (PRA).

The contact details for the PRA are: 20 Moorgate, London, EC2R 6DA.

Name and contact details of the external auditor of the company is:

Deloitte
Chartered Accountants and Statutory Audit Firm
Deloitte & Touche House
Earlsfort Terrace
Dublin 2.

Irish Life Assurance plc (ILA) is a member of the Great-West Lifeco group of companies, one of the world's leading life assurance organisations.

Great-West Lifeco (Lifeco) and its subsidiaries, including The Great-West Life Assurance Company (GWL), have approximately \$1.35 trillion Canadian dollars in consolidated assets under administration and at the end of 2017 had approximately 23,300 employees worldwide and are members of the Power Financial Corporation Group of companies. GWL is a wholly owned subsidiary of Lifeco which is incorporated in Canada and listed on the Toronto Stock Exchange.

Lifeco is the indirect parent company of The Canada Life Group (U.K.) Limited (CLG). CLG was established as the EU insurance holding company for GWL's European regulated insurance, reinsurance and asset management companies. CLG is the parent company of Canada Life Limited (CLL) which is a UK based insurance company.

CLL acquired Irish Life Group Limited in 2013. The Irish Life Group has a number of subsidiaries, and ILA is the most significant of these subsidiaries.

Irish Life Investment Managers Limited, Canada Life Asset Management Limited, and Setanta Asset Management Limited are sister companies within CLG. They provide ILA with asset management services and expertise.

Below is a simplified diagram of how our parent company is organised.

GREAT-WEST LIFECO INC.

THE CANADA LIFE GROUP (U.K.) LIMITED

CANADA LIFE LIMITED

IRISH LIFE GROUP LIMITED

IRISH LIFE ASSURANCE PLC

We are the largest life and pensions group in Ireland, serving over one million customers. The Irish Life brand is one of the most established and recognised financial brands in Ireland. Our strong brand is thanks to our large distribution network, product innovation, flexibility, and strong investment performance.

We operate through two main divisions, Irish Life Retail (Retail Life) and Irish Life Corporate Business (Corporate Life). We maintained our market share during 2017 at around 41%.

Retail Life provides pensions, life and investment products to personal and small business customers in Ireland. It leads the market with a comprehensive product range spanning protection, pensions, investment and regular savings products. It has the largest and most diverse distribution network of any life assurance company in Ireland, and has the largest direct sales force.

Retail Life has a multi-channel distribution strategy. This means that sales are split between:

- independent brokers and independently regulated tied agents
- · tied agents in bank branches
- its employed and self-employed sales force.

Retail Life has well established bancassurance arrangements with five of Ireland's leading bank networks (AIB, Ulster Bank, EBS, Permanent TSB and KBC). This gives Retail Life access to over 400 bank branches. Retail Life's total sales in 2017 of €1,873m were significantly ahead of the previous year (2016: €1,401m) due to strong single premium bond and pension sales.

Retail Life uses an external company to help measure customer service every month. At the end of 2017 we achieved our highest ever score of 87% (2016: 85%). This put us in the top quartile of companies for customer satisfaction based on a league table of over 700 companies across all business sectors in Ireland and the U.K.

Corporate Life sells pensions and risk products to employers and affinity groups in Ireland, mainly through pension consultants and brokers.

The key drivers of sales growth for Corporate Life are:

- employment and salary growth in the Irish economy
- the move towards defined contribution pensions, away from defined benefit pensions.

Corporate Life sales increased by over 41% to €1,341m, compared to €950m in 2016, mostly due to a number of large bulk annuities.

A.2 UNDERWRITING PERFORMANCE

We prepare our financial statements under International Financial Reporting Standards (IFRS), as adopted by the European Union. The information in this section about underwriting performance is provided on an IFRS basis.

UNDERWRITING PERFORMANCE

The tables below show the premiums, claims, expenses, and change in technical provisions, combined with the investment return for each of the Solvency II lines of business. We refer to the total of these items as the "underwriting result" in this report.

	2017					
€m	Health insurance	Insurance with profit participation	Index linked and unit-linked insurance	Other life insurance	Total	
Premiums earned (net of reinsurance)	96	2	6,239	733	7,070	
Claims (net of reinsurance)	(54)	(24)	(4,909)	(161)	(5,148)	
Change in technical provisions (net of reinsurance)	(4)	11	(3,332)	(376)	(3,701)	
Expenses	(28)	(1)	(243)	(118)	(390)	
Investment return	11	6	2,307	(21)	2,303	
Underwriting result	21	(6)	62	57	134	

Note: Over 90% of the gross written premiums are undertaken in Ireland.

2016					
€m	Health insurance	Insurance with profit participation	Index linked and unit-linked insurance	Other life insurance	Total
Premiums earned (net of reinsurance)	87	3	4,524	327	4,941
Claims (net of reinsurance)	(47)	(21)	(3,937)	(131)	(4,137)
Change in technical provisions (net of reinsurance)	(20)	8	(2,849)	(167)	(3,029)
Expenses	(26)	(1)	(269)	(164)	(460)
Investment return	12	15	2,576	246	2,850
Underwriting result	5	4	45	111	165

Note: Over 90% of the gross written premiums are undertaken in Ireland.

The different lines of business shown in the tables, and the factors which influence their underwriting performance, are explained as follows:

- (1) Health insurance: This line of business includes group and individual income protection business and group stand-alone serious illness business. The underwriting performance is influenced by:
 - changes in our morbidity experience
 - new business being written in the period.
- (2) Insurance with profit participation: This line of business includes products that offer policyholders bonuses which reflect the fund's experience on investment returns, mortality rates and expenses. The underwriting performance is influenced by:
 - changes in investment markets
 - mortality rates
 - · lapse experience
 - · payouts to policyholders.

Almost all the profits for this line of business are paid out to policyholders, so the profits are offset by an increase in the value of the non-controlling interest in the financial statements.

- (3) Index-linked and unit-linked insurance: This line of business includes unit-linked products, where the unit-linked policyholders bear all the financial risks associated with the related assets. Examples of these products are defined contribution pensions and savings and investment plans. For a small proportion of these unit-linked products, we offer guarantees that protect policyholders from market falls in the underlying investments. The underwriting performance is mainly influenced by:
 - management charges
 - other fee income from the unit-linked business
 - mortality, morbidity and lapse experience for unit-linked protection contracts.
- (4) Other life insurance: This line of business includes our life assurance products such as term assurance products and annuities. The underwriting performance is influenced by:

- · changes in mortality, morbidity and lapse experience
- · new business being written in the period.

The most material variance year-on-year in the underwriting result by product line was on Other Life Insurance, where the underwriting result has reduced from €111m in 2016 to €57m in 2017. This reduction is due to the positive impact of assumption changes on the underwriting result in 2016, which did not reoccur in 2017. The year-on-year variances in the underwriting result for other product lines are mainly driven by the difference in claims and investment experience in 2017 relative to 2016.

RECONCILIATION TO IFRS PROFITS

The table below shows the reconciliation between the underwriting result and IFRS profits.

€m	2017	2016
Underwriting result	134	165
Other income ²	10	16
Tax	(18)	(21)
Profit as per IFRS financial statements	126	160
Attributable to the non-controlling interest ³	(5)	3
Attributable to the Shareholder	131	157

² Other income includes deferred front-end fees, return on shareholder assets, and other items.

We made a profit of €131m after tax for the financial year (2016: €157m). This excludes losses of €(5)m (2016: profit €3m), which is attributed to the participating funds.

Some one-off items affected the profit:

- the impact of changes in the assumptions we use to calculate our insurance and investment contract liabilities was -€3m (2016: +€55m)
- * interest rate changes had an impact of +€5m (2016: -€17m)
- * the termination of a reinsurance treaty created a surplus of +€10m (2016: €nil).

The impacts above are shown net of tax.

A.3 INVESTMENT PERFORMANCE

A.3.1

Non-Linked Investments

The makeup of the asset classes in the portfolio remained largely unchanged throughout the year. The tables below show our investment income and investment performance during each year for each class:

	2017				
Asset Class €m	Dividends	Interest	Rent	Total Income	Gains and Losses
Equity and Unit Trusts	0	-	-	0	4
Fixed Income	-	88	-	88	(86)
Derivatives	-	0	-	0	(10)
Mortgages	-	1	-	1	(1)
Property	-	-	3	3	(3)
Cash and Deposits	-	(1)	-	(1)	(1)
Grand Total	-	88	3	91	(97)

³ Profit attributable to the non-controlling interest includes the underwriting result of -€4m (2016: +€4m) and a tax impact of -€1m (2016: -€1m).

		2016			
Asset Class €m	Dividends	Interest	Rent	Total Income	Gains and Losses
Equity and Unit Trusts	1	-	-	1	2
Fixed Income	-	94	-	94	180
Derivatives	-	0	-	0	(10)
Mortgages	-	1	-	1	(2)
Property	-	-	3	3	5
Cash and Deposits	-	(1)	-	(1)	0
Grand Total	1	94	3	98	174

The 2016 comparatives have been adjusted to be consistent with the disclosures in 2017.

INVESTMENT INCOME

Our net investment income from non-linked funds was €91m in 2017 (2016: €98m), which consists mainly of income from bond products of €88m (2016: €94m). This generated more than 96% (2016: 95%) of our overall investment income, with bonds achieving a rate of return of 2%.

INVESTMENT EXPENSES

Our non-linked investment managers are Irish Life Investment Managers Limited and Canada Life Asset Management Limited, who charge an arm's length fee based on assets under management.

INVESTMENT PERFORMANCE

Global and European sovereign bond yields rose in 2017 from their all-time lows in July 2016 on the back of improving global growth. This was helped by a rise in inflation partly due to the base effects of higher oil prices and expectations of reduced levels of policy accommodation from global central banks.

A.3.2 Unit-Linked Investments

The makeup of the asset classes in the portfolio remained largely unchanged throughout the year. The tables below show our investment income and investment performance during each year for each class:

		2017			
Asset Class €m	Dividends	Interest	Rent	Total Income	Gains and Losses
Equity and Unit Trusts	384	-	-	384	1,326
Fixed Income	-	186	-	186	(133)
Derivatives	-	0	-	-	461
Property	-	-	117	117	1
Cash and Deposits	-	(15)	-	(15)	(8)
Grand Total	384	171	117	672	1,646

2016					
Asset Class €m	Dividends	Interest	Rent	Total Income	Gains and Losses
Equity and Unit Trusts	361	-	-	361	1,358
Fixed Income	-	193	-	193	344
Derivatives	-	0	-	0	65
Property	-	-	126	126	133
Cash and Deposits	-	7	-	7	(1)
Grand Total	361	200	126	687	1,899

INVESTMENT INCOME

Our net investment income from unit-linked funds was €672m in 2017 (2016: €687m) which consists mainly of:

- dividend income of €384m (2016: €361m) which generated 57% (2016: 53%) of our overall investment income.
- income from bond products of €186m (2016: €193m) which generated more than 27% (2016: 28%) of our overall investment income.
- rental returns from properties of €117m (2016: €126m)
 which generated more than 17% (2016: 18%) of our overall
 investment income, from a portfolio of properties held in
 Ireland and the U.K.

Unit-linked funds earned management fee income of €237m (2016: €215m).

INVESTMENT EXPENSES

Our unit-linked investment managers are Irish Life Investment Managers Limited and Setanta Asset Management Limited, who charge an arm's length fee based on assets under management.

INVESTMENT PERFORMANCE

Throughout 2017 economic data in the Eurozone surprised to the upside more so than in other developed countries. This led to a growth premium in favour of the Eurozone compared to the US. The combination of the expectation of reduced levels of policy accommodation from the ECB, and this growth premium, put upward pressure on the Euro, which in turn led to a weaker investment performance in Euro terms.

Global equities generated positive returns over the course of 2017. Positive support for equities has been evident from an improving economic growth and earnings backdrop and relatively attractive valuations compared to other asset classes.

Global and European sovereign bond yields rose in 2017 from their all-time lows in July 2016 on the back of improving global growth. This was helped by a rise in inflation partly due to the base effects of higher oil prices and expectations of reduced levels of policy accommodation from global central banks.

In the Irish property market the largest impact on values in the year was the Finance Bill published in October that increased stamp duty from 2% to 6%, which reduced values by 3.7%. Otherwise, underlying property values have generated positive growth in 2017.

A.3.3 Other information

At the end of 2017 we did not hold investments in off balance sheet securitisation vehicles.

A €2m (2016: €3m) pre-tax gain was recognised in the Statement of Comprehensive Income when we revalued owner occupied property.

We also recognised a €14m (2016: €7m) pre-tax actuarial gain on our defined benefit pension scheme. This was primarily due to investment markets.

A.4 PERFORMANCE OF OTHER ACTIVITIES

There are no items to note.

A.5 OTHER INFORMATION

A.5.1 ILA Ownership Restructure

During 2016, Irish Life Group Limited (ILGL) acquired a 100% shareholding in Canada Life (Ireland) Limited (CLI). CLI distributed its 11.29% shareholding in ILA to ILGL. This means that ILGL now owns 100% of the equity of ILA. The company did not have any structure changes in 2017.

A.5.2 ILA Recapitalisation

On 8 December 2016, we issued €200m of equity to our parent company, ILGL, to facilitate our elected subordinated debt redemption on 8 February 2017. This election resulted in the €200m subordinated debt being successfully repaid on 8 February 2017 as planned.

A.5.3 ILA Subordinated Debt Repayment

On 9 January 2017, we notified the noteholders of the €200m 5.25% step-up perpetual capital notes, that we elected to redeem all of the notes at their principal amount (€200m) on 8 February 2017, the first reset date. The terms and conditions of the subordinated debt allowed us to redeem all of the notes on the first reset date.

On 31 December 2016, we held €200m of additional Tier 1 regulatory capital. This is because, as explained in A.5.2 ILA Recapitalisation, we had issued €200m of equity to our parent company, ILGL, on 8 December 2016 which was settled on the same date. We used these funds to redeem the debt on 8 February 2017.

Our solvency capital was temporarily higher at the end of 2016. This was because the equity issue occurred in 2016, before we redeemed the debt in February 2017. Adjusting for this temporary increase, our solvency ratio outlined in our annual report and financial statements would have been 154% at the end of 2016 (see section E. Capital Management).

A.5.4 Other Information

To facilitate the company's continued expansion, we purchased Block D of the Irish Life Campus from the Irish Life unit-linked property funds in September 2017. The market value of this property was €29m at the end of 2017.



This section describes the structures, systems and processes we have put in place to direct and control our operations and risks so we can balance the interests of our many stakeholders.

B.1.1 Governance structure

The Board of Directors of ILA is responsible for the governance and oversight of all of ILA's operations and risks.

As described in section A.1 Business, the company has two operating divisions: Retail Life and Corporate Life. Retail Life serves individual customers and some small group business. Corporate Life serves larger group business, including corporate customers and affinity groups with a large number of members. You can find more detail in section A. Business and Performance.

Each division has an executive management team, led by a managing director, in charge of day-to-day activities. Each division develops business plans, strategies and annual budgets, which consolidate into a total position for ILA. The divisional managing directors and their executive management teams are responsible for meeting the targets set for each division.

Control functions work at an ILA level. They oversee the primary operating divisions and all other business activities. IT and HR services are also provided at an ILA level.

Business and risk issues can be reported and escalated from the bottom up. Communication and guidance on policy and decisions happens from the top down.

The committees⁴ critical to the governance structure are set out below. A number of the committees are Board level committees,

and their members are Directors of ILA. The other committees

are executive level, and are made up of senior managers. The executive committees help the Board committees meet their

objectives. Control functions support the executive committees

and the Board Risk and Audit Committees. These are discussed in

Board of

Compliance . Management Management Committee

section B.1.5 Key Functions.

Investment Management Committee*

Executive

Operational Committee

* The Executive Investment Management Committee also reports to the Board

and

The executive committees shown in the chart are responsible for ILA and other companies within the Irish Life Group.

Directors Board **Board Nomination** Board Risk **Board Audit** Remuneration Committee Committee Committee Governance Committee

⁴ During 2017 the four Board Committees sat at the Irish Life Group level, ILA's parent company. From April 2018 ILA Board Audit and Board Risk Committees have been established.

	Main function	Main responsibilities
Board of Directors	Lead and control ILA.	 Makes all material strategic decisions. Establishes an organisational structure with clearly defined authority levels and reporting responsibilities. Agrees the rules on management authority levels and what the Board should be notified of.
Board Risk Committee	Responsible for ILA's risk governance, current risk exposures and current and future risk strategy.	 Reviews compliance within the Enterprise Risk Management (ERM) framework and advises the Board on risk oversight. Reviews the company's Risk Appetite Framework and Risk Strategy. Approves the operation of the Irish Life Risk Function, making sure it has the resources, authority and independence to meet its responsibilities. Recommends the appointment of CRO to the Board. Recommends changes to the risk framework. Promotes a company culture that supports risk management. Develops and approves responses when a risk exposure exceeds appetite.
Board Audit Committee	Act as an independent link between the Board and ILA's external auditors.	 Recommends and monitors the choice of external auditors. Reviews the scope of the external audit and reviews the independence of the external auditors. Reviews the company's annual report and financial statements, other public reports and reports we send to the regulatory authorities. Reviews the effectiveness of internal control systems. Manages the risks of financial reporting by reviewing significant financial reports. Reviews financial statements for ILA and Solvency II Pillar I and Pillar III requirements. Reports to the Board on financial statements it needs to approve. Monitors the Actuarial, Compliance, Internal Audit and Finance Functions. Ensures they have the resources, authority and independence to meet their responsibilities.
Board Remuneration Committee	Develop ILA's remuneration policy.	Decides, implements and operates our remuneration policies.
Board Nomination and Governance Committee	Recommend Board and Board Committee appointments to ILA's Board and for keeping the governance arrangements for ILA under review.	 Succession plans for the Board. Makes sure the Board and sub-committees have the right skills and resources. Arranges training for new directors and ongoing training for all directors. Oversee ILA's Corporate Governance.
Executive Risk Management Committee (ERC)	Manage all ILA's material risks, apart from operational and legal/ regulatory compliance risks.	 Oversees risk exposures and recommends suitable risk policy (including insurance risks, market risk, credit risks and liquidity risk). Monitors capital and how assets and liabilities are matched. Reviews new product developments. Approves significant transactions. Monitors and reviews risk experience. Reviews and recommends material risk management matters, including risk mitigations.

Executive Investment Management Committee (EIC)	Manage and oversee all investments undertaken by ILA.	 Reviews and recommends the ILA Investment Policy and monitors its implementation. Monitors and oversees the use of derivatives and stock lending activities. Oversees the performance of, and recommends the appointment or removal of investment managers and custodians. Monitors the operation of unit-linked funds, including the range of investment options available to policyholders. Ensures the management of the non-linked portfolio is aligned to ILA's risk appetite.
Group Operational Risk Committee (GORC)	Oversee and monitor ILA's operational risk including conduct risk.	 Acts as a forum for prioritising and reviewing existing and emerging material operational risks. Designs and monitors key risk indicators attached to these risks. Is supported by two Operational Risk Committees - one for each of ILA's operating divisions.
Compliance Management Committee (CMC)	Establish and oversee regulatory and compliance policies and standards and monitor compliance within the Company.	 Recommends appropriate regulatory and compliance policies and standards. Monitors compliance across the company. Monitors the company's regulatory relationships. Keeps under review the company's consumer protection and market conduct compliance frameworks.


The following table shows the members of our Board and Board Committees at 31 December 2017

Members	Position	Board	Board Audit Committee	Board Risk Committee	Board Remuneration Committee	Board Nomination and Governance Committee
Mr Arshil Jamal	Chairman of the Board, chairman of the nomination and governance committee and non-executive director	Y				Y
Ms Mary Finan	Non-executive director	Υ	Y	Υ		
Mr Brian Forrester	Independent non-executive director and chairman of the risk committee	Y	Y	Y	Y	Y
Mr David Harney	Chief Executive Officer and executive director	Υ				
Mr Cecil Hayes	Independent non-executive director and chairman of the audit committee	Y	Y	Υ	Y	Y
Mr Bill Kyle	Non-executive director	Υ		Υ		
Mr Allen Loney	Non-executive director	Υ		Υ		
Ms Rose McHugh	Independent non-executive director	Υ	Y	Υ	Υ	Υ
Mr Brendan P. Murphy	Independent non-executive director and chairman of the remuneration committee	Y	Y	Y	Y	Y
Mr Derek Netherton	Independent non-executive director	Y		Y	Y	Υ
Company secretary is Mr David Boyle.						

Mr Timothy Ryan resigned as director from 13 September 2017, and Mr Allen Loney resigned as director from 28 February 2018. Mr David Killeen was appointed 23 April 2018.

B.1.2 Key function holders

The organisational chart below sets out ILA's key management and key function holders. It shows our operational and day-to-day management reporting lines. However, in line with the control function mandates, the heads of the control functions have a direct reporting line and responsibility to the Board Committees for oversight matters.



B.1.3 Adequacy of and review of systems of governance

We are committed to best practice corporate governance. We are a high-impact rated entity under the Central Bank of Ireland's risk-based framework for the supervision of regulated firms. This is known as PRISM or Probability Risk and Impact SysteM.

We must comply with the Central Bank's Corporate Governance Requirements for Insurance Undertakings 2015 (the Requirements). These include requirements in relation to the composition of the Board and its Committees. We also submit a compliance statement to the Central Bank each year.

We review our systems of governance each year. We also annually review the performance of the governance committees listed in section B.1.1 Governance structure. This includes assessing their responsibilities and updating charters if appropriate. We commission independent reviews of governance periodically, and there is an independent evaluation of the overall performance of the Board and individual directors every three years.

In line with best practice, we have a strong governance process as shown by the structure outlined above. We support this process by following the Corporate Governance Code and introduced the following changes during 2017:

 extended the remit of the Nomination Committee to include that of a Nomination and Governance Committee established an ILA Executive Investment Management Committee with responsibility for the management and oversight of all investments undertaken on behalf of ILA.

During 2017 ILA was served by Board Audit and Risk Committees which sat at the Irish Life Group level, ILA's immediate parent company. From April 2018 separate ILA Board Audit and Risk Committees have been established.

B.1.4 Remuneration practices

Our Remuneration Policy is designed to attract, retain and reward qualified and experienced employees who will contribute to our success. We use our Remuneration Policy to:

- help generate long-term value for shareholders and customers
- motivate employees to meet annual corporate, divisional and individual performance goals
- encourage employees to achieve goals in line with our Code of Conduct
- align with sound risk management practices and regulatory requirements.

We support the Remuneration Policy with our performance management process. This helps to develop a risk-aware performance culture that reflects our Vision and Values. The process is based on three core principles:

- quality feedback and open conversations
- shared responsibility for the process
- treating staff fairly and recognising their positive contribution.

The umbrella policy for operational risk and the Great-West Lifeco 'Code of Conduct' set out the principles behind our approach to managing the risks associated with our Remuneration Policy.

The principles state that remuneration programmes should:

- promote sound and effective risk management and align with the risk strategy and preferences approved by the Board
- be consistent with business and risk strategy and shareholders' long-term interests
- · be communicated to all staff
- be competitive and fair
- attract, reward and motivate staff to deliver on objectives and achieve success
- be underpinned by clear, effective and transparent remuneration governance.

The Remuneration Policy is also designed to meet our regulatory requirements. We identified and assessed the applicable Solvency II principles around remuneration. Then we set up and documented the following compliance arrangements:

 establishing a Board Remuneration Committee to help the Board carry out its remuneration-related roles and responsibilities; the Remuneration Committee, based on data provided, makes sure we comply with the Remuneration Policy each year

- making sure there are specific remuneration arrangements (programmes) for the Board, senior leaders and the key control functions
- benchmarking base salaries against market rate for the role as defined in independent salary surveys
- assessing all bonus schemes against both personal and financial targets (the financial targets for senior oversight roles are not significantly linked to company performance)
- auditing and risk assessing the Remuneration Policy
- publishing our Remuneration Policy on our employee intranet site.

B.1.4.1 Share options, shares or variable components of remuneration


All remuneration packages consist of:

- a base salary
- annual incentive bonus
- retirement benefits
- benefits during employment.

Senior positions may also include a long-term incentive.

The proportion of each element in the overall package will vary based on the role.

The base salary reflects the skills, competencies, experience and performance level of the individual. Base salaries are based on market rate for the role as defined by independent salary surveys.



We also have an annual incentive bonus scheme that links an individual's overall remuneration to the performance of the company and the performance of the individual. The bonus depends on key business units meeting objectives that are high impact and closely aligned to our critical priorities. However, this does not apply to those in senior oversight roles. Their bonuses are not significantly linked to company performance.

In addition, we have a number of incentive schemes linked to the level of the role (each level attracts different payments for hitting specific targets, and has its own maximum bonus) and, where appropriate, the type of role (for example sales and investment roles). Each staff member has a number of operational and bonus objectives for the year, including an accountability heading of Risk and Management Control. We make our base salaries high enough to prevent employees being overly dependent on their bonuses.

Long Term Incentives are made up of stock options, issued by our parent company, and performance share units.

B.1.4.2

Supplementary pension or early retirement schemes for the members of the management body and other key functions

Our Remuneration Policy does not include any supplementary pension or early retirement schemes for Board members or other key function holders. We offer enhanced early retirement pensions to all members of our Irish Life Group Defined Benefit scheme who are aged over 60 and have completed 40 years' service.

The company has communicated that it is to close its defined benefit pension scheme to future accrual from 30 June 2018 and for existing members to join the company's defined contribution plan for future service pension provision beyond this date. Members will retain the benefits they have accrued up to the date of closure of the scheme and these benefits would still be linked to final salary.

B.1.4.3

Material transactions during the reporting period

There were no material transactions with senior ILA managers in the period, apart from transactions linked to their remuneration and transactions relating to insurance policies conducted on normal commercial terms.

B.1.5 Key functions

In line with the European Regulator's Guidelines on System of Governance, (EIOPA-BoS-14/253), we consider key functions to be Risk Management, Compliance, Actuarial and Internal Audit.

We also view Finance as a key function. Collectively, we refer to these five functions as 'control functions'. Control functions help the Board to manage ILA effectively. Each one reports to either the Board Audit or Risk Committee.

The Board Committee approves the mandate, resources and plans for the control functions annually.

The control functions report to each meeting of the Board Committees. The head of each control function has a direct line of communication with the relevant committee Chair.

Each control function is staffed by professionals with appropriate skills and experience, plus a deep knowledge of our business.

RISK

Overview

This independent second-line function is separate from business operations and looks at them objectively. It has authority across all operating divisions, and access to all ILA records, information and personnel needed to carry out its responsibilities and follow up on issues. In addition, the Chief Risk Officer (CRO) has the right to access, and to attend meetings of, the Board Risk Committee.

The CRO reports to the Board Risk Committee and the Canada Life Group CRO on oversight matters and to the CEO on operational matters and day-to-day management.

The Risk Function/CRO update each meeting of the Board Risk Committee, including producing a quarterly CRO Report.

The Risk Function's operational risk responsibilities are supported by operational risk resources within each business unit.

Main responsibilities

These are outlined in the Risk Function Mandate, which is set by the Board Risk Committee. Encompassing independent oversight of all forms of risk across all our business divisions, the Risk Function's responsibilities include:

- management and oversight of the Risk Appetite Framework
- monitoring and assessing risk culture
- setting risk principles
- · maintaining risk policies
- risk governance
- carrying out risk processes including
 - risk identification, assessment and prioritisation
 - risk measurement and limit setting
 - risk management, responses and mitigation strategies
 - risk monitoring
 - risk reporting

- ensuring that risk infrastructure is effective
- Own Risk and Solvency Assessment (ORSA) process
- · taking part in management committees.

Governance

The Board Risk Committee reviews the Risk Function Mandate annually, and makes sure the Risk Function complies with it. The Committee also assesses the Risk Function's performance each year.

ACTUARIAL

Overview

This independent second-line function is led by the Chief Actuary, who reports directly to the Board Audit Committee and to the Great-West Lifeco Chief Actuary for oversight matters. The Chief Actuary is responsible to the CEO for operational and day-to-day management.

The Actuarial Function is made up of:

- the actuarial reporting teams in each of our two business divisions - these teams carry out most of the actuarial calculations
- the Group valuation and reporting team which reviews, oversees and consolidates the results
- the actuarial development team which develops the actuarial models, processes and mechanisms behind the actuarial calculations.

Main responsibilities

These are outlined in the Chief Actuary Mandate, which is set by the Board Audit Committee. They include:

- calculating the value of our liabilities in relation to our insurance policies and reporting on this to the Board in line with regulatory requirements
- contributing to the effective implementation of our risk management system
- providing oversight of product development, pricing and reinsurance activities
- reviewing Policyholders' Reasonable Expectations (PRE) on an ongoing basis and reporting to the Board on the Head of Actuarial Function's interpretation of PRE
- calculating the value of our liabilities in relation to our life insurance business for inclusion in our financial statements
- providing an opinion to the Board on our underwriting and reinsurance arrangements.

Governance

The Board Audit Committee reviews the Chief Actuary Mandate annually, and makes sure the Actuarial Function complies with it. The Committee also assesses the Actuarial Function's performance each year.

COMPLIANCE

Overview

This independent second-line function is separate from business operations and looks at them objectively. It makes sure we comply with regulations by assessing, monitoring and testing the effectiveness of our regulatory compliance management controls across the company. It is made up of compliance units embedded in Retail Life and Corporate Life, plus a Group compliance unit.

It is led by the Chief Compliance Officer (CCO), Ireland, who is the statutory compliance officer for the company. The CCO reports directly to the Board Audit Committee and to the Great-West Lifeco Chief Compliance Officer on the oversight of compliance, and to the Chief Actuary on operational and day-to-day management.

Main responsibilities

These are outlined in the Compliance Function Mandate which is reviewed and approved annually by the Board Audit Committee. They include:

- creating and maintaining a sound compliance framework for the independent oversight and management of our regulatory compliance risks including those relating to conduct risk and the fair treatment of customers
- giving independent advice and guidance to the business units on regulatory developments and other compliance matters, including advice and oversight on new and changing regulatory requirements
- carrying out risk-based monitoring to assess our compliance requirements and procedures and how well we follow them
- making sure all directors, officers and employees acknowledge our Code of Conduct each year
- preparing the compliance budget and compliance plan and putting them into action
- co-ordinating our relationships with prudential and conduct regulators
- reporting each quarter to the Board Audit Committee and each month to senior management on key regulatory matters
- training our staff and directors on relevant compliance matters.

The Board Audit Committee reviews the Compliance Function Mandate annually, and makes sure the Compliance Function complies with it. The Committee also assesses the Compliance Function's performance each year.

FINANCE

Overview

This function is led by the Chief Financial Officer (CFO) who reports directly to the Board Audit Committee and the Great-West Lifeco European CFO on oversight matters. The CFO is responsible to the CEO for operational and day-to-day management.

It is made up of a central Group Financial Control (GF) team and finance teams in each of our two business divisions.

The divisional finance teams are our first line of defence in the Finance Function. They manage the financial control and reporting needs of their business lines, giving the GF team defined data through a centrally controlled general ledger and reporting platform.

The GF team are our second line of defence in the Finance Function. They review and oversee this data before adopting it for financial and regulatory reporting and performance management. The GF team, through the CFO, give the Board and Board Audit Committee periodic financial and performance updates along with detail that helps the Board assess and approve the annual statutory financial statements and regulatory returns.

Main responsibilities

These include:

- financial control and governance
- reporting statutory and regulatory financial information, including preparing the financial statements
- budgetary, cost and financial management.

Governance

The Board Audit Committee reviews the Chief Financial Officer's Mandate annually and makes sure the Chief Financial Officer is complying with it. The Committee also assesses the Chief Financial Officer's performance each year.

INTERNAL AUDIT

Overview

This function is independent of our business management activities. It is not involved directly in revenue generation, or in the management and financial performance of any business line. Internal auditors have neither direct responsibility for, nor authority over, any of the activities they review. Nor does their review and appraisal relieve others of their responsibilities.

The Chief Internal Auditor (CIA) reports directly to the Chief Internal Auditor for Europe within the GWL group, and to the Board Audit Committee for oversight matters. The CIA is responsible to the CEO for operational and day-to-day management.

Main responsibilities

These include:

 execution of a risk-based audit plan approved annually by the Board Audit Committee

- distributing audit reports to those in the company who are required to take corrective action
- working independently and objectively to assess whether our risk management, governance and internal control processes are appropriately designed and operate effectively
- preparing quarterly reports for the Board Audit Committee summarising audit activity in the quarter, identifying material weaknesses in the internal controls environments, recommendations to remedy material weaknesses and updates on previous recommendations.

Governance

Each year the Board Audit Committee:

- · reviews and approves the mandate of the CIA
- reviews and recommends the appointment/removal of the CIA to the Board
- assesses the performance of the CIA and the effectiveness of the Internal Audit function
- reviews and approves the organisational and reporting structure, department budget and resources.

The CIA maintains direct and unrestricted access to the Board Audit Committee, and meets regularly with the Chair of the Board Audit Committee, without other managers present.

The Board Audit Committee has the authority to promote independence, and make sure audit coverage is broad and audit reports are properly considered.

B.2 FIT AND PROPER REQUIREMENTS

B.2.1

Policies and processes in place to meet fit and proper requirements

We are committed to meeting all our fit and proper requirements. We ensure that everyone involved in this has the necessary qualifications, knowledge, skills and experience to carry out their role (fitness assessment); and is honest, ethical, financially sound and acts with integrity (probity assessment).

There is a job profile for all such roles. Typically, the job profile sets out the accountabilities for the job, the level of knowledge, skills and experience needed to do it, and the essential behavioural competencies.

We have documented HR processes for recruiting into roles that must meet fitness and probity requirements.

We also have a Fit and Proper Policy which the ILA Board reviews and approves annually.

The Fit and Proper Policy sets out the process for the fit and proper assessments that determine a person's fitness, probity and financial soundness.

Before we appoint anyone who effectively runs ILA or has another key function, we carry out due diligence to make sure that person is fit and proper for the role. The due diligence checks for assessing whether a person is fit and proper and is financially sound are set out in the Policy. These checks align to the Central Bank of Ireland's Guidance on Fitness and Probity Standards 2015 as follows:

 evidence of compliance with Minimum Competency Code (where relevant)

- evidence of professional qualifications where relevant
- evidence of Continued Professional Development (CPD) where relevant
- · record of interview and application
- reference checks
- · record of previous experience
- · record of experience gained outside of Ireland
- · confirmation of directorships held, and
- record of other employments.

The due diligence around probity and financial soundness checks takes the form of self-certification. We ask potential employees to complete a questionnaire on their probity and financial soundness. We then carry out independent directorship and judgements searches.

Most of the applicable roles are Pre-Approval Controlled Functions (PCFs) as defined in the Central Bank Reform Act 2010 (sections 20 and 22) Regulations. In addition to our internal due diligence, before making appointments into these functions, they are pre-approved by the Central Bank.

All those in a fit and proper role must reconfirm their adherence to the Fit and Proper standards and requirements every year. If we become aware of any concerns about the fitness and probity of someone in a role subject to the Fit and Proper Policy, we will investigate and take swift, appropriate action. We will also notify the Central Bank of any negative results of the actions we take.

B.3 RISK MANAGEMENT SYSTEM INCLUDING THE OWN RISK AND SOLVENCY ASSESSMENT

The Board manages all risks across the organisation, and has put in place a comprehensive risk management framework.

The framework includes a documented Enterprise Risk Management Policy. This establishes responsibilities for all key components of the risk management system, including the Board and Executive Risk Committees (see section B.1.1 Governance Structure). It also details the three lines of defence model we use, and establishes responsibilities and requirements for the first, second and third lines of defence.

The Board has also generated a Risk Appetite Statement and Risk Strategy document, which outline our appetite for each type of risk and our strategy for accepting, managing and mitigating risks. A further suite of risk policies details the management strategies, objectives, processes, and reporting procedures and requirements for all of the risks we accept.

The Chief Risk Officer (CRO) has primary responsibility for implementing the risk management system. The Risk Function, under the leadership of the CRO, has created processes to make sure we comply with risk policies. It confirms this compliance each year to the Board Risk Committee as part of the annual review of all risk policies. The Risk Function also monitors and reports on all risks. This includes reporting risk exposures and compliance with risk limits to the Board and executive risk committees every quarter.

There are more details of the key components of the risk management framework below. You can find greater detail on our risk profile and risk management strategies, objectives, processes and reporting procedures in section C. Risk Profile.

B.3.1 Enterprise Risk Management framework

Our Enterprise Risk Management (ERM) framework makes sure we can identify and manage all of our material risks, and that we can implement business strategy across the company while fully understanding the risks involved.

There are three broad ways in which each risk type can be treated: capitalisation (hold capital in respect of the risk), management and mitigation. We review the characteristics of each risk so we can identify the appropriate treatment. These reviews weigh up the:

- · current and prospective size and complexity of each risk
- potential impact of the risk
- · transferability of the risk
- market standard treatment of the risk.

The Irish Life Risk Appetite Framework and Risk Strategy documents set out our overall strategy for each type and level of risk we will assume. Our risk appetite may change as our resources and strategic objectives evolve.

We embed the risk appetite and tolerance for specific risks in the business through risk policies. These set out operational procedures, controls and limit structures that establish a risk management framework for each risk type. Together, our risk policies comprise our Risk Policy Framework.

B.3.2 Risk management model – three lines of defence

Risk taking is fundamental to a financial institution's business profile. Prudent risk management, limitation and mitigation are therefore integral to our governance structure.

We operate the 'three lines of defence' risk model shown in the diagram below.



THE FIRST LINE OF DEFENCE

This is the business divisions and our investment managers. As the ultimate owners of the risk, they are primarily responsible for day-to-day ERM operations within the established ERM Framework. They identify, measure, manage, monitor and report risk.

Business divisions are accountable for the risks they assume in their operations from inception throughout the risk lifecycle. They must make sure their business strategies align with the ERM Policy including the Risk Appetite Framework.

First-line responsibilities include:

- diversifying products and services, customers and distribution channels
- developing prudent investment underwriting processes and diversifying by asset type, issuer, sector and geography
- following a disciplined application of pricing standards and underwriting, and conducting extensive testing of the risks involved in new products and offerings

 thoroughly managing the business by regularly reviewing, assessing and implementing relevant changes.

THE SECOND LINE OF DEFENCE

This is the oversight functions – including the Risk, Compliance, Actuarial and Finance Functions.

The Risk Function oversees the ERM framework, using it to challenge the compliance of the first line of defence with it. The Function's specific responsibilities and accountabilities include independently reviewing risk identification, measurement, management, monitoring and reporting.

The Risk Function looks at the work of the Actuarial, Compliance and Finance Functions when assessing compliance with the ERM Framework. It makes sure there are no conflicts of interest and reinforces independence and objectivity. For example, the Risk Function may consider introducing internal peer reviews by another oversight function.

THE THIRD LINE OF DEFENCE

This is Internal Audit. It carries out independent risk-based assessments of the internal risk control framework and the oversight provided by the second line of defence.

Internal Audit independently assures and validates the operational effectiveness and design of the ERM Framework. This includes periodic audits of first- and second-line control processes to help promote effective and efficient operations, integrity of financial reporting, appropriate information technology processes and compliance with law, regulations and internal policies.

B.3.3 Risk appetite and strategy

The Board approved Risk Appetite Statement and Risk Strategy documents set out our appetite for each type of risk, our rationale for accepting risks, and our strategy for the type and level of risk we will assume. Our risk appetite will change as our resources and strategic objectives evolve.

The key objectives in the Risk Appetite Statement are below.

- Customer protection: customer outcomes and the avoidance of customer detriment will be key considerations in determining our strategy - meeting customer needs and expectations is a core principle in the design, distribution and administration of our products and services.
- **Strong capital position:** we maintain a strong balance sheet and do not take risks that would jeopardise our solvency.
- Strong liquidity: we maintain a high quality, diversified investment portfolio with enough liquidity to meet our policyholder and financing obligations under normal and stressed conditions.
- Mitigated earnings volatility: we aim to avoid substantial earnings volatility by managing risk concentration, limiting

exposure to more volatile lines of business and diversifying our exposure to risk.

• **Maintaining reputation:** we consider the potential impact on our reputation in all our business activities.

These objectives support both shareholder and policyholder interests since both are best served if we continue to be financially strong and profitable. Equally, we can only remain profitable if customers, financial advisors and other interested parties are satisfied that we are a secure company.

Risk appetite statements establish the core risk strategy across the business. We develop these statements through an iterative reviewing, monitoring and updating process that involves our key functions. The Board then approves these statements. Our strategic and business plans are aligned with the risk parameters within the risk appetite statement.

We achieve our Risk Strategy goals by embedding a risk awareness culture across all our business activities, and being prudent when taking and managing risks. We focus on:

- diversifying products and services, customers and distribution channels
- prudent investment management and diversifying by asset type, issuer, sector and geography
- disciplined application of pricing standards and underwriting, and extensively testing the risks involved in new products and offerings
- thoroughly managing the business through regular reviews
- safeguarding our reputation by operating a highly ethical business, based on the employee Code of Conduct, and sound sales and marketing practices
- increasing returns to shareholders through profitable and growing operations while maintaining a strong balance sheet.

The Irish Life Risk Appetite Framework sets out limits and thresholds for risks. The Risk Function then monitors these risks and reports on them each quarter to the executive and Board Risk Committee.


The Board sets or adopts risk policies that stipulate the type and level of risk the company is allowed to take on, along with the related risk management and reporting procedures. We then cascade this risk appetite and strategy into the business processes and controls. We establish risk processes and controls for each business division to enforce the specific risk policies approved by the Board.

B.3.4Risk management processes: identification, assessment and treatment

The Risk Function oversees the identification of both existing and emerging risks within the company. Risks are identified from the bottom up as well as the top down. Our business divisions, senior managers, risk specialists and specific risk committees all have significant input to this. We also use our stress-testing framework, which draws on scenario analysis to spot emerging and previously unidentified risks.

We use individual risk assessment frameworks at the divisional level, overlaid with our risk materiality framework, to assess identified risks. Senior managers across the company ratify any risks considered material and the Board Risk Committee then monitors these regularly.

Our risk materiality framework follows the iterative approach in the chart below.



We have three different treatments for the risks we identify, and combine these treatments as appropriate. These treatments are the basis of our risk policies.

- 1. We may hold capital so we remain solvent if the risk impact becomes severe.
- 2. We may manage the risk through controls.
- 3. We may mitigate the risk by choosing not to take it on or transferring it to a third party.

Every year we evaluate the way we categorise risk as part of our Risk Appetite Framework review.

We also run an emerging-risk identification process. This involves the risk teams in the operating divisions, divisional Operational Risk Steering Committees, central risk teams and the Senior Leadership Team

B.3.5 Risk management processes: monitoring, measurement and reporting

We monitor risk appetite limits and risk policy limits against selected measures of risk. We measure our exposure to risk in a variety of different ways, including monitoring sums assured, nominal or market value of exposures, the level of actual deviation from expected outcomes and the range of potential deviations from expected outcomes.

Our risk limits framework is multi-layered to make monitoring, evaluating and limiting risk-taking more effective. We monitor and review exposures regularly, and report to Board and Executive Risk Committees each quarter or more often if required.

The risk limits framework includes:

- limits linked to individual risks
- aggregate risk exposures for different risk categories, measured by how much they contribute to the capital we need.

The table below summarises how we measure different risks. In addition, we use our annual ORSA process to analyse the impact of different risks on company solvency under stress scenarios.

Risk category	The main ways we measure risk
Mortality risk	We measure mortality risk using the sum assured, both gross and net of reinsurance.
Longevity risk	We measure longevity risk by assessing the value of those liabilities that are exposed to it. We consider our exposure both gross and net of reinsurance.
Morbidity risk	We measure morbidity risk using the sum assured, both gross and net of reinsurance.
Expense risk	We measure expense risk using actual, budgeted and projected expense levels.
Lapse risk	We measure and monitor lapse risk by referring to the number of policyholders who surrender their policies early compared to the number we expected to do so.
Credit risk – fixed interest/cash assets	We measure credit risk by referring to the value of the assets we have invested with different counterparties. Our risk policy limits depend on the financial strength of counterparties.
Credit risk – reinsurance counterparties	We measure our exposure to reinsurance counterparties both gross and net of mitigations such as any collateral we hold. We set a minimum rating for the financial strength of counterparties, depending on the type of reinsurance we're looking for.
Equity/property risk	We measure market risks, such as equity/property risk, by referring to the most recent market/fund value of investments, and the value of the management charges we collect from unit-linked funds that invest in equity and property assets.
Interest rate risk	We measure interest rate risk by analysing how the value of our assets and liabilities change when interest rates move.
Liquidity risk	We measure liquidity risk by comparing the quantity of assets we can readily convert into cash to the potential demand we might face for cash.
Currency risk	We measure currency risk by analysing how the value of our assets and liabilities change when exchange rates move.
Operational risk	We measure operational risk, including cyber risk, retrospectively by analysing operational risk losses and near misses; and prospectively by monitoring relevant Key Risk Indicators.
Strategic risk	We do not measure strategic risk directly. Instead, we evaluate the existing and proposed key strategic initiatives that have been approved by the Board.
Legal and regulatory risk	We analyse legal and regulatory risks as part of our compliance framework, and mainly measure them qualitatively through risk reporting.
Customer advice risk	Customer advice is a core process that contributes to operational risk. We monitor and measure it in the same way we do for all other aspects of operational risk. We also report on consumer protection and conduct risk using our compliance framework.

B.3.6 Prudent Person Principle

Our Board approved Investment Policy sets out the criteria we use when we invest our assets.

The Policy makes sure that our approach to investment management follows the Prudent Person Principle defined in Solvency II regulations. The Policy covers the investment of all our assets including unit-linked assets.

The controls and processes set out in the policy make sure we invest in assets and instruments only when we can properly identify, measure, monitor, manage, control and report on their associated risks; and only when we can take these risks into account when we assess our solvency needs. The investment restrictions and requirements in the policy ensure the security, quality, liquidity and profitability of the investment portfolio, and that the assets are available when we need them.

The value of our liabilities change due to changing market conditions – for example when interest rates change or equity prices move. We invest in assets whose values move in a similar way to the liabilities.

Our Investment Policy also establishes principles and controls to manage potential conflicts of interest.

Other controls in the Policy include:

- using derivative instruments only if they help reduce risks or improve portfolio management
- limiting the amount of assets we can hold which are not publicly traded – apart from property assets, and we have minimal exposure to these
- diversifying our assets through strategic asset allocation limits, specified by asset type and individual counterparty exposure limits
- placing strict rules around who we can lend assets to, and what security we need them to provide, whenever we lend assets to other investors in order to increase returns
- how we report and monitor investment positions, and our oversight responsibilities
- the approval process for investment operations.

B.3.7 Credit assessments

We do not rely solely on external credit assessments when we assess the credit quality of counterparties.

We decide on the credit ratings for all fixed interest we take on – including bonds, cash and commercial mortgages, and investments – through an internal credit review by the appointed investment manager. We supplement this with any ratings available from external credit rating agencies. We make sure the

internal rating is not higher than the highest published rating from a major external credit rating agency. We refer to the regulatory guidelines for performing credit assessments and our Risk Function oversees the whole process.

The processes reflect the significance of the counterparty. We complete the rating process in advance of any investment with a new counterparty, and review it at least once each year.

Our Risk Function monitors the credit quality of the investment portfolio, along with our compliance with our investment limits, and reports these to the Executive Risk Management Committee and the Board Risk Committee each quarter.

The Risk Function also monitors and reports the credit quality of reinsurance counterparties to these committees each quarter.

B.3.8 ORSA

We see the Own Risk and Solvency Assessment (ORSA) process as key to our risk management system.

The ORSA evaluates our risk profile and solvency position in relation to business operations, strategy and plan.

Own: Reflects our business model and corporate

structure and is integrated with business plans and

strategy.

Risk: Evaluates risks, including emerging risks, relative

to appetite, and outlines our risk management techniques and risk governance structures.

Solvency: Reviews potential solvency needs under normal

and stress conditions and evaluates capital available compared to requirements.

Assessment: Assesses current and projected risk position and

solvency needs.

The ORSA is a year-round collection of processes, integrating our Enterprise Risk Management (ERM) Framework with capital management and business planning.

The ILA Board has put in place an ORSA Policy that sets out the roles and responsibilities for completing the ORSA. A regular ORSA is carried out each year. A non-regular ORSA may be performed following the occurrence of a material event at an interim date between annual ORSA reports or following a significant change in the Company's risk profile or appetite.

The Board, with significant support from the Board Risk Committee, owns and directs the ORSA, and reviews and approves the ORSA Policy annually. The CRO conducts the ORSA process, producing the ORSA report and maintaining the ORSA record. The Board and Board Risk Committee steer this process, and review and approve the key aspects of the process at various points throughout the year. The annual ORSA process culminates in the ORSA report, which the Board reviews and approves.

The Actuarial Function helps the Risk Function to produce various aspects of the ORSA - capital projections and stress testing in particular. The Head of Actuarial Function also gives an Opinion on the ORSA to the Board.

ORSA is the main link between our risk management system and capital management activities. We have listed the key steps in the ORSA process below. They include an assessment of our solvency capital requirements in light of our risk exposures. We carry out this assessment using the Standard Formula under Solvency II to evaluate our capital requirements, and by developing our own view of the appropriate level of capital. As part of this exercise we consider all the risks we're exposed to over the life-time of the insurance obligations, whether or not these risks are included in the Standard Formula calculation of capital requirements. A key output from the ORSA is an assessment of the level of capital we need to hold, which stems from our current and prospective risk profile.

We evaluate planned business strategies and proposed capital management activities as part of the ORSA process, capturing and reporting on their impact on the ORSA. The annual ORSA report projects our solvency resources for the following five years, under a base case and range of stress scenarios. The base case scenario reflects the approved business strategy and plans, but with certain adjustments where appropriate for the purpose of the ORSA.

We also look at how material developments to the strategy or to the capital position outside of the annual cycle would affect the ORSA.

KEY STEPS IN THE ORSA PROCESS

· Consider the business strategy

The first-line business divisions present the business strategy to the Board to be challenged and approved. The business plans are informed by the findings of the ORSA. This presentation includes a review of the key assumptions underlying the plan, including projected sales, expenses and new business margins. The Board considers the risks associated with the business strategy. Where the proposals include changes that may materially impact the risk profile of the business, those will be reviewed and analysed through an ORSA lens.

· Assess the appropriateness of the Standard Formula

We use the Standard Formula to calculate how much capital we must hold under the regulations. As part of the annual ORSA process the Board evaluates the risk profile of the business based on the assumptions underlying the Standard Formula. This tests whether the use of the Standard Formula is appropriate for our business.

Complete an Own Solvency Needs Assessment (OSNA):

Calculate an Own View of the Capital for the business:
 The ORSA will include our assessment of our Own View of the Capital required for the business, as distinct from the capital which the regulations say we must hold.

Buffer against volatility: The ORSA will include the
assessment of an appropriate additional layer of capital to
hold to make sure we will still meet the capital requirements
under the regulations even after adverse events.

Select stress tests

The Board, supported by the Risk Function, sets the stress and scenario tests we consider as part of the ORSA. The stress tests will be forward looking while also taking experience into account. We weigh up the impact of the stress tests on our business strategy.

Produce the ORSA report

The Risk Function produces an ORSA report and the CRO presents it to the Board. The report includes a solvency projection under the base assumptions as well as the result of the stress tests and an analysis of the results. The base assumptions will be consistent with the Board-approved business plans. The report will note any material changes in the company's risk profile since the previous ORSA and will analyse the projected changes in the company's risk profile over the projection period. The Board reviews and challenges the report. We submit the final report, approved by the Board, to the Central Bank of Ireland.

Review the level of capital held

After considering the insights on our risk profile gained from each of the key steps above, along with other relevant matters, the Board reviews what level of capital we should hold.

Addressing the ORSA findings

The ORSA may generate recommendations such as risk mitigation initiatives or adjustments to business plans. We assign these actions as appropriate to the relevant area, and the Risk Function reports to the Board regularly on our progress in addressing them.

Communicating the ORSA results

The Risk Function communicates the results from the ORSA to the business divisions and other key functions as appropriate.

Embedding the ORSA within decision making

Throughout the year we bring significant new initiatives, such as product development and acquisitions, to the Board for approval. Managers must analyse the impact of these on the ORSA and present their findings to the Board for consideration.

Reviewing risk policies

The Board reviews and approves all risk policies each year. We update our risk policies to reflect the outcome from the ORSA process.

B.4 INTERNAL CONTROL SYSTEM

B.4.1 Internal control framework

We maintain an internal control framework, a set of processes created by the company's board of directors, management and other personnel which gives reasonable assurance that the following objectives will be achieved:

- effective and efficient operations
- reliable financial and management reporting
- · compliance with applicable laws and regulations.

Our internal controls are key to managing significant risks to fulfilling our business objectives.

The Board determines our Internal Controls and Financial Management policy, and each year approves the policy following recommendation from the Board Audit Committee.

Five components of internal control underpin our internal control system.



1. Control Environment

This set of standards, processes and structures is the foundation for all other components of internal control, providing discipline and structure.

2. Risk Assessment

This is the process for identifying and assessing relevant risks to achieving our objectives, and the basis for deciding how to manage those risks.

3. Control Activities

We establish these actions through policies and procedures that help make sure we all carry out management's objectives.

4. Information and Communication

This helps us identify, capture and exchange internal and external information in a form and timeframe that enables us all fulfil our responsibilities.

5. Monitoring Activities

Ongoing evaluation enables us find out whether all components of the internal control system are present and functioning.

Our internal control system demands we have a combination of preventive, detective, directive and corrective control processes in place.

The Canadian Securities Administrators (CSA) requires the CEO and CFO of a company whose securities are publicly traded to verify that they evaluate the design of their Internal Controls Over Financial Reporting (ICOFR) every quarter and that they review the effectiveness of their ICOFR every year. We must comply with this regulation because we are a subsidiary of a Canadian company.

Internal Audit, on behalf of management, tests the design and effectiveness of the key ICOFR controls to make sure we meet the requirements. Each year we review the relevance of these key controls and edit them accordingly so they continue to reflect the existing control environment.

The CFO must review and approve the Internal Controls and Financial Management Policy before it goes forward for Board approval. Each year our Board assesses whether any new internal controls are required and validates the effectiveness of these new (if any) and all existing controls.

B.4.2 Compliance Function

You can find out more about the Compliance Function in section B.1.5 Key Functions above.

B.5 INTERNAL AUDIT FUNCTION

You can find out more about the Internal Audit Function in section B.1.5 Key Functions above.

B.6 ACTUARIAL FUNCTION

You can find out more about the Actuarial Function in section B.1.5 Key Functions above.

B.7 OUTSOURCING

DESCRIPTION OF OUR OUTSOURCING POLICY

When appropriate, we can outsource specific business functions to reduce or control costs, to free internal resources and capital, and to harness skills, expertise and resources not otherwise available to us. However, outsourcing specific business functions may also expose the company to additional risks – risks that we must identify and manage. Our Outsourcing Policy is a Board-approved policy that sets out the principles and requirements for managing outsourcing arrangements.

The Board and senior management retain ultimate responsibility for any functions and activities we outsource. They have the necessary expertise to manage outsourcing risks and oversee outsourcing arrangements.

Our Outsourcing Policy sets out the following general principles for identifying and managing outsourcing risks:

- · outsourcing arrangements must be identified and assessed based on their materiality
- outsourcing arrangements must be appropriately approved
- the capability of proposed service providers for material outsourcing must be thoroughly evaluated
- · outsourcing contracts for material outsourcing must contain certain mandatory terms and conditions
- material outsourcing arrangements must be effectively monitored and controlled by senior management and the executive Group Operational Risk Committee, with oversight from the Board Risk Committee.

We take a prudent and conservative approach to outsourcing.

DETAILS OF OUTSOURCED CRITICAL OR IMPORTANT OPERATIONAL FUNCTIONS AND ACTIVITIES

Internal Provider	Services provided	Jurisdiction
Irish Life Financial Services Ltd (ILFS)	Administration and distribution services for Retail Life within ILA.	Ireland
Irish Progressive Services International (IPSI)	Administration of Self Invested Funds for policy holders.	Ireland
Irish Life Investment Managers Ltd (ILIM)	Investment Management Services	Ireland
Setanta Asset Management Ltd	Investment Management Services	Ireland
Canada Life Asset Management Ltd (CLAM)	Investment Management Services	UK
External Provider	Services provided	Jurisdiction
Investment manager (2 firms)	Investment management services for a small portfolio of assets	Ireland
External consultancy firm	Certain Actuarial services	Ireland
External firm	Administration of a small portfolio of policies	UK
External printing firm	Certain printing and document management services	Ireland

OUTSOURCED KEY FUNCTIONS

We have not outsourced any of the key functions discussed in section B.1.5 Key Functions.

B.8 ANY OTHER INFORMATION

No other items to note.



This section categorises and explains our risk exposures under major risk headings.

Our risk profile reflects our main business activities, particularly those activities that are to do with creating and selling life insurance products, and unit-linked investment and saving products.

We control the way we accept risks, using our expertise to manage them and create shareholder value from them. The ILA Board approves our risk appetite at least once a year.

We outline the main points about our risk profile and management strategy below:

RISK APPETITE

The ILA Board sets our risk appetite, defining a risk preference level for all significant risks. The risk preferences range from 'no appetite' to 'readily accepts'. We have the highest appetite for risks related to core business activities, particularly those related to insurance products and unit-linked investment management services.

RISK STRATEGY: SOLVENCY AND CAPITAL

The main objective of our risk strategy is to keep our commitments while growing shareholder value. This risk strategy involves generating returns to sustainably grow shareholder value through profitable and growing operations, while maintaining a strong balance sheet and taking a conservative approach to risk management.

RISK STRATEGY: CAPITAL USAGE AND GROWTH

We aim to maximise how efficiently we use capital and how well we control the risk to this capital. We achieve this through product design and setting target returns on the capital we invest.

We believe that controlled organic growth is essential to our continued profitability.

RISK STRATEGY: FUNDING

We will self-finance our sales plan and the payment of equity dividends. We do not currently plan to raise any new sources of capital.

In section A.5.3 ILA Subordinated Debt Repayment you can find details about subordinated debt capital which we repaid in February 2017.

RISK EXPOSURES

In this section we describe our main risk exposures and how we assess and mitigate them.

The table below shows our Solvency Capital Requirement (SCR), split by risk type. This is the capital needed to cover the '1 in 200 year' adverse outcome, as set out in the Solvency II regulations. This capital can therefore be viewed as a measure of the total risk exposure to each risk type, net of risk mitigations.

€m	End 2017		End 2016	
Market risk	722		733	
Life underwriting risk	712		665	
Health underwriting risk	220		207	
Counterparty risk	33		40	
Requirement before diversification		1,687		1,644
Post diversification		1,277		1,259
Operational risk		81		57
Deferred tax adjustment		(169)		(164)
Total SCR		1,189		1,152

Note: In the table above, we have shown the SCR for each risk category after allowing for the impact of the loss absorbing capacity of technical provisions. This mainly impacts the market risk category. In Appendix 6, the SCR for each risk category is shown before allowing for the loss absorbing capacity of technical provisions, and the loss absorbing capacity of technical provisions is shown separately. Another reason for a difference in the SCRs in comparison to Appendix 6 is how the adjustment for diversification due to ring fenced funds is allocated to the individual SCRs. The presentation of the QRT in Appendix 6 is in line with the EIOPA SFCR guidelines.

The market risk SCR mainly relates to interest, equity, currency and property risks (see section C.2 Market Risk for more details) and credit risk (see section C.3 Credit Risk for more details). The life and health underwriting risk SCR relates to lapse, expense, mortality, morbidity and longevity risks (see section C.1 Underwriting Risk for more details).

C.1 UNDERWRITING RISK

Insurance (underwriting) risk is linked to contractual promises and obligations made under insurance contracts. Exposure to this risk results from adverse events that occur under specified perils and conditions covered by the terms of an insurance policy.

Insurance risk includes uncertainties around:

- the ultimate amount of net cash-flows (premiums, commissions, claims, pay-outs and related settlement expenses)
- when these cash-flows are received in and paid out
- how the policyholder will behave (e.g. if and when policyholders decide to stop paying into their policies).

RISK DESCRIPTION

Insurance risks comprise mortality, longevity, morbidity, lapse, expense, and catastrophe risks. These risks could cause losses from the changing level, trend or volatility of claims as well as by a single catastrophic event.

Mortality risk

This relates to the risk of loss from higher than expected mortality rates. We are exposed to mortality risks through individual and group insurance policies which pay benefits to insured policyholders upon death.

Longevity risk

This relates to the risk of loss from lower than expected mortality rates. We are exposed to longevity risk primarily through annuity

contracts, where regular payments are made to policyholders while the policyholder is alive.

Morbidity risk

This relates to the risk of loss from higher than expected levels of illness or injury, or lower than expected rates of recovery from illness or injury. We are exposed to morbidity risk when we sell income-replacement contracts (which pay a replacement income to policyholders who are unable to work due to illness or injury) and through specified-illness cover policies (which pay a lump sum on diagnosis of one of a number of specified illnesses).

Lapse risk

This is the risk of losses due to policy-holders ending their contracts early.

Expense risk

This is the risk of losses due to higher than expected expenses that we incur when administering our business. This includes the impact of inflation rates.

Catastrophe risk

This relates to losses caused by catastrophic events, for example a pandemic affecting the population or an industrial accident at a single location. We are exposed to catastrophe risk on our insured business, particularly where we provide group insurance coverage for the lives of many people who routinely work at the same location.

Throughout 2017 we were exposed to each of these insurance risks

RISK ASSESSMENT AND MITIGATION

We use a series of techniques to assess, manage and mitigate underwriting risks.

Own Risk and Solvency Assessment (ORSA)

We assess all material risks, both qualitatively and quantitatively, as part of the annual ORSA process.

Risk limits

We have a series of risk limits that measure risk exposure from different sources of underwriting risk. Our Risk Function monitors these limits and reports on them each quarter to the Executive Risk Management Committee and the Board Risk Committee. By monitoring exposures, we can see trends in the risk profile over time and identify material deviations from business plans or from our appetite for each risk.

Stress testing

We use stress testing as part of the ORSA process to assess risk exposures and their potential impact. Stress testing can also be useful in helping us decide how to mitigate our exposure to risk.

Reinsurance

We set retention limits to restrict the insurance risks we retain that relate to an individual policy or a group of exposures. We reinsure amounts that are more than the limits.

Assumption/experience monitoring

When writing an insurance policy, we make a series of assumptions around the insurance risks that will define the way the policy will perform over the term of the contract. If the actual experience is worse than we assumed, the result will be lower profits or even losses.

Our Actuarial Function investigates insurance risk experience for our main exposures every year. This allows the Chief Actuary and the Board to assess the suitability of the assumptions made when pricing business, setting reserves and calculating the value of our liabilities for inclusion in our financial statements. Each year, after considering recommendations from the Chief Actuary, the Board approves the assumptions used to determine the value of our liabilities in relation to our insurance policies. The Executive Risk Management Committee and the Board Risk Committee also review the insurance risk experience and the results of experience investigations each year.

We monitor risk experience against assumed/expected experience regularly through monthly business division management information, budget tracking and quarterly profit reporting. If this regular monitoring identifies a potential deviation in experience, the Actuarial Function investigates and feeds back into the pricing and reserving processes, as appropriate.

Underwriting

Our underwriting process includes an assessment of insurance risks before we issue policies. This assessment includes a medical underwriting assessment and a financial assessment for certain product lines. We also carry out underwriting assessments when a claim is made.

Risk pricing

We control the development of new products and the pricing of new and existing products to minimise the risk of underwriting risks at a loss. The profitability of new and existing products depends on the applicable experience assumptions used to price the product (e.g. expense, claim and investment experience assumptions).

We monitor the profitability of new business against targets set through our annual budget process. Our operating divisions regularly monitor and report on sales volumes and profitability levels. We report results to the Executive Risk Management Committee and the Board Risk Committee each quarter.

RISK CONCENTRATION

Our insurance concentration risks take a number of forms:

- We operate mainly within Ireland, and a significant portion
 of the Irish population lives in the greater Dublin area, so our
 insurance risk exposure is relatively concentrated to a specific
 place. This is an on-strategy risk for us and we do not seek to
 reduce it.
- Individual policyholders with large sums assured can lead to some concentration risk. We actively manage this risk by using reinsurance. We reinsure large policies so that the retained sum assured is limited to the maximum specified in our Reinsurance & Risk Mitigation Policy.
- We actively write group business and can face site concentration risk for certain corporate schemes. We use reinsurance to manage this risk.
- The sale of bulk annuities can lead to longevity risk exposures
 concentrated in certain industries. Our portfolio is large
 relative to the size of individual bulk annuity arrangements,
 which reduces this concentration risk. We further reduce this
 risk with tailored pricing for each bulk arrangement and by
 using reinsurance.

SENSITIVITIES / STRESS TESTING

You can find out more about the stress testing and sensitivity analysis we carry out in section C.7.1 Risk Sensitivities.

C.2 MARKET RISK

RISK DESCRIPTION

Market risks comprise equity/property risk, currency risk, interest rate risk, inflation risk and liquidity risk (see section C.4 Liquidity Risk). We are willing to accept market risk in certain circumstances as a consequence of our business model and seek to mitigate the risk wherever practical by matching our assets and liabilities.

Equity risk

This relates to losses due to falls in equity prices. We have no significant direct shareholder investments in equity markets. We do give policyholders access to equity markets through unit-linked products. Any gains or losses from those investments are incurred by policyholders. However, we are indirectly exposed to market levels as our charges depend on the value of the unit-linked funds. So if fund values fall due to falls in equity markets, our charges will fall as well. We also have some products, which are now closed, that provide investment guarantees.

Property risk

This relates to losses due to falls in property prices. It is similar to equity risk in that we also have indirect exposure to property market levels through charges collected from unit-linked funds. In addition, we have some direct property holdings, mainly owner-occupied premises.

Currency risk

This relates to losses due to changes in currency exchange rates. We have no significant direct exposure to currency market levels, as we hedge exposures that arise. It is similar to our equity risk exposure, in that we have indirect exposure to currency markets. If a change in currency exchange rates affects the value of unit-linked funds, it will also affect the value of the charges we collect.

Interest rate risk

This relates to losses due to changes in interest rates. The values of our liabilities linked to insurance policies are sensitive to prevailing long-term interest rates. However, we largely mitigate this exposure by holding assets whose values also move when interest rates change, offsetting the change in the values of our liabilities.

Inflation risk

This relates to losses due to changes in inflation rates. Some of our policies pay benefits to policyholders that increase in line with prevailing inflation rates, so higher than expected inflation rates may lead to losses. We partly mitigate this risk by holding assets that have a higher return when inflation rates are higher.

Defined benefit pension schemes

An indirect source of our market risks relates to the risk of economic loss caused by uncertainty around required contributions to our defined benefit pension schemes.

We consider this risk to be a part of expense risk as a deterioration in the pension scheme position could lead to the need for greater contributions from the employer, which would increase expenses. Deterioration in the pension scheme position would stem from adverse market movements affecting the value of the pension scheme's assets or liabilities.

RISK ASSESSMENT AND MITIGATION

We use a series of techniques to assess, manage and mitigate market risks.

ORSA

We assess all material risks, both qualitatively and quantitatively, as part of our annual ORSA process.

Risk limits

We have a series of risk limits that measure market risk exposure from different sources. Our Risk Function monitors these limits and reports on them each quarter to the Executive Risk Management Committee and the Board Risk Committee. By monitoring exposures we can see trends in the risk profile over time and identify material deviations from business plans or from our appetite for each risk.

Stress testing

We use stress testing as part of the ORSA process to assess risk exposures. Stress testing can also be useful in helping us decide how to mitigate our exposure to risk.

Asset Liability Matching (ALM)

We invest in matching assets to mitigate the market risks linked to policy liabilities.

- We invest in unit-linked assets to match the surrender value of unit-linked policies.
- We mitigate the interest rate and inflation rate exposure of non-linked products by matching liabilities with appropriate assets. That means the value of the liabilities and assets move by similar levels when interest rates change. The residual exposure of the insurance business to interest rate movements is low.
- We mitigate currency risk by holding assets of the same currency as liabilities or by hedging currency risks that arise.

Equity hedge

We operate an equity hedge to partially mitigate residual exposure to equity risk.

Reinsurance

We reinsure some market risks linked to certain legacy unit-linked products that gave investment guarantees to policyholders.

Prudent investment strategy

We invest our assets prudently, including assets that back policy

liabilities and other shareholder assets. This is in line with the Prudent Person Principle, as required by Solvency II regulations. You can find out more in section B.3.6 Prudent Person Principle about how we apply this. Our investment principles include:

- establishing strategic asset limits to make sure our investments are appropriately diversified
- maintaining a high level of liquidity, above the level we foresee we will need
- restricting the use of derivatives to make sure we only hold these instruments to manage investments efficiently or reduce investment risk
- keeping shareholder investments in equity/property assets low

The Executive Investment Management Committee also oversees our market risks through its oversight of the company's investments.

RISK CONCENTRATION

Our shareholder assets include owner-occupied properties in a single campus in central Dublin. Other than these assets, we do not have any significant concentrated holdings of individual equity or property assets.

You can find out more about concentration risks linked to our fixed interest assets holdings in section C.3 Credit Risk.

SENSITIVIES / STRESS TESTING

You can find out more about the stress testing and sensitivity analysis we carry out in section C.7.1 Risk Sensitivities.

C.3 CREDITRISK

RISK DESCRIPTION

Credit risk relates to risks from a counterparty's potential inability or unwillingness to meet its obligations. Our counterparties include sovereign governments and corporate entities who issue fixed interest assets, reinsurers, insurance intermediaries, policyholders and derivative counterparties.

Our main source of credit risk is investments in fixed interest assets issued by borrowers, including sovereign governments and corporate entities. These assets are highly liquid and traded on various market exchanges. Credit risk also stems from deposits and other assets we place with banks.

We cede insurance risk to mitigate insurance risk, and are therefore willing to accept reinsurance counterparty risk. Similarly, we are willing to accept derivative counterparty risk because we use derivatives to mitigate other risks.

We are also willing to accept credit risk that results from our business model, e.g. through our dealings with group clients, brokers, intermediaries, policyholders, suppliers, service providers etc.

RISK ASSESSMENT AND MITIGATION

We use a series of techniques to assess, manage and mitigate credit risk.

ORSA

We assess all material risks, both qualitatively and quantitatively, as part of the annual ORSA process.

Risk limits

We have a series of risk limits that measure credit risk exposure from different sources. Our Risk Function monitors these limits and reports on them each quarter to the Executive Risk Management Committee and the Board Risk Committee. By monitoring exposures we can see trends in the risk profile over time and identify material

deviations from business plans or from our appetite for each risk.

Stress testing

We use stress testing as part of the ORSA process to assess risk exposures. Stress testing can also be useful in helping us decide how to mitigate our exposure to risk.

Prudent investment strategy

Our overarching investment strategy involves targeting a diversified portfolio of assets from counterparties that are in the upper tier for credit quality. We establish limits in the ILA Investment Policy by referring to aggregate portfolio and individual counterparty limits, as applicable. We then link these to credit ratings that assess the financial strength/creditworthiness of counterparties. Implementation of this investment strategy is overseen by the Executive Investment Management Committee, Executive Risk Management Committee, and the Board.

Reinsurance

In relation to our reinsurers, we deal only with counterparties that meet the specific creditworthiness requirements outlined in our Reinsurance & Risk Mitigation Policy. We actively monitor the financial strength of our reinsurers. We also seek contractual protection such as offset rights and collateral where appropriate.

RISK CONCENTRATION

We have set fixed interest and cash counterparty credit risk limits within our Investment Policy to manage credit concentration risk. Our largest counterparty is the German sovereign.

Our operations also lead to some concentration risk exposure linked to reinsurance counterparties. We diversify across reinsurers to reduce this risk, although only a few reinsurers are active in Ireland. We also look for collateral, where appropriate, to reduce the risk.

SENSITIVITIES / STRESS TESTING

You can find out more about the stress testing and sensitivity analysis we carry out in section C.7.1 Risk Sensitivities.

C.4 LIQUIDITY RISK

RISK DESCRIPTION

Liquidity risk stems from a company's inability to generate the necessary funds to meet its obligations as they fall due.

Our business model does not lead to significant liquidity risk as we hold assets that are greater than the value of our liabilities. Our business model is also cash-generating.

RISK ASSESSMENT AND MITIGATION

We monitor and assess potential liquidity risk regularly.

Day-to-day/expected liquidity strains

For day-to-day liquidity needs, we maintain adequate funds in instant-access bank accounts. Our Finance Function monitors and maintains balances daily.

The need to pay policyholders is the main generator of ongoing liquidity needs. For unit-linked policies, we fund claims by selling the unit-linked assets. For non-linked policies, we make sure liquid resources are available when we need them by investing in assets that generate cash when we need it to pay benefits to our policyholders.

Unexpected liquidity strains

Unexpected liquidity strains can stem from a number of sources. These include higher-than-expected insurance claims and collateral calls linked to derivatives or reinsurance arrangements. Liquidity strains could also arise from higher than expected policyholder encashment requests, and the assets held by ILA prove to be difficult to liquidate - for example, high levels of surrender requests from unit-linked property funds may cause a liquidity strain if the underlying properties held by the funds are difficult to sell in a timely manner.

We invest our assets to make sure we have ample liquidity to meet unexpected liquidity needs. Our Investment Policy establishes minimum and maximum strategic investment limits for different liquid and illiquid asset categories.

We hold significant assets to provide solvency capital cover for the company. These act as a buffer for unexpected liquidity strains.

SENSITIVITIES / STRESS TESTING

The Risk Function carries out regular stress testing to make sure we have sufficient liquidity to meet conceivable needs, even during times of severe strain. We report the results of stress testing each quarter to the Executive Risk Management Committee and the Board Risk Committee.

The stress testing considers the potential liquidity strains we face. We compare these liquidity strains to the available liquid assets to make sure the available assets exceed our requirements.

RISK CONCENTRATION

As noted earlier, most of our insurance risks are located in Ireland. The associated concentration risk could lead to material liquidity strains from higher-than-expected insurance claims, as described above. And as explained above, high levels of surrender requests from unit-linked property funds could cause some liquidity strain. Most of the properties held by these funds are located in Ireland.

Our stress testing of liquidity risk captures these factors, and we hold ample liquidity to address the risk.

C.4.1 Expected profit included in future premiums

The regulations require us to state in this report the amount of expected profit included in future premiums.

This is relevant for contracts where we allow for expected future premiums when we calculate the value of our liabilities, in line with the regulations. For ILA, this includes non-linked protection contracts, unit-linked protection contracts and group risk contracts. For these contracts, the expected profit in future premiums is the amount by which, allowing for the receipt of future premiums, reduces the values of our liabilities, net of reinsurance.

At the end of 2017, expected profit included in future premiums was €250m (2016: €207m) gross of tax. As this figure contributes to the Own Funds of ILA, it increases the assets we have available to cover our required capital. The amount of capital we have to hold also increases as a result of recognising these future premiums, and so this amount is not available as free capital to ILA.

When we assess whether our liquid resources are adequate, as described above, we do not count the expected profit included in future premiums as it is not a liquid asset.

C.5 OPERATIONAL RISK

RISK DESCRIPTION

Operational risk is the risk linked to inadequate or failed internal processes, people and systems or from external events. Operational risks relate to all business processes.

We accept limited operational and other risks as part of our business model. However, we have controls in place to mitigate them through integrated and complementary policies, procedures, processes and practices, keeping in mind the cost/ benefit trade-off.

We advise customers, and this brings its own operational risks. We use best management practices to mitigate and manage this risk.

Operational risks also include the risk of failing to identify and comply with new or emerging legal and regulatory requirements. To mitigate such risks and factor them in to new business decisions, we monitor regulatory developments closely, keep in regular contact with relevant regulators and capitalise on our internal communication processes.

Strategic risk stems from the potential inability to implement appropriate business plans and strategies, make decisions, allocate resources or anticipate business change. We instigate strategic risk management at the individual business division level and consolidate it upwards. Our senior leadership team makes decisions at the ILA level for subsequent review and approval by the Board.

RISK ASSESSMENT AND MITIGATION

The Group Operational Risk Team, which sits within the Risk Function, co-ordinates operational risk management activities. In addition, the Internal Audit Function is key to auditing the processes and associated controls that manage operational risks.

We record operational risks, their associated controls and associated loss events for each of our business divisions. We identify our top operational risks and assess them for specific monitoring. We maintain Key Risk Indicators (KRIs) for each top operational risk, and report on these each quarter as part of a risk dashboard to the Group Operational Risk Committee (GORC). This committee escalates operational risk issues as appropriate to the Board Risk Committee. The GORC also receives quarterly reports on actual loss events and additional reporting on

significant losses. We also monitor a series of risk limits and report on them each quarter to the GORC. In addition, the Risk Function reports risk limits and operational KRIs each quarter, with additional commentary, to the Board Risk Committee.

As part of the annual ORSA process, we assess our operational risks both qualitatively and quantitatively.

Business Continuity Planning (BCP) is key to mitigating operational risks. It helps ensure continuity of business in a crisis situation. The BCP framework requirements that apply across our business are set out in a Board-level policy for Business Continuity Management.

Stress testing is a key tool in assessing operational risks. We carry out a range of operational risk stress tests each year. These help us develop our approaches to mitigation and management of operational risk.

We will not take on opportunities if we think they pose a risk to our reputation. When we design products and advice processes for customers, we consider any potential impact on our reputation.

As part of a large insurance group, we have a number of relationships with other group companies and rely on them for certain services.

We have formal outsourcing agreements in place to manage external and inter-group outsourcing arrangements. These agreements set out the responsibilities of both parties and we monitor and review them regularly. This level of formality ensures we manage the associated risks with appropriate rigour.

RISK CONCENTRATION

Our business operations and policy administration are based mainly in a single campus in Dublin, so we have centred most of the servicing of policies here too. We have partially mitigated the associated concentration risks through business continuity planning. In case of an incident at the Dublin campus, we use offsite centres for data backup and restoration.

We have noted other concentration risks, such as providing insurance products within Ireland, in sections C.1 Underwriting Risk to C.4 Liquidity Risk above.

C.6 OTHER MATERIAL RISKS

No other items to note.

C.7 ANY OTHER INFORMATION

C.7.1

Risk sensitivities

We use a number of sensitivity tests to understand the volatility of our capital position. We regularly produce sensitivity tests on our key risk exposures to help inform our decision-making and planning processes, and as part of the framework we use to identify and quantify our risks.

Like every long-term business, we make a number of assumptions when we compile our financial results. These assumptions relate to future expense, mortality and other insurance experience rates, and lapse rates. Our assumptions are informed by an analysis of historic and expected experience.

We have set out the results of key risk sensitivity tests below. We produce these results from our financial reporting models. For each sensitivity test, we have shown the impact of a change in a single factor, and left other assumptions unchanged. You can see the change in our Solvency Capital Requirements (SCR) coverage ratio that would result from the sensitivities shown.

INTEREST RATES

The impact of a 0.5% increase or decrease in market interest rates. The test considers the impact on the value of our liabilities, net of reinsurance, offset by changes to the value of the assets we hold.

CREDIT SPREADS

The impact of a 0.5% increase in credit spreads on corporate bonds and our other non-sovereign assets. The test considers the impact on the value of our liabilities, net of reinsurance, offset by changes to the value of the assets we hold.

EQUITY/PROPERTY MARKET VALUES

The impact of a 10% fall in the market value of our equity and property assets.

EXPENSES

The impact of a permanent 10% increase in maintenance expenses.

LAPSES

The impact of a permanent 10% increase or decrease in policyholder lapse rates.

MORTALITY

The impact of a permanent 5% increase in mortality rates, excluding the mortality rate of the people we pay annuities to.

MORBIDITY

The impact of a permanent 5% deterioration in morbidity. We assume a 5% increase in incidence rates and a 5% reduction in recovery rates for those products where these assumptions are relevant.

ANNUITANT MORTALITY

The impact of a permanent 5% decrease in the mortality rate of the people we pay annuities to.

The table below shows the sensitivity test results as they impact the SCR coverage ratio. These sensitivities have been selected on the basis of our key risk exposures. We accept these risks in line with the Company's business strategy and risk appetite.

Sensitivity Test	Impact on SCR Coverage Ratio 2017	Impact on SCR Coverage Ratio 2016
0.5% increase in interest rates	+8%	+10%
0.5% decrease in interest rates	-9%	-8%
0.5% increase in credit spreads	+17%	+20%
10% fall in equity and property values	-5%	-4%
10% increase in maintenance expenses	-5%	-4%
10% increase in policy lapse rates	+3%	+3%
10% decrease in policy lapse rates	-3%	-3%
5% increase in mortality rates (assured lives)	0%	-1%
5% deterioration in morbidity rates	-3%	-3%
5% decrease in annuity mortality rates *	-4%	-3%

Changes in sensitivities between 2017 and 2016 reflect portfolio growth, changes to asset mix and underlying changes in market interest rate and asset prices.

C.7.2

Use of Special Purpose Vehicles

The regulations require us to include in this report details of any Special Purpose Vehicles (SPVs) we use to transfer risks off our balance sheet.

We do not use SPVs in this way. We do hold some SPVs as part of our investment activity, but we recognise the associated risks appropriately on our balance sheet.

^{*} The 2016 figures have been reclassified in order to present information on a basis consistent with the current year.



D.1 ASSETS

This section is about our valuation of each kind of asset for Solvency II basis. This includes explanations of:

- 1. how the value of each asset for Solvency II is different from valuing it for statutory financial reporting purposes that meets the EU's International Financial Reporting Standards (IFRS).
- 2. the valuation bases, methods and main assumptions used for Solvency II and those used for statutory IFRS financial statements for the financial year ended 31 December 2017.

The Solvency II Balance Sheet is in Appendix 1.

1. VALUATION DIFFERENCES - SOLVENCY II V IFRS

Balance Sheet Extract - Assets

The IFRS values in the following tables are as recorded in our annual report and financial statements. The Asset Type categorisation here is per the Solvency II balance sheet and not directly comparable to categorisation applied in the IFRS Statement of Financial Position.

2017					
Asset Type (€m)	Note	IFRS	Reclassification Adjustments	Valuation Adjustments	Solvency II
Deferred Acquisition Costs	1	289	0	(289)	0
Intangible assets	2	10	0	(10)	0
Property, plant & equipment held for own use	3	110	0	0	110
Property (other than for own use)	4	23	0	0	23
Equities	5	54	0	0	54
Government Bonds	6	3,064	0	0	3,064
Corporate Bonds	6	1,879	0	0	1,879
Collateralised securities	6	50	0	0	50
Investment funds	7	52	0	0	52

2017					
Asset Type (€m)	Note	IFRS		Valuation Adjustments	Solvency II
Derivatives	8	8	0	0	8
Deposits other than cash equivalents	9	60	0	0	60
Unit linked assets	10	40,196	0	0	40,196
Loans and Mortgages	11	53	0	0	53
Reinsurance recoverables	Section D.2	1,953	0	(366)	1,587
Insurance & intermediaries receivables	12	28	0	0	28
Reinsurance receivables	13	87	0	0	87
Cash and cash equivalents	9	79	0	0	79
Any other assets, not elsewhere shown	14	104	0	0	104

2016					
Asset Type (€m)	Note	IFRS	Reclassification Adjustments	Valuation Adjustments	Solvency II
Deferred Acquisition Costs*	1	267	0	(267)	0
Intangible assets	2	13	0	(13)	0
Property, plant & equipment held for own use	3	79	0	0	79
Property (other than for own use)	4	22	0	0	22
Equities	5	74	(13)	0	61
Government Bonds	6	2,828	(1)	0	2,827
Corporate Bonds	6	1,872	0	0	1,872
Collateralised securities	6	65	0	0	65
Investment funds	7	172	0	0	172
Derivatives	8	14	0	0	14
Deposits other than cash equivalents	9	89	0	0	89
Unit linked assets	10	36,838	13	0	36,851
Loans and Mortgages	11	20	0	0	20
Reinsurance recoverables	Section D.2	2,376	0	(419)	1,957
Insurance & intermediaries receivables	12	46	0	0	46
Reinsurance receivables	13	102	0	0	102
Cash and cash equivalents	9	50	0	0	50
Any other assets, not elsewhere shown	14	128	1	0	129

 $^{^{*}}$ The 2016 comparatives have been adjusted to be consistent with the disclosures in 2017.

2. VALUATION BASES, METHODS AND MAIN ASSUMPTIONS - SOLVENCY II V IFRS

Solvency II sometimes uses a different set of valuation bases, methods and main assumptions than companies use for IFRS statutory financial statements. In this section we show where there are differences, and what those differences are, across various asset types as they apply for the financial year ended 31 December 2017.

Note 1: Deferred Acquisition Costs

Solvency II purposes:	IFRS reporting purposes:
As per Article 12 of the Delegated Act, Deferred Acquisition Costs are valued at nil for Solvency II purposes.	Acquisition costs for investment contracts represent those costs directly associated with acquiring new investment management service contracts. The company defers these costs to the extent that they are expected to be recoverable out of future revenues to which they relate.

Note 2: Intangible Assets

Solvency II purposes:	IFRS reporting purposes:
As per Article 12 of the Delegated Act, intangible assets are valued at nil for Solvency II purposes, unless the intangible asset can be sold separately, and the company can demonstrate that there is a value for the same or similar assets derived in accordance with Article 10 of the Delegated Act.	Computer Software Computer software is carried at cost, less amortisation (over a period of three to fifteen years) less provision for impairment, if any. The external costs and identifiable internal costs of acquiring and developing software are capitalised where it is probable that future economic benefits that exceed its cost will flow from its use over more than one year.
	Purchased shareholders' value of in force (VIF) business We have two business portfolios of long-term insurance and investment contracts that we acquired from other companies. The fair value of the portfolios is based on the net present value of the shareholders' interest in the expected cash flows of the in-force business. On acquisition of these contracts the fair value was capitalised in the statement of financial position as an intangible asset. That part of the shareholders' interest which will be recognised as profit over the lifetime of the in-force policies is amortised and the discount is unwound on a systematic basis over the anticipated life of the related contracts (up to 20 years). All intangible assets are subject to an impairment review at least once a year. Events or changes in circumstances might mean that the carrying amount is not recoverable. If that is the case, it is written down through the income statement by the amount of any impairment loss identified in the year.

Note 3: Property, plant and equipment held for own use

Solvency II purposes:

Property

Owner Occupied Properties (OOP) are carried at fair value with changes in fair value included in the income statement within investment return.

External chartered surveyors value OOP at least once a year at open market value. This is in accordance with the Appraisal and Valuation Standards published by the Royal Institution of Chartered Surveyors (RICS) in UK and Ireland and follows the guidelines on the most appropriate way to value OOP.

The company revalues OOP at least once a quarter, using a commercial property price index as a guide. The revalued premises, excluding the land element, are depreciated to their residual values over their estimated useful lives (50 years), which the directors assess once a year.

Plant and Equipment

Plant and equipment are stated at cost, less accumulated depreciation and impairment losses. This valuation is assumed to materially approximate the fair value of these assets.

The company calculates depreciation to write off the costs of such assets to their residual value over their estimated useful lives, which the directors assess once a year. The estimated useful lives are as follows:

Office equipment 5 - 15 years Fixtures and fittings 5 - 15 years Computer hardware 3 - 10 years Motor vehicles 5 years

IFRS reporting purposes:

Property

External chartered surveyors value owner occupied properties (OOP) at least once a year at open market value. This is in line with IAS 40 Investment Property and IFRS 13 Fair Value Measurement and with guidance set down by their relevant professional bodies (RICS).

An increase in the fair value is included within the statement of other comprehensive income ("OCI"). In the event of a decrease in the fair value, the amount is included in the OCI where a revaluation surplus exists. Where no surplus exists, the amount is recognised in the income statement as an impairment. For Solvency II, all fair value movements are recorded in the income statement.

Plant and Equipment

There is no valuation difference between Solvency II and IFRS basis.

Note 4: Property (other than for own use)

'Property (other than for own use)' means property we are holding for long-term rental yields and capital growth. It can be land or buildings.

Solvency II purposes:

Investment properties are carried at fair value with changes in fair value included in the income statement within investment return.

External chartered surveyors value property at least once a year at open market value. This is in line with the Appraisal and Valuation Standards published by the Royal Institution of Chartered Surveyors (RICS) in UK and Ireland and follows the guidelines on the most appropriate way to value property. Fair values take into account the highest and best use of the property and are based on yields which are applied to arrive at the property valuation.

Investment properties are revalued at least once a quarter using a commercial property price index as a guide.

IFRS reporting purposes:

External chartered surveyors value property at least once a year at open market value. This is in line with IAS 40 Investment Property and IFRS 13 Fair Value Measurement and with guidance set down by their relevant professional bodies (RICS).

There is no valuation difference between Solvency II and IFRS basis.

Note 5: Equities

Equities include common shares, preferred shares and exchange traded funds.

Solvency II purposes:	IFRS reporting purposes:
The company values quoted equities based on the fair value determined by the closing bid price from the exchange where they are principally traded.	There is no valuation difference between Solvency II and IFRS basis.
Management value unquoted equities in line with principles set down by the European Venture Capital Association. They present an unquoted report to the board at least once a year for review and approval.	

Note 6: Government Bonds, Corporate Bonds and Collateralised Securities

Solvency II purposes:	IFRS reporting purposes:
The company values bonds based on the fair value determined by referring to quoted market bid prices. These are primarily from third-party independent pricing sources. If there are price movements above specified tolerances, the company makes sure those movements are correct by checking a second pricing source.	There is no valuation difference between Solvency II and IFRS basis.
Where prices are not quoted in an active market, the company determines fair values by valuation models. The company maximises the use of observable inputs and minimises the use of unobservable inputs when measuring the fair value. The company uses a 'mark to model' valuation basis to determine a value appropriate to the industry sector. The model uses public bond spread data as a proxy for current spreads on fixed-interest assets. The company then uses this to develop a yield curve to discount the cash flows underlying the private placement to obtain its value.	
For a limited number of small exposures or short duration bonds, the company uses amortised cost as a proxy for the mark to model valuation basis.	

Note 7: Investment Funds

Investment funds principally include Money Market Funds (MMFs).

Solvency II purposes:	IFRS reporting purposes:
The company values MMFs at fair value based on a quoted market price where the asset is traded.	There is no valuation difference between Solvency II and IFRS basis.

Note 8: Derivatives

Derivatives include:

- currency forward rate contracts
- currency and interest rate swaps
- · futures contracts
- forward rate agreements and options.

Solvency II purposes:	IFRS reporting purposes:
The company values derivatives based on a counterparty valuation which is verified by an independent third-party valuation service.	There is no valuation difference between Solvency II and IFRS basis.
The company obtains fair values from quoted prices prevailing in	
active markets, where available. Otherwise, the company values	
the instruments using valuation techniques including discounted	
cash-flow analysis and option pricing models.	

Note 9: Deposits other than cash equivalents; Cash and cash equivalents

'Deposits other than cash equivalents' means deposits we hold for investment purposes. 'Cash and cash equivalents' means cash we have in a bank or deposit account we hold ready to use for business operations.

Solvency II purposes:	IFRS reporting purposes:
The company values cash and deposits at their face value.	There is no valuation difference between Solvency II and IFRS basis.

Note 10: Unit-Linked Assets

We hold unit-linked assets for the benefit of policyholders. They are made up of several kinds of investment assets, primarily:

- 1. property
- 2. equities
- 3. bonds
- 4. derivatives
- 5. deposits.

Both the Solvency II balance sheet and the IFRS statutory balance sheet present unit-linked assets as one line.

Note 10.1: Property (other than for own use)

This means property we are holding for long-term rental yields and capital growth. It can be land or buildings.

Solvency II purposes:	IFRS reporting purposes:
The company carries investment properties at fair value, with changes in fair value included in the income statement within investment return. External chartered surveyors value property at least once a year at open-market value. This is in accordance with the Appraisal and Valuation Standards published by the Royal Institution of Chartered Surveyors (RICS) in UK and Ireland and follows the guidelines on the most appropriate way to value property. Fair values take into account the highest and best use of the property and are based on yields which are applied to arrive at the property valuation. The company revalues investment properties at least once a quarter, using a commercial property price index as a guide.	External chartered surveyors value property at least once a year at open-market value. This is in line with IAS 40 Investment Property and IFRS 13 Fair Value Measurement and with guidance set down by their relevant professional bodies. This does not give rise to any valuation difference between Solvency II and IFRS basis.

Note 10.2: Equities

Equities include common shares, preferred shares and investments in collective investment schemes.

Solvency II purposes:	IFRS reporting purposes:
The company values quoted equities based on the fair value determined by the closing bid price from the exchange where they are principally traded.	There is no valuation difference between Solvency II and IFRS basis.
Management value unquoted equities in accordance with principles set down by the European Venture Capital Association. An unquoted valuation report is presented to the board at least once a year for review and approval.	
The external manager values unlisted unit trusts using the latest published Net Asset Value (NAV). For funds providing daily liquidity, the most recent NAV for underlying listed unit trusts is rolled forward using the latest performance statistics that the relevant external manager has provided.	

Note 10.3: Bonds

Bonds include government bonds, corporate bonds and collateralised securities.

Solvency II purposes:	IFRS reporting purposes:
The company values bonds based on the fair value determined by referring to quoted market bid prices. These are primarily from third-party independent pricing sources. If there are price movements above specified tolerances, the company makes sure those movements are correct by checking a second pricing source. Where prices are not quoted in an active market, the company determines fair values by valuation models. The company maximises the use of observable inputs and minimises the use of unobservable inputs when measuring the fair value. The company uses a 'mark to model' valuation basis to determine a value appropriate to the industry sector. The model uses public bond spread data as a proxy for current spreads on fixed-interest assets. The company then uses this to develop a yield curve to discount the cash flows underlying the private placement to obtain its value.	There is no valuation difference between Solvency II and IFRS basis.

Note 10.4: Derivatives

Derivatives include Over-The-Counter derivatives (OTC), exchange traded derivatives, foreign exchange traded derivatives, currency forward rate contracts, futures contracts, forward rate agreements and options.

Solvency II purposes:	IFRS reporting purposes:
The company uses the bid value supplied by the counterparty to value OTC Derivatives. Where possible, the company uses independent third-party software to confirm the counterparty value is reasonable.	There is no valuation difference between Solvency II and IFRS basis.
The company values exchange traded derivatives by using the closing price from the exchange in which they are traded.	
The company values foreign exchange traded derivatives using a market feed of forward points and corresponding interest rate.	

Note 10.5: Deposits

Solvency II purposes:	IFRS reporting purposes:			
The company values deposits at their face value.	There is no valuation difference between Solvency II and IFRS basis.			

Note 11: Loans and Mortgages

Solvency II purposes:	IFRS reporting purposes:
The company records loans and mortgages at fair value, determined by discounting expected future cash-flows using current market rates. Valuation inputs typically include benchmark yields and risk-adjusted spreads based on current lending activities and market activities.	There is no valuation difference between Solvency II and IFRS basis.

Note 12: Insurance & intermediaries receivables

'Insurance & intermediaries receivables' includes outstanding premiums that policyholders are due to pay us.

Solvency II purposes:	IFRS reporting purposes:				
The company records receivables at their fair value, net of any amounts deemed as doubtful debts.	There is no valuation difference between Solvency II and IFRS basis.				

Note 13: Reinsurance receivables

Reinsurance receivables include:

- the money that reinsurers are still due to pay us
- the money we're due to receive from multinational pooling (MNP) arrangements.

Solvency II purposes:	IFRS reporting purposes:
The company estimates amounts receivable from reinsurers in a manner consistent with the claim liability associated with the reinsured policy.	There is no valuation difference between Solvency II and IFRS basis.
The company records MNP receivables on an accruals basis to account for premiums and claims activity that has not yet been agreed with the MNP.	

Note 14: Any other assets, not elsewhere shown

'Any other assets, not elsewhere shown' includes other unit-linked assets not shown anywhere else on the balance sheet, for example, broker outstanding balances. This section also includes other non-linked assets not shown anywhere else on the balance sheet, for example, intercompany debtors, accrued external fees and management charges due.

Solvency II purposes:	IFRS reporting purposes:				
The company records receivables at their fair value, net of any amounts deemed as doubtful debts.	There is no valuation difference between Solvency II and IFRS basis.				

There have been no changes to the recognition and valuation basis during the year for the assets noted above. During 2016, there was a change to the financial statement accounting policy for insurance contracts.

There are no classes of assets subject to operating or finance lease arrangements.

For estimation uncertainty, please refer to section D.4 Alternative Methods for Valuation.

D.2 TECHNICAL PROVISIONS

Technical provisions represent the value of our liabilities under policies we have written.

Solvency II technical provisions include:

- account values (unit liabilities)
- best estimate technical provisions (BETPs)
- risk margin.

D.2.1 Solvency II Technical Provisions and Reinsurance Recoverables: Overview

These tables show the value of technical provisions and reinsurance recoverables split by line of business:

€m	2017					
	Technical Provisions			Reinsurance Recoverables		
Line of business	Calculated as a whole	Best estimate technical provisions	Risk Margin	Calculated as a whole	Other	
Contracts with profit participation	0	132	0	0	0	
Other Life Assurance	0	4,221	159	0	1,507	
Health	0	536	84	0	55	
Unit-linked	40,027	(528)	161	28	(3)	
Total	40,027	4,361	404	28	1,559	

€m	2016						
	Technical Provisions			Reinsurance Recoverables			
Line of business	Calculated as a whole	Best estimate technical provisions	Risk Margin	Calculated as a whole	Other		
Contracts with profit participation	0	150	0	0	0		
Other Life Assurance	0	4,252	138	0	1,857		
Health	0	529	79	0	58		
Unit-linked	36,704	(430)	140	30	12		
Total	36,704	4,501	358	30	1,928		

The increase in technical provisions calculated as a whole (€3,323m) is due to investment returns on assets backing unit-linked funds and net inflows into the funds.

The reduction in best estimate technical provisions on Other Life Assurance (€31m) is due to a reduction in provisions due to assumption changes, offset by an increase in provisions arising from the impact of new business and in force movements. The reduction in best estimate technical provisions on Unit-Linked (€109m) is mainly due to a combination of assumption changes and investment market returns during 2017.

The increase in risk margin (€46m) is mainly driven by new business growth and assumption changes. The reinsurance recoverables (€371m) is mainly driven by assumption changes and the run-off of legacy reinsurance arrangements on Other Life Assurance.

D.2.1.1

Technical provisions calculated as a whole

Under Solvency II rules, certain technical provisions can be calculated "as a whole" which means that separate calculation of the best estimate and risk margin is not required. For ILA, unit liabilities representing the current account value of unit-linked contracts are classified as technical provisions as a whole. The value is based on the value of the underlying assets to which the contracts are linked. Other technical provisions are calculated as a best estimate plus a risk margin, as discussed in the sections below.

D.2.1.2

Best estimate technical provisions

Best estimate technical provisions (BETPs) represent the best estimate of the value of our obligations under the policies we have written.

The BETPs represent the probability-weighted average of future cash-flows, taking into account the time value of money. To allow for the time value of money we use the relevant risk-free interest rate term structure.

D.2.1.3

Reinsurance recoverables

We have a number of reinsurance arrangements in place which reduce our exposure to risks such as mortality risk, morbidity risk and longevity risk.

We work out the value of reinsurance recoverables like this:

The present value of the payments we expect to receive from reinsurers (under existing reinsurance arrangements) minus

The present value of the payments we expect to make to reinsurers (under existing reinsurance arrangements)

In general, the way we work out the value of reinsurance recoverables is the same as the way we work out the BETPs and in general, we use the same assumptions.

We do not have any reinsurance arrangements with special purpose vehicles.

D.2.1.4

Risk margin

The risk margin is meant to represent the extra premium that another insurer would require for taking on our insurance portfolio. It reflects the cost of holding the policy-related capital – the Solvency Capital Requirement (SCR) – for all our policies.

We work out the risk margin like this:

The present value of the projected capital on our existing business

multiplied by a cost-of-capital rate,

where the future capital in any given year is equal to the projected SCR arising on our existing business in that year.

EIOPA has prescribed a cost-of-capital rate of 6%.

We work out our aggregate risk margin and then split it between the lines of business, as in the table above.

D.2.2

Solvency II Technical Provisions and Reinsurance Recoverables: bases, methodology and assumptions

We work out the value of our BETPs and our reinsurance recoverables in line with Solvency II regulations. For most of our business, we use a projection of future cash-flows based on central assumptions. We make an adjustment to reflect a best estimate of catastrophe costs. In some cases we use different methods, which we discuss in the sections below covering the individual lines of business.

These are the three main categories of assumptions we use to work out the BETPs and reinsurance recoverables:

- demographic assumptions
- expense assumptions
- economic assumptions.

Demographic assumptions: include assumptions about how long policyholders will live, the rate at which they will die or get ill, and how many of them will let their policies lapse. We discuss these assumptions in the sections below that cover the demographic assumptions on each of the individual lines of business.

Expense assumptions: include assumptions about maintenance and investment expenses. We have set the expense assumptions based on the most recent expense investigation. We have taken into account the level of expenses we expect from different types of products and the amount of business in force.

The main **economic assumptions** are:

- · the discount rate
- · the rate of investment return on unit-linked funds
- the rate of increase of future benefits which are linked to inflation
- expense inflation.

We project future investment returns on unit-linked funds using the risk free yield curve specified by the EIOPA. We use the same risk free yields to discount the value of future cash-flows. We use the yield curve with the volatility adjustment for calculating BETPs. (We discuss the volatility adjustment further in section D.2.5 Long Term Guarantee Measures). In line with the Solvency II requirements, we do not use the volatility adjustment when we work out the risk margin.

Our assumption about the inflation of future benefits is set considering the results of stochastic modelling. This considers a large number of possible future inflation scenarios. Our assumption about the inflation of expenses is based on long term assumptions about how we expect prices to go up, plus how we expect salaries to go up in excess of prices.

Our approach for working out expense and economic assumptions is similar across all lines of business.

Other than the difference in the yield curve noted above, the projected capital requirements we use to calculate the risk margin are based on the same assumptions we use to calculate the BETPs.

D.2.2.1 Demographic assumptions: Contracts with profit participation

This line of business includes participating endowment and whole life policies, as well as a small number of participating deferred annuity contracts.

The main demographic assumptions for this line of business are assumptions about the rate at which policyholders die or let their policies lapse. We generally make these assumptions based on our experience investigations. We apply expert judgement to make sure there is enough allowance for relevant trends or factors we expect to change.

D.2.2.2

Demographic assumptions: Other Life Insurance

This line of business includes annuity business, individual and group non-linked protection business.

The main demographic assumptions for this line of business are assumptions about the rate at which policyholders will die or get ill, and how many of them will let their policies lapse. We generally make these assumptions based on our experience investigations. We apply expert judgement to make sure there is enough allowance for relevant trends or factors we expect to change.

D.2.2.3

Demographic assumptions: Health

This line of business includes group and individual income protection business, and group serious illness business.

The main demographic assumptions for this line of business are assumptions about when policyholders will get ill, and when policyholders who are receiving income protection benefits will recover or die. We generally make these assumptions based on our experience investigations. We apply expert judgement to make sure there is enough allowance for relevant trends or factors we expect to change.

D.2.2.4

Demographic assumptions: Unit-Linked

This line of business includes unit-linked investment policies.

For most unit-linked business we use a projection of future cash-flows based on central assumptions to work out the BETPs and reinsurance recoverables. This is based on our best estimate assumptions. For material investment guarantees, we work out the BETPs using stochastic models. This means we use a large number of possible economic scenarios to work out the cost of the guarantees. The BETP is the average cost under all those scenarios.

The main demographic assumptions for this line of business are assumptions about the rate at which policyholders will die or get ill, and how many of them will surrender their policies early or let them lapse. We generally make these assumptions based on our experience investigations. We apply expert judgement to make sure there is enough allowance for relevant trends or factors we expect to change.

D.2.2.5

Significant simplifications used in the calculation of technical provisions

We use some simplifications when we work out the risk margin.

The actuarial valuation system produces an accurate projection of most of the SCR components used to work out the risk margin. Where this is not possible due to system constraints, we use a simplified method, which Solvency II regulations allow. Where we have adopted a simplified approach for projecting a component of the SCR, we use the risks that drive that component to project that component.

We do not use any other significant simplifications in the way we work out our technical provisions.

D.2.3 Level of uncertainty associated with the value of technical provisions

The value of the BETPs is based on expected future cash-flows. We work these out based on a number of assumptions. We explain the main assumptions in section D.2.1 Solvency II Technical Provisions and Reinsurance Recoverables: Overview above.

There is inherent uncertainty. Actual experience may differ from our assumptions over time, and this may result in us changing our assumptions in the future.

Some of the key sources of uncertainty within the BETPs are the rate at which policyholders will die or get ill, how long they live, how many of them will let their policies lapse, and expenses.

- If the rate at which life insurance policyholders die the
 mortality rate or the rate at which they get ill the morbidity
 rate goes up, so will our BETPs. We partly mitigate against
 this uncertainty with our reinsurance arrangements.
- If people with annuities from us live longer, our BETPs go up. Again we partly mitigate against this uncertainty with reinsurance arrangements on some annuity blocks.
- Generally, if more policyholders let their policies lapse a
 higher lapse rate our BETPs go up. This is because the
 BETPs allow for the expected value of future profits, which
 will go down if more policyholders let their policies lapse.
- If expenses go up, so will our BETPs.

Our BETPs also vary depending on market movements, in particular movements in interest rates and the equity and property markets.

When interest rates change, the impact on our BETPs is usually offset, to a broad extent, by changes in the value of the assets backing our BETPs.

Equity and property values have an impact on future profits on unit-linked business. So they have an impact on our BETPs. If equity or property values fall, this will reduce our future profits on unit-linked business and increase our BETPs.

This table shows how our main assumptions affect our BETPs, net of reinsurance (excluding participating business):

Sensitivity Test	2017	2016	
	Impact on BETPs (€m)	Impact on BETPs (€m)	
10% fall in equity and property values	+78	+65	
10% increase in maintenance expenses	+71	+69	
10% increase in policy lapse rates	+22	+22	
10% decrease in policy lapse rates	-23	-23	
5% increase in mortality rates (assured lives)	+16	+22	
5% deterioration in morbidity rates	+33	+34	
5% decrease in annuity mortality rates	+21	+19	

The impact on movements in bonds, equity and property values on technical provisions calculated as a whole is offset by a movement in the value of the assets matching the technical provisions.

The most material year on year movement is a 10% fall in equity and property values. The impact on BETPs increased from €65m at year-end 2016 to €78m at year-end 2017. This increase was driven by a combination of factors including assumption changes, market growth and the acquisition of a new property.

D.2.4

Differences between Solvency II technical provisions and insurance contract liabilities and investment contract liabilities included in the financial statements

We prepare financial statements under International Financial Reporting Standards (IFRS). The basis of how we value our liabilities for IFRS is different from the basis Solvency II requires. The main differences are:

INVESTMENT CONTRACTS

IFRS allow for some recognition of future profits, through the recognition of Deferred Acquisition Costs (DAC) asset, net of the Deferred Front End Fees (DFEF). Solvency II gives a greater allowance for the present value of future profits on investment contracts within the BETPs, subject to some restrictions.

INSURANCE CONTRACTS

There are three main differences in the approach to valuing insurance contracts:

1. Under IFRS, we value insurance contracts using best estimate assumptions, but we allow for margins for adverse deviation. These margins allow for the possibility of mis-estimation and for our best estimate assumptions deteriorating in the future. The margins also provide reasonable assurance that insurance contract liabilities cover a range of possible outcomes.

Under Solvency II, we value all contracts (both investment and insurance contracts) using best estimate assumptions and a prescribed yield curve. We also allow for the risk associated with the business (quantified as the cost of capital) through the risk margin.

- 2. Under IFRS, the liability on any policy which is allowed to surrender is subject to a floor of zero.
 - Under Solvency II, there is no similar restriction on liability valuations.
- 3. Under IFRS, for participating business, the value of liabilities in the financial statements does not allow for future terminal dividends. The excess of assets over liabilities is reflected in the non-controlling interest line of the financial statements.

Under Solvency II, the technical provisions reflect the best estimate of future terminal dividends.

For each line of business, the tables show the differences between the Solvency II technical provisions and the technical provisions included in the financial statements (including insurance contract liabilities, investment contract liabilities and unit-linked liabilities):

€m	2017				
	Participating contracts	Other Life	Health	Unit- Linked	Total
Solvency II technical provisions (net of reinsurance recoverables)	132	2,874	564	39,635	43,205
Valuation methodology differences for investment contracts	0	0	0	752	752
Valuation methodology differences for insurance contracts (margins for adverse deviation, and zeroisation of negative liabilities, allowance for terminal dividends for participating business)	(75)	777	46	66	814
Risk margin not held under IFRS	0	(159)	(84)	(161)	(404)
Value of insurance contract liabilities, investment contract liabilities and unit-linked liabilities per IFRS financial statements (net of reinsurance asset) *	57	3,491	526	40,293	44,367

^{*}There was a minor presentational change during 2017 between the Unit-Linked and Other Life lines of business. This change was not material and was not reflected within the underwriting result.

€m			2016		
	Participating contracts	Other Life	Health	Unit- Linked	Total
Solvency II technical provisions (net of reinsurance recoverables)	150	2,533	549	36,372	39,604
Valuation methodology differences for investment contracts	0	0	0	667	667
Valuation methodology differences for insurance contracts (margins for adverse deviation, and zeroisation of negative liabilities, allowance for terminal dividends for participating business)	(80)	712	48	73	753
Risk margin not held under IFRS	0	(138)	(79)	(140)	(358)
Value of insurance contract liabilities, investment contract liabilities and unit-linked liabilities per IFRS financial statements (net of reinsurance asset)	70	3,106	518	36,972	40,667

In summary, at the end of 2017 our liabilities under Solvency II are €1,162m (2016: €1,062m) lower than under our local financial statements.

However, under Solvency II, future profits recognised within the calculation of liabilities must be stressed within the calculation of the Solvency Capital Requirement (SCR). This is to allow for market shocks and severe adverse changes in rates of mortality, morbidity, longevity, and lapses.

So, the SCR allows for the impact of severe adverse stresses on the future profits. The SCR was €1,189m at 31 December 2017 (2016: €1,152m). In section E.2 Solvency Capital Requirement Split by Risk Module we outline the calculation of the SCR in more detail.

During 2017, the difference between our liabilities under Solvency II and our local financial statements grew by €100m, mainly due to a combination of assumption changes and investment market returns during 2017.

D.2.5 Long Term Guarantee Measures

Long Term Guarantee measures are optional measures available to companies under the Solvency II regime. Long Term Guarantee

measures can help to reduce the impact of credit spread changes on a company's solvency position.

The Long Term Guarantee measures available to us include the matching adjustment and the volatility adjustment:

- The matching adjustment allows a company to adjust the Solvency II yield curve when they value policy liabilities. The company can adjust it by an amount that is linked to the yield on the backing assets it holds.
- The volatility adjustment allows a company to adjust the Solvency II yield curve by an amount which varies based on credit spreads on a specified asset portfolio.

We do not apply the matching adjustment.

We use the volatility adjustment for calculating technical provisions. At the end of 2017, the volatility adjustment represented an increase in the Solvency II forward rate yield curve of 4 basis points for the first 20 years.

These tables show the impact of reducing the volatility adjustment to zero on technical provisions (net of reinsurance recoverables), eligible Own Funds, the SCR and the MCR.

€m	2017		
	With volatility adjustment	Without volatility adjustment	Impact of volatility adjustment reducing to zero
Technical Provisions (net of reinsurance recoverables) ⁵	43,205	43,221	16
Basic Own Funds	1,903	1,889	(14)
Eligible Own Funds	1,903	1,889	(14)
Solvency Capital Requirement (SCR)	1,189	1,193	4
Minimum Capital Requirement (MCR)	498	499	0
Solvency Margin Ratio	160%	158%	(2)%

€m	2016		
	With volatility adjustment	Without volatility adjustment	Impact of volatility adjustment reducing to zero
Technical Provisions (net of reinsurance recoverables) ⁵	39,604	39,649	44
Basic Own Funds	1,772	1,733	(39)
Eligible Own Funds	1,772	1,733	(39)
Solvency Capital Requirement (SCR)	1,152	1,158	7
Minimum Capital Requirement (MCR)	460	461	1
Solvency Margin Ratio	154%	150%	(4)%

⁵ The impact on technical provisions net of reinsurance recoverables is comprised of an increase in gross of reinsurance technical provisions of €23m (2016: €73m) and an increase in reinsurance recoverables of €7m (2016: €29m).

The year on year reduction in the impact of reducing the volatility adjustment to zero is mainly due to a reduction in the magnitude of the adjustment to the yield curve arising from the volatility adjustment during 2017.

D.2.6 Transitional Measures

We do not apply the transitional risk-free interest rate-term structure. Nor do we apply the transitional deduction to technical provisions.

D.2.7

Changes to assumptions compared to previous reporting period

The main changes to our assumptions since 31 December 2016 calculations are:

- we updated our assumptions about mortality, including mortality improvements, morbidity and lapse rates, based on the results of our most recent experience investigations
- we updated assumptions about expenses, based on the results of our most recent expense investigations
- we updated the discount rate and the assumed rate of future investment returns on unit-linked funds based on changes in the risk free yield curve specified by EIOPA
- we refined some of our methods used to value investment guarantees.

D.3 OTHER LIABILITIES

This section is about our valuation of each kind of 'other liability' for Solvency II purposes. This includes explanations of:

- how the value of each other liability for Solvency II is different from valuing it for statutory financial reporting that meets the EU's International Financial Reporting Standards (IFRS)
- 2. the valuation bases, methods and main assumptions used for Solvency II and those used for statutory IFRS financial statements for the financial year ended 31 December 2017.

The Solvency II Balance Sheet is in Appendix 1.

VALUATION DIFFERENCES – SOLVENCY II V IFRS

Balance Sheet Extract - Other Liabilities

The IFRS values in the following tables are as recorded in our annual report and financial statements. The Liability Type categorisation here is per the Solvency II balance sheet and not directly comparable to categorisation applied in the IFRS Statement of Financial Position.

		2017			
Liability Type (€m)	Note	IFRS	Reclassification Adjustments	Valuation Adjustments	Solvency II
Other provisions	1	(40)	0	35	(5)
Pension benefit obligations	2	(2)	0	0	(2)
Deposits from reinsurers	3	0	0	0	0
Deferred tax liabilities	4	(61)	0	(123)	(184)
Derivative liabilities	Section D.1.2	(2)	0	0	(2)
Insurance & intermediaries payables	5	(303)	0	0	(303)
Reinsurance payables	6	(28)	0	0	(28)
Payables (trade, not insurance)	7	0	0	0	0
Subordinated liabilities	8	0	0	0	0
Other liabilities	9	(143)	0	0	(143)

		2016			
Liability Type (€m)	Note	IFRS	Reclassification Adjustments	Valuation Adjustments	Solvency II
Other provisions*	1	(53)	0	42	(11)
Pension benefit obligations	2	(3)	0	0	(3)
Deposits from reinsurers	3	(41)	0	0	(41)
Deferred tax liabilities	4	(56)	0	(114)	(170)
Derivative Liabilities	See Section D.1.2	(3)	0	0	(3)
Insurance & intermediaries payables	5	(314)	0	0	(314)
Reinsurance payables	6	(39)	0	0	(39)
Payables (trade, not insurance)	7	(6)	0	0	(6)
Subordinated liabilities	8	(210)	0	0	(210)
Other liabilities	9	(163)	0	0	(163)

^{*} The 2016 comparatives have been adjusted to be consistent with the disclosures in 2017.

2. VALUATION BASES, METHODS AND MAIN ASSUMPTIONS - SOLVENCY II V IFRS

In this section you'll find the valuation basis for Solvency II purposes for each class of liability in the table above. We also explain the differences between Solvency II and the IFRS statutory financial statements when it comes to valuation bases, methods and main assumptions used for the financial year ended 31 December 2017.

Note 1: Other provisions

'Other provisions' include onerous contract provisions, severance provisions, customer complaints provisions and legal provisions.

We expect to settle onerous contract provisions by 2021. We expect to settle severance provisions in the next financial year. Customer complaints provisions and legal provisions are ongoing.

The valuation adjustment to other provisions is in relation to Deferred Front End Fees (DFEF).

Solvency II purposes: IFRS reporting purposes: The company derives the value of each provision by management Initial fees earned and incremental costs (mainly reviewing and evaluating the expected outflow required to settle the commission) paid on sale of an investment contract are liability to which the provision applies. These reviews are presented deferred and recognised over the expected life of the to the Board Audit Committee for approval and inclusion in the contract. The company estimates the expected life of the Annual Financial Statements. contracts based on current experience and the term of the contracts. The company reviews this at least once a year. Similar to DAC, as per Article 12 of the Delegated Act, DFEF are The maximum amortisation period for DFEF is 20 years. valued at nil for Solvency II purposes. There is no valuation difference between Solvency II and

Note 2: Pension benefit obligations

We operate a defined benefit pension scheme which is now closed to new members and a hybrid scheme with a defined benefit element. Some staff participate in a defined benefit pension scheme - an Irish scheme sponsored by Canada Life Irish Holding Company Limited (CLIH), a member of the Canada Life Group. That scheme is also closed to new members.

IFRS basis for the other provisions listed above.

We have communicated that the company is to close our defined benefit pension scheme to future accrual from 30 June 2018 and for existing members to join our defined contribution plan for future service pension provision beyond this date. Members will retain the benefits they have accrued up to the date of closure of the scheme and these benefits will still be linked to final salary. As at 31 December 2017 agreement has been reached on this with the Trustees of the Irish Life Staff Benefits Scheme while negotiations on the Hybrid Defined Benefit Scheme were ongoing.

These schemes are funded by contributions into separately administered trust funds. The benefits paid from the defined benefit schemes are based on percentages of the employees' final pensionable pay for each year of credited service. Under the rules of each of the Irish Life schemes, pension increases are wholly at the discretion of the schemes' principal employer.

Solvency II purposes:	IFRS reporting purposes:
The net obligation of the company's defined benefit schemes represent the present value of the obligation to employees in respect of past service, less the fair value of the plan assets. It is based on the IAS19 accounting standard.	There is no valuation difference between Solvency II and IFRS basis.
The external scheme actuary calculates the present value of the obligation once a year. The present value of the obligation is determined by discounting the estimated future cash flows.	
The discount rate is based on the market yield of high quality corporate bonds that have maturity dates approximating to the terms of the pension liability.	
The estimated future cash-flows are based on the accrued past service benefits and future salary inflation, inflation and assumptions about mortality.	

This table shows the nature and composition of our liabilities:

Benefit obligation	2017 (€m)	2016 (€m)
Benefit obligation as at 1 January	(1,202)	(1,085)
Current service cost	(29)	(26)
Net interest cost	(24)	(30)
Actuarial loss (experience adjustments & financial assumption changes)	(33)	(78)
Contributions by plan participants	(4)	(4)
Curtailment gain	2	1
Benefits paid	23	20
Benefit obligation as at 31 December	(1,267)	(1,202)

This table shows the nature and composition of our plan assets:

Asset Type	2017 Fair Value (€m)	2017 Plan assets (%)	2016 Fair Value (€m)	2016 Plan assets (%)
Equities	622	49	636	53
Bonds	519	41	449	38
Property	117	9	109	9
Cash and cash equivalents	7	1	5	0
Fair value of plan assets at 31 December 2017	1,265	100	1,199	100

Note 3: Deposits from reinsurers

Deposits from reinsurers are funds held by the company under reinsurance contracts. Premiums and claims due in the period are paid to or withdrawn from the funds withheld account. During 2017, these funds were released due to the wind up of the reinsurance treaty.

Solvency II purposes:	IFRS reporting purposes:
The company estimates amounts payable to reinsurers in a manner consistent with the claim liability associated with the reinsured policy.	There are no valuation differences between Solvency II and IFRS basis.

Note 4: Deferred tax liabilities

Deferred tax is recognised in respect of all timing differences that have originated, but not yet reversed, at the balance sheet date. This means where transactions or events have occurred at that date it will result in an obligation to pay more tax or a right to pay less tax.

When calculating a net deferred tax liability, deferred tax assets are offset only to the extent that it is more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted. The tax rate used to calculate the deferred tax balance is the rate that's expected to be in-force at the time the tax becomes payable. There is no expiry date of taxable temporary differences.

Solvency II purposes:	IFRS reporting purposes:
Article 15 of the Delegated Act dictates how the company accounts for deferred tax. It says that the company should:	There are no valuation differences between Solvency II and IFRS basis. However there is a deferred tax effect,
 Recognise and value deferred taxes in relation to all assets and liabilities, including technical provisions. 	resulting from the various accounting differences between Solvency II and Financial Statements as discussed throughout this document.
 Value deferred taxes on the basis of the difference between the values ascribed to assets and liabilities recognised and valued in accordance with Article 82 of SI 485 of the European Union (Insurance and Reinsurance) Regulations 2015 and in the case of technical provisions in accordance with Articles 83 to 98 and the values ascribed to assets and liabilities as recognised and valued for tax purposes. 	uiscusseu tiiloughout tiils uocument.
Only ascribe a positive value to deferred tax assets where it is probable that future taxable profit will be available against which the deferred tax asset can be used, taking into account any legal or regulatory requirements on the time limits relating to the carry forward of unused tax losses or the carry forward of unused tax credits.	

Note 5: Insurance and intermediaries payables

'Insurance and intermediaries payables' refers to the balance of outstanding claims payable to policyholders, commissions payable and premiums on deposit.

Solvency II purposes:	IFRS reporting purposes:
The company records payables on an accruals basis.	There are no valuation differences between Solvency II and IFRS basis.

Note 6: Reinsurance payables

Reinsurance payables represent the balance due to reinsurers for outstanding reinsurance premiums and experience rating refunds for monies due to multinational pooling (MNP) arrangements.

Solvency II purposes:	IFRS reporting purposes:
The company records payables on an accruals basis. The company records MNP payables on an accruals basis to account for premiums and claims activity that has not yet been agreed with the MNP.	There are no valuation differences between Solvency II and IFRS basis.

Note 7: Payables (trade, not insurance)

Payables (trade, not insurance) represent the current tax liability of the company.

Solvency II purposes:	IFRS reporting purposes:
The company provides corporation tax payable on taxable profits at current tax rates.	There are no valuation differences between Solvency II and IFRS basis.

Note 8: Subordinated liabilities

Subordinated debt was repaid on 8 February 2017. It represented €200m step-up perpetual capital notes, with a 5.25% fixed interest rate for 10 years until 8 February 2017, the first reset date. We had an interest rate swap in place to hedge our exposure to fluctuations in the interest rate.

Solvency II purposes:	IFRS reporting purposes:
The company initially recognised the subordinated debt at fair value plus directly attributable transaction costs. This liability, which was part of a hedging relationship, was carried at amortised cost, calculated on an effective interest basis, adjusted for changes in the fair value of the hedged risk. The change in the fair value of the hedged risk was recognised together with the movement in the fair value of the derivative positions hedging the liability in the income statement. The company recorded interest expense on an effective interest basis in the income statement as interest payable.	There are no valuation differences between Solvency II and IFRS basis.

Note 9: Other liabilities

'Other liabilities' includes other unit-linked liabilities not shown anywhere else on the balance sheet, for example outstanding balances with brokers. This section also includes other non-linked liabilities not shown anywhere else on the balance sheet, for example intercompany liabilities, other taxation balances (PAYE, Exit Tax) and accruals.

Solvency II purposes:	IFRS reporting purposes:
The company records payables on an accruals basis.	There are no valuation differences between Solvency II and IFRS basis.

During the year there have been no changes to the recognition and valuation basis of the liabilities noted above.

We lease various offices under non-cancellable operating leases. These leases typically run for 25 years, with an option to renew the lease after that date.

During 2017 we granted a legal charge over a block of assets (€279m) to support liabilities to a specific policyholder. We have substantially retained the benefit of all the risks and rewards associated with these assets and continue to recognise them as available to meet the liability to the policyholder. In certain circumstances, the policyholder could enforce the charge and obtain control of the assets to offset our obligation to them under the policy, the likelihood of which is remote.

For estimation uncertainty, please refer to section D.4 Alternative Methods for Valuation.

D.4 ALTERNATIVE METHODS FOR VALUATION

OVERVIEW OF METHODOLOGY FOR VALUING INVESTED ASSETS

The Technical Specification (EIOPA 14/209) outlines the Solvency II rules on how to value assets and liabilities, other than technical provisions. It says that, unless otherwise stated, the default reference framework should be the international accounting standards, as adopted by the European Commission in line with Regulation (EC) No 1606/2002.

In most cases those international accounting standards (IFRS) and Solvency II give consistent valuations.

For our annual statutory financial statements we recognise assets and liabilities in line with IFRS. For our regulatory reporting we

follow Central Bank guidelines.

As required under IFRS 13 (Fair Value Measurement), our annual audited statutory financial statements disclose how we value assets and liabilities across level 1, 2 and 3. This is the fair value hierarchy.

- Level 1: fair value measurements based on quoted market prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.
- Level 2: fair value measurements based on inputs other than quoted prices included within level 1 that are observable for the asset or liability either directly (i.e. as prices) or indirectly (i.e. derived from prices).

• Level 3: fair value measurements based on valuation techniques that include inputs for the asset and liability that are based on unobservable market data.

Level 1 and 2 show what's known as a 'mark to market' approach. This means values are based on readily available prices in orderly transactions that are sourced externally.

Level 3 shows a 'marked to model' approach. This means values are based on assumptions or financial models.

Where assets are 'marked to model' the relevant primary investment manager must maintain supporting documentation addressing:

- a description of the process followed (model design) and the data/assumptions used by the approach (including assessment of data quality)
- the reason why a 'mark to market' approach is not possible
- the sign-off process applied in reviewing the valuation and other applicable controls (such as any applicable benchmarking of valuation output to other comparable methods)
- the level of uncertainty inherent in the valuation approach and an assessment of the model's performance in this case, which should include any particular circumstances where the approach would be expected to be ineffective
- the results of any independent check performed in relation to model outputs
- possible alternative valuation models where primary models are complex.

At least once a year, the relevant primary investment manager presents a report to our Board Audit Committee for review and approval. The report outlines how the manager priced the asset, what management considered appropriate and the resulting valuation of unquoted securities we hold. These unquoted securities primarily consist of bonds, venture capital and unit trusts.

The Financial Reporting Committee (FRC) is made up of the Chief Financial Officer (Chairman), Chief Actuary, Head of Group Valuation and Reporting and Head of Group Finance. The FRC is responsible for monitoring and reviewing the Financial Reporting and Disclosure Policy, including making recommendations to the Board Audit Committee and assessing the application of the policy.

Among other responsibilities, the FRC is required to assess the relevance and adequacy of the policies associated with the valuation of assets and liabilities at least once a year. This has to include taking into consideration changes in accounting rules and policies as governed by the international accounting standards. The FRC then presents these policies to the Board Audit Committee for verification and to the Board for approval.

For invested assets, we expect that our primary investment managers maintain:

- sufficient independence in valuing assets
- sufficient documentation of applicable standards and guidelines
- sufficient control over valuation models
- sufficient management information
- consistent governance between internally and externally managed funds.

This is set out in our investment management agreements.

Where the unit-linked and non-linked investment managers hold units in the same fund, both investment managers will ensure they use the same fund price at the end of each quarter. Where this is not practical, the investment managers will contact the group financial control team to assess options. If the investment managers propose to use different prices for the same assets at the end of the financial year, this will be brought to the attention of the Board Audit Committee and set out the reasoning behind their proposal. The Board Audit Committee will review and, if appropriate, ratify the proposal.

We base estimates and associated assumptions on experience and various other factors that we believe to be reasonable under the circumstances. These factors are reflected in our judgements about the carrying amounts of assets and liabilities that are not objectively verifiable. We review estimates and underlying assumptions on an on-going basis. Where necessary, we revise them to reflect current conditions. This applies to uncertainties that arise on estimations we use when we value assets and liabilities.

ILA-invested assets are managed by three separate entities, all of which are part of the GWL group. ILA's unit-linked invested assets are primarily managed by Irish Life Investment Managers Limited (ILIM). A small percentage of ILA's unit-linked invested assets comprise the third-party Self Directed Funds (SDFs). These are managed by Irish Progressive Services International Limited (IPSI), Irish Life Group's third-party administration company. ILA's non-linked invested assets are managed by Canada Life Asset Management Limited (CLAM).

D.5 ANY OTHER INFORMATION

No other items to note.



This section describes the components of our Own Funds as at 31 December 2017, as well as the policies and processes we use to make sure we meet all regulatory capital requirements when we manage Own Funds.

E.1 OWN FUNDS

'Own Funds' refers to the excess of the value of our assets over the value of our liabilities, where the value of our liabilities includes technical provisions and other liabilities.

Own Funds are divided into three tiers based on their permanence, and how well they can absorb losses. Tier 1 funds are of the highest quality.

E.1.1

Management of Own Funds

Our policy is to manage the capital base so that we meet all regulatory requirements. We also aim to maintain investor, creditor and market confidence, and to make sure there is enough capital to support our future growth. Our business planning process, which considers projections over a five year time frame, informs our capital management.

We manage our Own Funds so that we maintain high quality capital, mainly equity. The assets backing our Own Funds are mainly made up of:

- relatively secure assets such as fixed interest assets, as well as some owner occupied property holdings
- the expected value of future profits from our existing business, which we include when we calculate technical provisions (as discussed in section D.2 Technical Provisions). A large part of this value is offset by capital requirements in the Solvency Capital Requirement (SCR).

E.1.2 Components of Own Funds

This table sets out and assesses the way we value and calculate our Own Funds:

Solvency II Own Fund Item	How we value Own Funds (according to Solvency II rules)	Assessment	
Ordinary share capital	WI II WANTE 6	This is the share capital and share premium, based on the company's statutory accounts.	
Share premium account related to ordinary share capital	Valued in accordance with Article 75 of Directive 2009/138.	All of the company's share capital and share premium is classed as Tier 1 unrestricted.	
Surplus funds	Article 91 of Directive 2009/138 (Article 106 of SI 485) defines surplus funds: "1. Surplus funds shall be deemed to be accumulated profits which have not been made available for distribution to policy holders and beneficiaries" Tiering is in line with Article 69 of the	The definition is understood to mean surplus available to With Profit fund holders.	
	Delegated Act.	The reconciliation reserve equals the excess of assets over liabilities from the company Solvency II balance sheet. It is reduced by the following amounts:	
	Valued in accordance with Article 70 of the Delegated Act.	i) Own shares – n/a	
		ii) Foreseeable dividends	
Reconciliation reserve		iii) The basic own fund items listed above – ordinary share capital, share premium and surplus fund	
		iv) Restrictions relating to the company's ring-fenced funds – see below	
		In line with Article 69, all reconciliation reserve is classed as Tier 1 unrestricted.	
Restrictions in respect of the company's ring-fenced funds	Valued in accordance with Article 81 of the Delegated Act.	Restrictions apply in respect of the assets in the company's ring-fenced funds. The amount which must be deducted from Own Funds is calculated separately for each ring-fenced fund as: the value of assets held within the ring-fenced fund minus the value of the liabilities of the ring-fenced fund minus the SCR for the ring-fenced fund. The deduction in respect of each ring-fenced fund is subject to a minimum of zero.	
Subordinated debt ⁶	Valued in accordance with Article 75 of Directive 2009/138. Classified as Tier 1 in accordance with the transitional clause of Article 308b(9) of the Directive.	The company's subordinated debt was issued on 8 February 2007. This debt was eligible under Solvency I. In line with the transitional clauses, this debt is eligible to be counted as Tier 1 capital for Solvency II.	

⁶ Subordinated debt was redeemed on 8 February 2017. See further details below.

Solvency II Own Fund Item	How we value Own Funds (according to SII rules)	Assessment
Expected profits included in the future premiums	Valued in accordance with Article 70 of the Delegated Act.	Expected profit in future premiums contributes to the company's Own Funds, as discussed in section C.4.1 Expected Profit Included in Future Premiums. This is classed as Tier 1 unrestricted and is already included in the reconciliation reserve amount.

We do not hold any hybrid instruments.

This table shows the breakdown of our Own Funds:

€m	31 December 2017	31 December 2016
<u>Tier 1 - unrestricted</u>		
Issued share capital	1	1
Share premium account	340	340
Surplus funds	0	0
Reconciliation reserve	1,635	1,485
<u>Tier 1 - restricted</u>		
Subordinated debt	0	201
Available Own Funds (before foreseeable dividends and adjustments)	1,976	2,027
Foreseeable dividends, distributions and charges	(73)	(55)
Ring-fenced funds adjustment (Participating Funds)	0	0
Total available Own Funds to meet the SCR	1,903	1,972
Less subordinated debt repaid February 2017	N/A	(200)
Total after allowing for February 2017 subordinated debt repayment	N/A	1,772

RECONCILIATION RESERVE

The reconciliation reserve will vary over time based on the experience of the company, including lapse and claims, expense levels and the impact of writing future new business.

SUBORDINATED DEBT

At year-end 2016 ILA had subordinate debt outstanding, which was classified as restricted Tier 1 own funds. This was fully redeemed on 8 February 2017. The redemption was planned and was reflected in the year-end 2016 position shown in the table above.

CHANGES IN OWN FUNDS IN 2017

Overall, Own Funds have increased by \in 131m in 2017, after allowing for the planned dividend payment.

The €131m increase is mostly due to:

- margins which emerged from our existing business
- experience gains and the impact of assumption changes
- the impact of investment market returns during 2017 on the insurance business
- partly offset by the planned dividend payment.

Movements in the company's Own Funds in the future will depend on the company's experience and dividend payments. We intend to manage our Own Funds so that the solvency position stays within a targeted range, as discussed at the beginning of Section E.1 Own Funds.

RING-FENCED FUNDS

We have three ring-fenced funds relating to our pension schemes, and two ring-fenced funds relating to our Participating Business.

In the table above, there is a \leq 0.3m deduction for ring-fenced funds on 31 December 2017 (2016: \leq 0.2m). This relates to the excess of the surplus over the SCR in our ring-fenced Participating Funds.

For our pension schemes, the excess of liabilities over assets is €3m (2016: €5m). We show this on the balance sheet as a liability, and so it does not result in any additional available assets. As a result, we do not need to make any deductions to Own Funds relating to these pension schemes.

DEDUCTIONS TO OWN FUNDS AND RESTRICTIONS ON TRANSFERABILITY

There are no other deductions to Own Funds. There are also no significant restrictions on how we can transfer our Own Funds.

LIMITS ON ELIGIBILITY OF CAPITAL

The limits on eligible Tier 2 capital, Tier 3 capital and restricted Tier 1 capital have no impact on our eligible Own Funds to cover the SCR

ILA has no restricted Tier 1, Tier 2 or Tier 3 capital as at 31 December 2017.

E.1.3 Eligible Own Funds to cover Solvency Capital Requirement (SCR) and Minimum Capital Requirement (MCR)

This table sets out our eligible Own Funds to cover the SCR and MCR:

€m	31 December 2017	31 December 2016
Tier 1 - unrestricted	1,903	1,771
Tier 1 - restricted	0	201
Tier 1 - restricted (impact of subordinated debt repaid February 2017)	0	(200)
Eligible Own Funds to meet SCR (after allowing for February 2017 subordinated debt repayment)	1,903	1,772
Solvency Capital Requirement (SCR)	1,189	1,152
Solvency ratio	160%	154 % ⁷
Minimum Capital Requirement (MCR)	498	460
Eligible Own Funds as a percentage of MCR	382%	385% ⁷

⁷ The reported 2016 solvency ratio in the Quantitative Reporting Templates (QRTs) was based on our actual position on 31 December 2016, so it does not take into account our repayment of the subordinated debt (discussed above). As a result, the Own Funds reported in the QRT (of €1,972m) are €200m higher than shown in the table above, the solvency ratio (of 171%) is 17% higher than shown in the table above, and the ratio of eligible Own Funds to the MCR (of 429%) is 44% higher than shown in the table above.

E.1.4 Equity in financial statements compared to Solvency II Own Funds

 $We prepare our financial statements under International Financial Reporting Standards (IFRS) \ rules.$

There are some differences between the equity in our financial statements and the Solvency II Own Funds:

- The way we value insurance contract liabilities (including reinsurance assets) and investment contract liabilities in the financial statements differs from how technical provisions are valued under Solvency II (as discussed in section D.2 Technical Provisions).
- The financial statements allow us to defer incremental acquisition costs and upfront fees through a Deferred Acquisition Costs (DAC) asset and Deferred Front End Fees (DFEF) liability. These are not allowed under Solvency II valuation rules (as discussed in section D.1 Assets and D.3 Other Liabilities above).

- Our intangible assets are valued as nil under Solvency II (as discussed in section D.1 Assets above).
- We adjust deferred tax liabilities to reflect the impact on tax when assets and liabilities are valued differently (as discussed above).

This table shows the difference between the equity in the financial statements and the Solvency II Own Funds:

€m	31 December 2017	31 December 2016
Solvency II Own Funds	1,903	1,772
Differences in technical provisions	(1,162)	(1,062)
Investment contracts DAC and DFEF	254	225
Differences in valuation of intangible assets	10	13
Deferred tax	123	114
Proposed dividends	73	55
Other	0	(1)
Financial statements: shareholder equity plus non-controlling interest	1,201	1,116

The difference between Solvency II Own Funds and shareholder equity plus non-controlling interest in the financial statements has increased from €656m at 31 December 2016 to €702m at 31 December 2017. This is mainly due to reduction in technical provisions under Solvency II, relative to the policy liabilities in the financial statements, due to a combination of assumption changes and investment market returns during 2017.

E.1.5 Transitional arrangements

We do not use any Solvency II transitional arrangements.

E.1.6 Ancillary Own Funds

We do not have any ancillary own fund items.

E.2 SOLVENCY CAPITAL REQUIREMENT SPLIT BY RISK MODULE

We calculate the SCR using the standard formula. The SCR includes:

- the Basic Solvency Capital Requirement (BSCR)
- the SCR for operational risk
- any adjustments for the loss-absorbing capacity of deferred taxes and technical provisions.

We calculate the BSCR using these six risk modules:

- market
- counterparty (default)
- life underwriting
- non-life underwriting
- health underwriting
- intangible assets.

We combine the results from each of these risk modules using correlation factors.

The table to the right shows the split of the SCR. The non-life underwriting and intangible assets risk modules do not apply to us, so are not included in the table.

€m	31 December 2017	31 December 2016
Market risk	722	733
Counterparty risk	33	40
Life Underwriting risk	712	665
Health Underwriting risk	220	207
Operational risk	81	57
Diversification impacts	(410)	(385)
Loss absorbing capacity of deferred tax	(169)	(164)
SCR	1,189	1,152

Note: In the table above, we have shown the SCR for each risk category after allowing for the impact of the loss absorbing capacity of technical provisions. This mainly impacts the market risk category. In Appendix 6, the SCR for each risk category is shown before allowing for the loss absorbing capacity of technical provisions, and the loss absorbing capacity of technical provisions is shown separately. Another reason for a difference in the SCRs in comparison to Appendix 6 is how the adjustment for diversification due to ring fenced funds is allocated to the individual SCRs. The presentation of the QRT in Appendix 6 is in line with the EIOPA SFCR guidelines.

The SCR increased by €37m during 2017, from €1,152m at 31 December 2016 to €1,189m at 31 December 2017. The increase is mainly due to:

- a €47m increase in the Life Underwriting Risk, mainly due to the impact of assumption change and investment market returns during 2017 on lapse risk
- a €24m increase in operational risk, mainly driven by business growth
- partly offset by a €25m increase in diversification benefits.

E.2.1 Use of simplified methods

Every stress or shock impact we used to calculate our overall SCR was produced separately on a full calculation basis. This means that we do not use any of the simplifications allowed in the Delegated Acts when we calculate the SCR except for the ones mentioned below.

We did use some simplifications when we worked out the counterparty SCR:

- We used a simple 85% factor to reduce the value of the collateral assets for reinsurance, which allowed for market risk.
- For Retail Life, we split the overall risk mitigating effect from reinsurance by counterparty. We assumed that the risk mitigating effect was split between counterparties in the same proportion as the best estimate reinsurance asset is split between counterparties.

E.2.2 Undertaking specific parameters and capital add-ons

We do not use undertaking specific parameters. No capital addons apply to us.

E.2.3 Calculation of the Minimum Capital Requirement

The tables below show the inputs to the MCR on 31 December 2017 and 31 December 2016:

2017			
€m	Amount	Factor	Contribution to MCR
Obligations with profit participation: guaranteed benefits	82	3.7%	3
Obligations with profit participation: future discretionary benefits	50	(5.2)%	(3)
Unit-linked insurance obligations	39,475	0.7%	276
Other life and health obligations	3,194	2.1%	67
Capital at risk	220,838	0.07%	155
Total MCR			498

2016			
€m	Amount	Factor	Contribution to MCR
Obligations with profit participation: guaranteed benefits	91	3.7%	3
Obligations with profit participation: future discretionary benefits	59	(5.2)%	(3)
Unit-linked insurance obligations	36,232	0.7%	254
Other life and health obligations	2,865	2.1%	60
Capital at risk	208,597	0.07%	146
Total MCR			460

The growth in MCR of \le 38m from \le 460m at end 2016 to \le 498m at end 2017 is due to growth in the best estimate technical provisions on unit-linked business (+ \le 22m), an increase in the capital at risk (+ \le 9m) and growth in the best estimate technical provisions on other life and health obligations (+ \le 7m).

E.2.4

Changes since the previous reporting period

The SCR increased by €37m over 2017. This is mostly due to changes in investment markets, assumption changes and new business growth.

The MCR increased by €38m over 2017. This is mostly due to changes in investment markets which increased technical provisions, as well as increases in the capital at risk.

E.3 USE OF DURATION BASED SUB-MODULE IN THE CALCULATION OF THE SOLVENCY CAPITAL REQUIREMENT

We do not use the duration based equity risk sub-module.

E.4 DIFFERENCES BETWEEN STANDARD FORMULA AND ANY INTERNAL MODEL USED

We use the standard formula to calculate the SCR, so there are no differences between the standard formula and our internal model.

E.5 NON-COMPLIANCE WITH THE MINIMUM CAPITAL REQUIREMENT AND NON-COMPLIANCE WITH THE SOLVENCY CAPITAL REQUIREMENT

During 2017 we were in compliance with the SCR and MCR requirements.

E.6 ANY OTHER INFORMATION

No other items to note.



Ancillary own funds

Investment or capital that's been promised to a company but not paid. For Solvency II, this counts as capital towards an insurer's Solvency Capital Requirement. However, it only counts as Ancillary Own Funds – and therefore towards Solvency II requirements – if:

- the insurer could call in the capital at any point
- there are no conditions attached to transferring the capital
- the regulator has approved the commitment to transfer the capital.

Assets under administration

Assets managed by a financial institution on behalf of a client.

Bancassurance

Partnership between a bank and an insurance company to allow a bank to sell insurance products.

Bulk annuity

A group of policies written by an insurer that pays retirement income to policyholders. We typically sell bulk annuities when a defined benefit pension scheme wants to insure its liabilities. This usually happens when a pension scheme is being wound up.

Capital add-on

An additional amount of capital which the supervisory authority may, in exceptional circumstances, require a company to hold over and above the Solvency Capital Requirement.

Capital at risk

The loss that an insurance company would make if someone with a policy dies. The capital at risk for any policy cannot be less than zero.

It is calculated like this:

- the amount that the company would pay if the person died,
- the amount that the company would receive from reinsurers if the person died, under its reinsurance arrangements, minus
- the technical provisions minus reinsurance recoverables that the company holds for that policy.

The total capital at risk is the sum of the capital at risk for all the policies the company has written.

Correlation factors

Factors which reflect the relationships between the risks included in the calculation of the Solvency Capital Requirement.

Delegated act

One of the tools the EU uses to put a law in place. Generally, they use an 'implementing act' for ruling on procedure and on how to follow legislation that already exists in other acts. They use a 'delegated act' for ruling on the content of legislation. A delegated act might, for example, add or change elements of a piece of legislation that are not fundamental to that legislation's essence.

The Solvency II regime involves both implementing acts and delegated acts.

Derivatives

Financial products made up of assets packaged together. The value of the product depends on – or 'derives' from – the value of the underlying assets. The asset could be, for example, currency or a commodity. Futures and options are examples of derivatives.

Duration based equity risk sub-module

This allows a company to hold a lower SCR in respect of some equity holdings, as long as it meets certain conditions and gets approval from the supervisory authority.

Forward rate agreements

An agreement to buy a particular amount of currency at a fixed price on a fixed date in the future.

Future discretionary benefits

Benefits which ILA may pay in addition to the minimum benefits payable under a policyholders' contract. For example, for participating business (see definition), bonuses may be paid to policyholders based on the profits of the participating fund.

Hybrid instruments

An investment product that combines two or more different financial instruments, usually an equity and a debt security.

Lapse rate

A measure of how often customers cancel their policies early or stop paying premiums. It is usually calculated as the number of policies which lapsed in a given year out of the total number of policies that were in place in that year.

Loss absorbing capacity of technical provisions

The reduction in the SCR which arises due to reductions in future discretionary benefits (see definition) expected in adverse scenarios.

Netted off

When income and expenditure, or assets and liabilities, are related to each other, they can cancel each other out – in part or in full. Companies are allowed to offset these related items against each other if the legal right exists. This is called 'netting off'.

Off balance sheet

Not on a company's balance sheet. Items that are considered off balance sheet are generally ones the company does not have legal claim to or responsibility for.

Onerous contract provisions

A contract where the unavoidable costs of meeting the obligations under the contract exceed its expected economic benefits.

Own Risk and Solvency Assessment (ORSA)

A set of processes which assess a company's risk profile and the capital it needs to hold in light of these risks. It assesses both the current risk profile, and what it is likely to be in the future. It helps us make decisions, and analyse strategy and risk. In line with standard insurance regulations, we carry out an ORSA each year.

Participating business

Policies where the benefits paid to policyholders include bonuses which vary depending on the profits earned by a fund (the 'participating fund') which the company maintains.

Ring-fenced fund

A fund where a company cannot use the assets within the fund to meet liabilities outside the fund.

Securitisation

Different types of contractual debt being pooled, and then sold to various investors.

Special purpose vehicle

An entity formed by a company for a particular project or task, usually to hold assets.

Step-up perpetual capital notes

A bond with a coupon – or interest rate – that increases – 'steps up' – at regular intervals, and has no maturity date.

Subordinated liabilities/debt

A loan that ranks below other loans in terms of claims on a company's assets or earnings. If borrowers do not meet the conditions of a loan, then creditors who own subordinated liabilities/debt will not be paid until higher ranking debtholders and policyholder are paid in full.

Transitional arrangements

Arrangements which allow companies to gradually switch from the Solvency I to Solvency II capital calculation basis.

With profit fund holders

Policyholders whose benefits include bonuses which vary depending on the profits earned by a 'participating fund' (see 'participating business' definition).



Amounts in the tables that follow are in €'000s.

BALANCE SHEET

R0360 Insurance and intermediaries receivables

R0380 Receivables (trade, not insurance)

R0420 Any other assets, not elsewhere shown

R0370 Reinsurance receivables

R0390 Own shares (held directly)

R0410 Cash and cash equivalents

R0500 Total assets

S.02.01.02

	Assets	C0010
R0030	Intangible assets	0
R0040	Deferred tax assets	0
R0050	Pension benefit surplus	0
R0060	Property, plant & equipment held for own use	109,764
R0070	Investments (other than assets held for index-linked and unit-linked contracts)	5,191,514
R0080	Property (other than for own use)	22,755
R0090	Holdings in related undertakings, including participations	63
R0100	Equities	54,281
R0110	Equities - listed	54,281
R0120	Equities - unlisted	0
R0130	Bonds	4,993,721
R0140	Government Bonds	3,064,264
R0150	Corporate Bonds	1,879,175
R0160	Structured notes	0
R0170	Collateralised securities	50,282
R0180	Collective Investments Undertakings	52,270
R0190	Derivatives	8,108
R0200	Deposits other than cash equivalents	60,315
R0210	Other investments	0
R0220	Assets held for index-linked and unit-linked contracts	40,196,038
R0230	Loans and mortgages	53,270
R0240	Loans on policies	1,879
R0250	Loans and mortgages to individuals	109
R0260	Other loans and mortgages	51,281
R0270	Reinsurance recoverables from:	1,587,135
R0280	Non-life and health similar to non-life	0
R0290	Non-life excluding health	0
R0300	Health similar to non-life	0
R0310	Life and health similar to life, excluding index-linked and unit-linked	1,562,444
R0320	Health similar to life	55,396
R0330	Life excluding health and index-linked and unit-linked	1,507,048
R0340	Life index-linked and unit-linked	24,691
R0350	Deposits to cedants	0

Solvency II value

27,695

87,140

79,481

104,328

47,436,365

0

0

R0400 Amounts due in respect of own fund items or initial fund called up but not yet paid in

S.02.01.02

APPENDIX 1 BALANCE SHEET continued

		Solvency II value
	Liabilities	C0010
R0510	Technical provisions - non-life	0
R0520	Technical provisions - non-life (excluding health)	0
R0530	TP calculated as a whole	0
R0540	Best Estimate	0
R0550	Risk margin	0
R0560	Technical provisions - health (similar to non-life)	0
R0570	TP calculated as a whole	0
R0580	Best Estimate	0
R0590	Risk margin	0
R0600	Technical provisions - life (excluding index-linked and unit-linked)	5,132,250
R0610	Technical provisions - health (similar to life)	619,219
R0620	TP calculated as a whole	0
R0630	Best Estimate	535,496
R0640	Risk margin	83,723
R0650	Technical provisions - life (excluding health and index-linked and unit-linked)	4,513,031
R0660	TP calculated as a whole	0
R0670	Best Estimate	4,353,272
R0680	Risk margin	159,759
R0690	Technical provisions - index-linked and unit-linked	39,660,086
R0700	TP calculated as a whole	40,027,112
R0710	Best Estimate	-527,550
R0720	Risk margin	160,523
R0740	Contingent liabilities	0
R0750	Provisions other than technical provisions	4,881
R0760	Pension benefit obligations	2,491
R0770	Deposits from reinsurers	0
R0780	Deferred tax liabilities	183,707
R0790	Derivatives	2,163
R0800	Debts owed to credit institutions	184
R0810	Financial liabilities other than debts owed to credit institutions	0
R0820	Insurance & intermediaries payables	302,959
R0830	Reinsurance payables	27,961
R0840	Payables (trade, not insurance)	163
R0850	Subordinated liabilities	0
R0860	Subordinated liabilities not in BOF	0
R0870	Subordinated liabilities in BOF	0
R0880	Any other liabilities, not elsewhere shown	142,915
R0900	Total liabilities	45,459,759
R1000	Excess of assets over liabilities	1,976,606

S.05.01.02

PREMIUMS, CLAIMS AND EXPENSES BY LINE OF BUSINESS

		Lin	Line of Business for: life insurance obligations	life insurance	obligations		Life reinsuran	Life reinsurance obligations	
	Health insurance	Insurance with profit a	Index-linked and unit-linked insurance	Other life insurance	Annuities stemming from non-life insurance contracts and relating to health insurance obligations	Annuities stemming from non-life insurance contracts and relating to insurance obligations other than health insurance obligations	Health reinsurance	Life reinsurance	Total
	C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0300
Premiums written									
0 Gross	109,224	2,341	6,257,085	898,876					7,267,526
0 Reinsurers' share	9,489	0	18,582	167,477					195,548
0 Net	99,735	2,341	6,238,503	731,399					7,071,978
Premiums earned									
0 Gross	105,754	2,341	6,257,085	900,624					7,265,804
) Reinsurers' share	9,489	0	18,582	167,477					195,548
) Net	96,264	2,341	6,238,503	733,147					7,070,256
Claims incurred									
0 Gross	64,435	24,391	4,923,793	421,627					5,434,246
) Reinsurers' share	6,639	0	15,102	260,951					285,992
0 Net	54,496	24,391	4,908,690	160,676					5,148,254
Changes in other technical provisions									
0 Gross	7,292	-11,112	3,311,831	-25,233					3,282,778
0 Reinsurers' share	3,147	0	-20,206	-400,951					-418,010
) Net	4,144	-11,112	3,332,037	375,718					3,700,787
0 Expenses incurred	27,885	480	243,279	117,892					389,536

389,536

R1900 Expenses incurred R2500 Other expenses R2600 Total expenses

R1720 Reinsurers' share

R1800 Net

R1710 Gross

R1520 Reinsurers' share

R1600 Net

R1510 Gross

R1620 Reinsurers' share

R1700 Net

R1610 Gross

R1420 Reinsurers' share

R1500 Net

R1410 Gross

APPENDIX 3 S.12.01.02LIFE AND HEALTH SLT TECHNICAL PROVISIONS

		Index-linked	Index-linked and unit-linked	d insurance	8	Other life insurance	ice	Annuities stemming from			Health insu	Health insurance (direct business)	ousiness)	Annuities		
	Insurance with profit participation		Contracts without options and guarantees	Contracts with options or guarantees		Contracts without options and guarantees	Contracts with options or guarantees			Total (Life other (Life other than health reinsurance insurance, including Unit-Linked)		Contracts without w options and guarantees	Contracts with options or guarantees	stemming from non-life insurance contracts and relating to health insurance obligations	Health reinsurance (reinsurance accepted)	Total (Health similar to life insurance)
	C0020	C0030	C0040	C0050	09000	C0070	C0080	06000	C0100	C0150	C0160	C0170	C0180	C0190	C0200	C0210
R0010 Technical provisions calculated as a whole		40,027,112								40,027,112						0
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default R0020 associated to TP calculated as a whole		28,125		1						28,125						0
Technical provisions calculated as a sum of BE and RM																
Best estimate R0030 Gross Best Estimate	131,901		-543,805	16,255		4,040,418	180,953			3,825,722		535,668	-172			535,496
Total Recoverables from reinsurance/SPV and Finite Re after R0080 the adjustment for expected losses due to counterparty default			-2,067	-1,367		1,390,410	116,639			1,503,614		55,396	0			55,396
$_{\rm R0090}$ Best estimate minus recoverables from reinsurance/SPV and Finite Re	131,901		-541,738	17,622		2,650,008	64,314			2,322,108	1	480,272	-172			480,100
R0100 Risk margin	357	160,523			159,402					320,282	83,723					83,723
Amount of the transitional on Technical Provisions R0110 Technical Provisions calculated as a whole										0						0
R0120 Best estimate										0						0
R0130 Risk margin										0						0
R0200 Technical provisions - total	132,258	39,660,086			4,380,773		_			44,173,116	619,219					619,219

S.22.01.21

IMPACT OF LONG TERM GUARANTEES MEASURES AND TRANSITIONALS

transitional on transitional on technical provisions cooso coco cooso co	C0030
	0
	0
	0
	0
	0

Basic own funds	Eligible own funds to m	Solvency Capital Requir	Eligible own funds to m
R0020	R0050	R0090	R0100

R0010 Technical provisions

leet Solvency Capital Requirement

Solvency Capital Requirement
Eligible own funds to meet Minimum Capital Requirement

R0110 Minimum Capital Requirement

75

S.23.01.01

OWN FUNDS

Basic own funds before deduction for participations in other financial sector as foreseen in article 68 of Delegated

Tier 3

Tier 2

Tier 1 restricted

Tier 1 unrestricted

Total

1,127

1,127

339,873

1,562,001

1,562,001

Regulation 2015/35

arec)	(5)	
ross of own charge)	5	
gross of	5000	
canita (a	-	
charb	5	
Ordinary	, ,,,,,,,	
80010		

- Initial funds, members' contributions or the equivalent basic own-fund item for mutual and mutual-type undertakings

- R0030 Share premium account related to ordinary share capital R0040 Initial funds, members contributions or the equivalent basic on R0030 Subordinated mutual member accounts R0070 Surplication and member accounts R0070 Surplications shares R0140 Share premium account related to preference shares R0140 Share premium account related to preference shares R0140 Sharoninated tiabilities R0140 Subordinated tiabilities R0140 Subordinated tiabilities R0140 Subordinated tiabilities R0140 Outber own fund items approved by the supervisory authority as R0180 Other own fund items approved by the supervisory authority as
- Other own fund items approved by the supervisory authority as basic own funds not specified above
- Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds R0220

1,903,274

1,903,274

- Deductions for participations in financial and credit institutions R0230

 - Total basic own funds after deductions R0290

Ancillary own funds

- Unpaid and uncalled ordinary share capital callable on demand R0300
- Unpaid and uncalled initial funds, members' contributions or the equivalent basic own fund item for mutual and mutual type undertakings, callable on demand R0310
- Unpaid and uncalled preference shares callable on demand
- A legally binding commitment to subscribe and pay for subordinated liabilities on demand
- Letters of credit and guarantees other than under Article 96(2) of the Directive 2009/138/EC Letters of credit and guarantees under Article 96(2) of the Directive 2009/138/EC R0320 R0330 R0340 R0350
- Supplementary members calls under first subparagraph of Article 96(3) of the Directive 2009/138/EC R0360 R0370 R0390
 - Supplementary members calls other than under first subparagraph of Article 96(3) of the Directive 2009/138/EC
 - Other ancillary own funds
 - Total ancillary own funds R0400

Available and eligible own funds

- Total available own funds to meet the SCR R0500

1,903,274 1,903,274

1,903,274 1,903,274

1,188,964 498,389 160.08% 381.88%

- Total available own funds to meet the MCR
- Total eligible own funds to meet the SCR Total eligible own funds to meet the MCR R0510 R0540 R0550

 - R0600 R0620 R0640 R0580
- Ratio of Eligible own funds to SCR
- Ratio of Eligible own funds to MCR
- Reconcilliation reserve
- Own shares (held directly and indirectly) Excess of assets over liabilities
- Foreseeable dividends, distributions and charges
- Other basic own fund items R0700 R0710 R0720 R0730 R0740
- Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds Reconciliation reserve

- Expected profits

- - Total Expected profits included in future premiums (EPIFP)

Expected profits included in future premiums (EPIFP) - Life business R0770 R0780 R0790

250,084

250,084

73,000 341,273 1,562,001

1,976,606

09000

- Expected profits included in future premiums (EPIFP) Non-life business

S.25.01.21SOLVENCY CAPITAL REQUIREMENT - FOR UNDERTAKINGS ON STANDARD FORMULA

USP Simplifications	C0090 C0120																						
Gross solvency capital requirement	C0110	772,968	34,756	743,263	229,308	0	-478,317	0	1,301,977	C0100	81,161	-24,810	-169,364	0	1,188,964	0	1,188,964		0	1,033,890	155,074	0	0
		R0010 Market risk	R0020 Counterparty default risk	R0030 Life underwriting risk	R0040 Health underwriting risk	R0050 Non-life underwriting risk	R0060 Diversification	R0070 Intangible asset risk	R0100 Basic Solvency Capital Requirement	Calculation of Solvency Capital Requirement	R0130 Operational risk	R0140 Loss-absorbing capacity of technical provisions	R0150 Loss-absorbing capacity of deferred taxes	R0160 Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC	R0200 Solvency Capital Requirement excluding capital add-on	R0210 Capital add-ons already set	R0220 Solvency capital requirement	Other information on SCR	R0400 Capital requirement for duration-based equity risk sub-module	R0410 Total amount of Notional Solvency Capital Requirements for remaining part	R0420 Total amount of Notional Solvency Capital Requirements for ring fenced funds	R0430 Total amount of Notional Solvency Capital Requirements for matching adjustment portfolios	R0440 Diversification effects due to RFF nSCR aggregation for article 304

S.28.01.01

MINIMUM CAPITAL REQUIREMENT - ONLY LIFE OR ONLY NON-LIFE INSURANCE OR REINSURANCE ACTIVITY

Linear formula component for non-life insurance and reinsurance obligations

R0010	MCR _{NL} Result	0		
			Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months
			C0020	C0030
R0020	Medical expense insurance and proportional reinsurance			
R0030	Income protection insurance and proportional reinsurance			
R0040	Workers' compensation insurance and proportional reinsurance			
R0050	Motor vehicle liability insurance and proportional reinsurance			
R0060	Other motor insurance and proportional reinsurance			
R0070	Marine, aviation and transport insurance and proportional reinsurance			
R0080	Fire and other damage to property insurance and proportional reinsurance			
R0090	General liability insurance and proportional reinsurance			
R0100	Credit and suretyship insurance and proportional reinsurance			
R0110	Legal expenses insurance and proportional reinsurance			
R0120	Assistance and proportional reinsurance			
R0130	Miscellaneous financial loss insurance and proportional reinsurance			
R0140	Non-proportional health reinsurance			
R0150	Non-proportional casualty reinsurance			
R0160	Non-proportional marine, aviation and transport reinsurance			
R0170	Non-proportional property reinsurance			
	Linear formula component for life incurance and reincurance obligations			
		C0040		
R0200	Linear formula component for life insurance and reinsurance obligations MCR. Result	C0040 498.389		
R0200	MCR _L Result	C0040 498,389		
R0200			Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance/SPV) total capital at risk
R0200			reinsurance/SPV) best estimate and TP	reinsurance/SPV) total
			reinsurance/SPV) best estimate and TP calculated as a whole	reinsurance/SPV) total capital at risk
	MCR _L Result		reinsurance/SPV) best estimate and TP calculated as a whole	reinsurance/SPV) total capital at risk
R0210	MCR _L Result Obligations with profit participation - guaranteed benefits		reinsurance/SPV) best estimate and TP calculated as a whole	reinsurance/SPV) total capital at risk
R0210 R0220	MCR _L Result Obligations with profit participation - guaranteed benefits Obligations with profit participation - future discretionary benefits		reinsurance/SPV) best estimate and TP calculated as a whole C0050 81,513 50,388	reinsurance/SPV) total capital at risk
R0210 R0220 R0230	MCR _L Result Obligations with profit participation - guaranteed benefits Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations		reinsurance/SPV) best estimate and TP calculated as a whole C0050 81,513 50,388 39,474,871	reinsurance/SPV) total capital at risk
R0210 R0220 R0230 R0240	MCR _L Result Obligations with profit participation - guaranteed benefits Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations	498,389	reinsurance/SPV) best estimate and TP calculated as a whole C0050 81,513 50,388 39,474,871	reinsurance/SPV) total capital at risk
R0210 R0220 R0230 R0240 R0250	MCR _L Result Obligations with profit participation - guaranteed benefits Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations Overall MCR calculation	498,389 C0070	reinsurance/SPV) best estimate and TP calculated as a whole C0050 81,513 50,388 39,474,871	reinsurance/SPV) total capital at risk
R0210 R0220 R0230 R0240 R0250	MCR _L Result Obligations with profit participation - guaranteed benefits Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations Overall MCR calculation Linear MCR	C0070 498,389	reinsurance/SPV) best estimate and TP calculated as a whole C0050 81,513 50,388 39,474,871	reinsurance/SPV) total capital at risk
R0210 R0220 R0230 R0240 R0250 R0300 R0310	Obligations with profit participation - guaranteed benefits Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations Overall MCR calculation Linear MCR SCR	C0070 498,389 1,188,964	reinsurance/SPV) best estimate and TP calculated as a whole C0050 81,513 50,388 39,474,871	reinsurance/SPV) total capital at risk
R0210 R0220 R0230 R0240 R0250 R0300 R0310 R0320	Obligations with profit participation - guaranteed benefits Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations Overall MCR calculation Linear MCR SCR MCR cap	C0070 498,389 1,188,964 535,034	reinsurance/SPV) best estimate and TP calculated as a whole C0050 81,513 50,388 39,474,871	reinsurance/SPV) total capital at risk
R0210 R0220 R0230 R0240 R0250 R0300 R0310 R0320 R0330	Obligations with profit participation - guaranteed benefits Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations Overall MCR calculation Linear MCR SCR MCR cap MCR floor	C0070 498,389 1,188,964 535,034 297,241	reinsurance/SPV) best estimate and TP calculated as a whole C0050 81,513 50,388 39,474,871	reinsurance/SPV) total capital at risk
R0210 R0220 R0230 R0240 R0250 R0300 R0310 R0320	Obligations with profit participation - guaranteed benefits Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations Overall MCR calculation Linear MCR SCR MCR cap	C0070 498,389 1,188,964 535,034	reinsurance/SPV) best estimate and TP calculated as a whole C0050 81,513 50,388 39,474,871	reinsurance/SPV) total capital at risk
R0210 R0220 R0230 R0240 R0250 R0310 R0320 R0330 R0340 R0350	MCR _L Result Obligations with profit participation - guaranteed benefits Obligations with profit participation - future discretionary benefits Index-linked and unit-linked insurance obligations Other life (re)insurance and health (re)insurance obligations Total capital at risk for all life (re)insurance obligations Overall MCR calculation Linear MCR SCR MCR cap MCR cap MCR floor Combined MCR	C0070 498,389 1,188,964 535,034 297,241 498,389	reinsurance/SPV) best estimate and TP calculated as a whole C0050 81,513 50,388 39,474,871	reinsurance/SPV) total capital at risk

Notes:

SOLVENCY AND FINANCIAL CONDITION REPORT 2017



